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ABSTRACT 
This thesis investigates the development of an HPLC assay for vitamin K, and the 
synthesis of carboxylic acid functionalised analogues of vitamin K and coenzyme Q. 
These analogues were used to investigate the feasibility of an immunoassay based 
method for the measurement of vitamin K. 
Chapter one outlines the biochemistry of vitamin K and coenzyme Q. The 
biological functions of these quinones and their proposed role in many diverse disease 
states are discussed. 
Chapter two contains a review of literature methods for the assay of vitamin K in 
plasma, food and tissue samples. The development of an HPLC assay for vitamin K 
using a metal catalyst, in the presence of an alcohol, to effect reduction of the quinone 
to the fluorescent hydro quinone for detection is presented. An investigation of a 
.number of metal catalyst/alcohol reduction systems showed platinum black/methanol 
to give the largest fluorescent response. The generality of this system towards a series 
of quinones showed that naphthoquinones (including vitamin Kl, vitamin K3, 1,4-
naphthoquinone and 2-hydroxy-l ,4-naphthoquinone) were efficiently reduced, while 
the reduction of various benzoquinones (including CoQ-lO and CoQ-O) was also 
achieved. This chemistry was then applied to the measurement of vitamin K in both 
standard solutions and plasma samples, via an HPLC system with fluorescence 
detection. 
The synthesis of two side chain functionalised analogues of vitamin K (3.70 and 
3.80) is presented in chapter three. Two synthetic routes to side chain functionalised 
vitamin K analogues were investigated. The first involved the conjugation of a 
functionalised allylic bromide (3.60) to a protected naphthoquinone core (3.11). The 
second approach developed involved the functionalisation of the natural isoprene side 
chain of vitamin K. This method was applied to a K vitamin synthesised via cuprate 
coupling of 3.11 and geranyl bromide, and to vitamin K2 (MK-4). 
The results of initial immunological studies are reported in chapter four. The 
production of antibodies recognising the naphthoquinone core of vitamin K was 
unsuccessful, postulated to be due to the 'bridge effect' leading to antibodies that 
recognise the isoprenoid side chain of the vitamin K analogue. From the results of 
these studies three short chain vitamin K analogues (4.5, and 4.7) were designed. 
Synthesis of 4.5 proceeded via oxidation of an aldehyde intermediate from the 
synthesis of3.70. Compound 4.7 was obtained from the cuprate coupling of core 3.11 
with ethyl bromoacetate, and subsequent functional group interconversions and 
deprotection. The coupling of analogues 3.70, 4.5, and 4.7 to protected lysine and a 
protected gly-Iys dipeptide was investigated to model the coupling of these 
compounds to a carrier protein for immunological study. The conjugates produced 
(4.2, 4.4, and 4.13-4.15) were subsequently studied by NMR spectroscopy and mass 
spectrometry. 
The above synthetic work is applied to the structurally related quinone coenzyme 
Q and is presented in Chapter five. Using the synthetic methods developed for the 
synthesis of vitamin K analogues two carboxylic acid functionalised analogues of 
coenzyme Q (5.37 and 5.38) were synthesised. These analogues were also conjugated 
to protected lysine and gly-lys dipeptide, and studied by NMR spectroscopy and mass 
spectrometry. 
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CH TE ONE 
INTRODUCTION 
Chapter 1 I 
1.1 VITAMIN K 
Vitamins are cofactors, required in minute amounts for the maintenance of 
growth and many biochemical processes. These organic compounds are not 
synthesised by the body but are produced by plants and lower animals, and are a 
dietary requirement for good health. A deficiency of any given vitamin will lead to a 
disease state. The vitamins, all of which are denoted by letters, may be classified into 
two groups, the water-soluble vitamins (including vitamins B and C) and the fat-
soluble vitamins (including vitamins A, D, and K). The role of the vitamins in 
biochemical systems is extremely diverse, from the growth and repair of body tissues, 
and the synthesis and degradation of amino acids, to adsorption of minerals such as 
calcium and phosphorus. A balance of many vitamins is also necessary for the 
maintenance of healthy teeth, bones and gums, and aids in the digestion of fats and 
carbohydrates. Each vitamin may function in many diverse ways and in conjunction 
with a range of other elements. 
The K family of vitamins are fat-soluble vitamins, which since their eady 
discovery have been implicated in processes such as blood coagulation, bone 
metabolism and cell growth. Vitamin K-dependent proteins have been identified in a 
variety of human tissues including the kidneys, spleen, lungs, uterus, placenta, 
thyroid, thymus, testes and bones. 1 Some of the conotoxins isolated from the marine 
snail Conus are also thought to be dependent on vitamin K for synthesis.2 Vitamin K 
is responsible for the post-translational conversion of glutamic acid residues to y-
carboxyglutamic acid residues in these proteins. 
1.1.1 HISTORY 
Vitamin K was first discovered by Henrik Dam who was studying the possible 
essential role of cholesterol in the diet of the chick. During his studies Dam noticed 
that chicks fed on a diet which had been extracted with non-polar solvents had 
impaired blood clotting.3 Subsequent studies showed that this condition could not be 
reversed by the administration of any of the known vitamins or physiologically active 
lipids.3 In 1935 Dam proposed that the antihaemorrhagic vitamin of the chick was a 
new fat-soluble vitamin which he called vitamin K (the first letter of the German word 
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Koagu[ation).4 The active vitamin was first isolated from alfalfa as a yellow oil and 
was characterised as 2-methyl-3-phytyl-l,4-naphthoquinone (see figure 1).3 The 
identification was confirmed by independent analysis and synthesis of this compound 
by Almquist and Klose,5 and Fieser 6 in 1939. 
A form of the vitamin was also isolated from putrefied fish meal, but in contrast 
to the oil isolated from alfalfa this was isolated as a yellow crystalline solid.3 Studies 
showed that this compound, called vitamin K2, contained an unsaturated side chain at 
the 3 position of the naphthoquinone core (see figure 1).3 Early investigations 
recognized that many sources of this vitamin contained a series of compounds 
differing in the number of carbons in the polyprenyl side chain.3 Compounds with 4 
13 isoprene units are now recognised as being commonly found throughout nature. 
1.1.2 NOMENCLATURE AND ACTIVITY 
The term vitamin K is commonly used to describe any compound that displays 
vitamin K activity. More specifically the form of the vitamin with a phytyl chain at 
the 3 position is termed vitamin Kl or phylloquinone, and the series with repeating 
unsaturation in the isoprene side chain vitamin K2, or the menaquinones. The 
menaquinones may be denoted MK-n, where n indicates the number of isoprene units 
in the side chain (see figure 1.1). 
Vitamin Kl - Phylloquinone 
Vitamin K2 - Menaquinone (MK-n) 
Figure 1.1: Structure of the K vitamins 
The other form of vitamin K commonly encountered is 2-methyl-1,4-
naphthoquinone, vitamin K3 or menadione, which lacks any substitution at the 3 
position. Although biologically active in vivo this compound is not found in nature. 
It has, however, been extensively used as a vitamin K supplement, especially in 
animal feeds. 
The stereochemistry at the side chain alkene of vitamin Kl has been shown to be 
essential for biological activity.7 The natural form of vitamin Kl and the MK's has a 
trans configuration, and the syntheticcis isomer exhibits little or no activity.7,8 Of the 
menaquinone series MK-3 to MK-5 appear to be the most biologically active in vivo.3 
The longer chain menaquinones have been shown to be highly active in vitro but they 
may be less well absorbed, due to increased hydrophobicity, leading to a lower 
biological activity.9 The unnatural vitamin K3 has also been shown to exhibit 
biological activity but it is unknown if this is alkylated in vivo to produce an active 
compound.3 
The investigation of the biological activity of a series of analogues of vitamin K 
has given some structure activity information on these compounds.3 2-Methyl-4-
amino-I-naphthol. and 2-methyl-l-naphthol were shown to have biological activity 
similar to menadione. 3 The diphosphate, disulfate, diacetate and dibenzoate forms of 
the reduced K series exhibited full biological activity,3 possibly due to the fact that it 
is the reduced form of vitamin K that is biologically active. The methyl substituent at 
the 2 position is essential for activity, with the 2-ethyl and other alkylated derivatives 
showing no activity.7,8 In addition to this the 2-chloro and 2-bromo derivatives are 
both potent antagonists of vitamin K.3 2-Phytyl-I A-naphthoquinone has been shown 
to exhibit biological activity, however it is thought to be methylated in vivo to vitamin 
Kl.3 Saturation of the double bond of vitamin Kl reduces activity considerably, but 
still exhibits more activity than branched chain Kl analogues.3 Finally alteration of 
the naphthoquinone core in any manner also leads to a loss in biological activity.3 
1.1.3 SOURCES OF VITAMIN K 
As vitamin K is not synthesised by higher animals it is necessary to obtain the 
required daily allowance through dietary sources. The K vitamins are synthesised via 
the shikimic acid pathway, which is also utilised in the production of the aromatic 
amino acids.3 The various prenyl side chains are synthesised via the terpene 
biosynthetic pathway, before incorporation in the final compound.lo 
Vitamin Kl is synthesised by plants and it is found at significant levels in green 
leafy vegetables, certain legumes, and some vegetable oils such as rapeseed and 
soyabean oiL 11 Most fish, skeletal meats, cereals and beverages also contain low, but 
measurable amounts of vitamin KJ .11 
Vitamin K2 is predominantly synthesised by anaerobic bacteria including many 
species that inhabit the lining of the gut. The major forms of vitamin K2 from this 
source are MK-IO and MK-ll produced by the bacteroides, MK-8 from 
enterobacteria, MK-7 from veillonella sp and MK-6 from Eubacterium lentumY 
Vitamin K2 is also available through the diet in animal livers and fermented foods, 
including cheeses. I I 
Another potential source of vitamin K is via dihydrovitamin KJ, which is 
produced during hydrogenation of vegetable oils, and found in significant quantities 
in foods prepared using these. I2 Dihydrovitamin KI has been detected in human 
plasma after the consumption of these foods but it's bioavailability is unknown. I2 As 
it is estimated that in America dihydrovitamin KI may account for up to 30% of the 
daily vitamin K intake, this could become very important in assessing vitamin K 
status. 12 
1.1.4 ABSORPTION, TRANSPORT AND STORAGE 
The intestinal absorption of vitamin K is a similar process to that of other fat 
soluble vitamins and lipid-soluble nutrients. This process, which takes place in the 
small intestine, involves the solubilization of vitamin K into mixed micelles 
composed of bile salts and the products of pancreatic lipolysis.7 Consistent with this 
model is the observation that patients who lack bile salts or pancreatic enzymes have 
impaired vitamin K absorption.7 Once in the mucosal cells of the intestine vitamin K 
is incorporated into chylomicrons and enters the circulation via the thoracic-duct 
lymph, chemically unchanged.7 After hydrolysis by the capillary endothelium, 
chylomicron remnants are taken up by the liver and a fraction of vitamin K is 
resecreted into the circulation after incorporation into very low density lipoproteins 
(VLDL).7 A healthy adult has been shown to absorb approximately 80% of an oral 
dose of vitamin Kl.7 
Vitamin K is transported between tissues by triglyceride rich lipoproteins, 11 
which accounts for the fact that patients with hyperlipidaemia show grossly elevated 
plasma levels of vitamin K.13 This is also consistent with the rmding that plasma 
vitamin Kl levels increase with age as do the corresponding plasma triglyceride 
concentrations. I4 The main storage site for vitamin K is the liver, but it is also found 
in many other tissues including the adrenal glands, lungs, bone marrow, kidneys, and 
lymph nodes? The distribution of the different vitamers of K varies between tissues 
with vitamin KI the predominant form in the heart and liver and relatively high 
amounts of MK-4 detected in the brain, kidney and pancreas. IS The accumulation of 
vitamin K in the heart is of particular interest as no vitamin K-dependent carboxylase 
activity has been observed in this tissue. I6 This may mean that there is another 
function of vitamin K as yet undetermined. The detection of MK-4 in almost all 
tissues is also of interest, as MK-4 is not found in significant amounts in any food 
sources. IS Dietary vitamin KI has been shown to be a source of tissue MK-4, 
suggesting some unknown cellular role for this particular vitamer. IS 
Although vitamin K is stored in a variety of tissues the half life is thought to be 
short, with the entire body pool of vitamin K being replaced as often as every two and 
a. half hours. 3 
The bioavailability of vitamin K from various sources is still under debate. 
Although green leafy vegetables are high in phylloquinone, absorption of the vitamin 
through the intestine is low/4 as the vitamin is tightly bound to the thylakoid 
membrane of the chloroplasts. I7 The absorption of menaquinones produced in the gut 
is also uncertain. The detection of significant amounts ofMK-10 to MK-13 in human 
liver, with no significant levels detected in foods, would suggest that these 
compounds originate from intestinal synthesis. I8 Conversely it has been suggested 
that absorption of the highly lipophilic menaquinones is unlikely as they are tightly 
bound to the cytoplasmic membrane and in the presence of bile salts the only 
perceivable mechanism for absorption would be via the portal route.19 
Having been absorbed through the intestine, and transported to sites of action or 
storage, vitamin K will act in a number of different biochemical roles. 
1.1.5 VITAMIN AND BLOOD CLOTTING 
As implied by the experiments of Dam4 which led to the discovery of vitamin K, 
this family of compounds is important in blood clotting. In the mid 1950's, and the 
following decade, clotting factors VII, IX, X and prothrombin were discovered as 
being vital to blood clotting, and dependant on vitamin K for synthesis.3 The plasma 
glycoproteins, or clotting factors, involved in blood coagulation are synthesised as 
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proenzymes, and activated as required in order to control the clotting process. These 
proteins, including factors XII, XI, IX, VII and prothrombin, are zymogens of serine 
proteases.20 
Blood clotting is a complicated biochemical process that consists of 2 major 
pathways, the intrinsic pathway where all the protein components are contained 
within the blood, and the extrinsic pathway where the cell membrane tissues play an 
important role (see fif:,'llre 1.2).20 The intrinsic pathway begins with the activation of 
factor XII by proteins, including kininogen and kallikrein. 2 ! This is initiated by 
damage to non-endothelial cells which leads to activation of prekallikrein to 
kallikrein, in turn activating factor XII to factor XIIa (activated factor XlI).22 When 
activated each protein in turn acts to cleave the next protein in the cascade, often in 
conjunction with other factors or bound calcium ions, and in this way the intrinsic 
pathway involves the activation of factors XII, XI and IX.z2 The activation of factor 
X to factor Xa involves not only factor IXa, but also factor VIlla which is not a serine 
protease, but is thought to act as a receptor for factor IXa.23 
I intrinsic pathway I I extrinsic pathway I 
XII-XIIa 
~Ca2+ VIla/lF. IF VII 
Xl-Xla 5Z !ca2+ Ca2+ Ca2+ IX .. IXa 
Ca
2
+ j iJ.IIa 
Ca2+ 
X to Xa 
PI. = platelet 
phospholipids 
IF= tissue factor 
j~2' 
prothrombin --""""'----_to thrombin 
XIII 
fibrinogen _1'--..... fibrin monomer 
~ 
fibrin clot 
thrombin. XIIIa-! 
©1994 Encyclopaedia Britannica, Inc. stabilized fibrin clot 
Figure 1.2: The blood clotting cascade 
The extrinsic pathway is a rapid response mechanism to tissue injury via the 
production of activated tissue factor (TF).23 Tissue factor activates factor VII to 
factor VIla, which is then able to activate factor X to Xa.23 At this point the extrinsic 
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and intrinsic pathways converge. Factor Xa is a serine protease which binds to the 
phospholipid membranes released by platelet aggregation, and cleaves prothrombin to 
thrombin. 21 The activation of prothrombin occurs on the platelet and requires calcium 
ion mediated binding of prothrombin to the anionic phospholipid head groups via 
vitamin K-dependent y-carboxyglutamic acid residues. The platelets also contain 
factor V which, when activated to Va, acts as a receptor for factor Xa.23 Cleavage of 
prothrombin, and subsequent release of thrombin leads to clot formation by activation 
of fibrinogen to fibrin, the structural protein that assembles into the fibrin polymer of 
the clot.2o 
The blood-clotting cascade is tightly controlled, and this process involves three 
vitamin K-dependent anticoagulation proteins, protein C, protein S and protein Z. 
Although protein Z has been described its function is unknown. 3 Protein C is a 
zymogen of a serine protease which is converted to activated protein C by thrombin, 
and inactivates factors Va and VIla by limited proteolysis thereby halting 
coagulation.2 Thrombin, upon binding to the endothelial cell receptor thrombodulin 
changes conformation allowing the activation of protein C, and in tum converting 
thrombin from a strong procoagulant to an anticoagulant. 22 The presence of 
thrombodulin on healthy endothelial cells to bind any circulating thrombin prevents 
the formation of clots in undamaged vessels?2 
Protein S acts as a non-enzymatic cofactor for activated protein C. The exact 
mechanism by which this occurs is unknown, but a role in anticoagulation is 
suggested, as patients deficient in protein S display problems associated with the 
control of the clotting process.2 Approximately 50% of circulating protein S is bound 
as a bimolecular complex to C4b-binding protein and it has been shown that only free 
protein S is active as a cofactor?,1? 
Although vitamin K is involved in these two opposing pathways the mechanism 
by which it is involved in post-translational modification of the proteins is the same. 
1.1.6 VITAMIN K CYCLE 
Vitamin K in the presence of vitamin K carboxylase, molecular oxygen and 
carbon dioxide will selectively carboxylate specific glutamic acid (Glu) residues to 'Y-
carboxyglutamic acid (Gla) residues in a protein precursor (see figure 1.3).11 
~ CO2 02 ~ 
( ~\ .. H02Cy 
C02H vitamin KH2 C02H 
Glu Carboxylase Gla 
Figure 1.3: Conversion of Glu to Gla by vitamin K -dependent carboxylase 
The process shown in figure three is the product of a catalytic cycle involving 
vitamin K, sometimes referred to as the vitamin K cycle (see figure 1.4). The active 
form of vitamin K in vivo is the hydroquinone (KH2)' produced from vitamin K by a 
nicotinomide dinucleotide phosphate (NAD(P)H) dependent flavoprotein reductase.24 
During the course· of the carboxylation reaction Glu is converted to Gla and vitamin 
KH2 is converted to vitamin K oxide?4 As any carboxylation event will be 
energetically unfavourable, it must be linked to an energetically favourable process to 
generate a product In this case the energy is provided by the direct oxidation of 
vitamin KH2 to vitamin K oxide.2 Whether the carboxylation and oxidation are 
concerted and require only one enzyme, or involve 2 separate enzymes is still largely 
unresolved with literature supporting both hypotheses.24 The final step of the cycle is 
the reduction of vitamin K oxide to vitamin K by vitamin K oxide reductase?4 
'-':::: 
0 
VitaminK 
Vitamin K oxide 
Reductase ! VitruninK 
Reductase, 
OR 
NAD(P)R 
'-':::: 
OR 
Vitamin KHz 
o 
Vitamin K oxide 
Figure 1.4: The vitamin K cycle 
( l cO:
u 
~02H02Y 
COzR 
Gla 
The anticoagulant drugs warfarin and dicumarol act by inhibiting vitamin K 
reductase and vitamin K oxide reductase.25 This interrupts the catalytic cycle of 
vitamin K and therefore ceases the production of the vitamin K-dependent clotting 
factors? Although vitamin K can no longer be recycled, and builds up in the liver as 
vitamin K oxide, dietary vitamin K can still feed into the cycle, through reduction by 
a second NAD(P)H dependent enzyme which is insensitive to warfarin? For this 
reason anticoagulant therapy is dependent on a balance between the inhibition of the 
recycling enzymes and the amount of dietary vitamin K which can enter the cycle.? 
Certain antibiotics have also been shown to inhibit vitamin K oxide reductase, namely 
those bearing a N-methylthiotetrazole (NMTT) side chain (e.g. cefamanadole) or a 
methylthiadiazole-thiol (MTD) side chain (e.g. cefazoin).9 
Although the vitamin K cycle has been established for some time the exact 
mechanism by which vitamin K effects the carboxylation of Glu to Gla in the 
presence of vitamin K-dependent carboxylase is still a matter of some debate. The 
carboxylation of Glu to Gla requires the cleavage of a CH bond and replacement with 
a carboxyl group. It has been proposed that this occurs via a free-radical or anionic 
intermediate?4 In 1991 Paul Dowd et at. proposed a novel base strength 
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amplification mechanism for this carboxylation reaction (see figure 1.5).24 This 
hypothesis was established in an attempt to explain how vitamin K could be 
transformed into a base strong enough to remove a proton from Glu. Vitamin KH2 is 
moderately acidic and can therefore ionize in the enzymatic environment to produce 
equilibrium concentrations of the mono- and dianion.25 Reaction of the dianion with 
oxygen will yield a peroxide anion intermediate which can add to the enone to give a 
dioxetane. This can then further rearrange by ring opening to give the dialkoxide.25 It 
is proposed that this dialkoxide could remove the proton from Glu as required for 
carboxylation?5 A similar series of reaction and rearrangements from the monoanion 
of vitamin KH2 would produce a tertiary alkoxide also capable of proton abstraction.24 
Dowd et ai. have carried out a series of model experiments24 to substantiate this 
hypothesis and at present this is the generally accepted carboxylation mechanism. 
vitaminKH2 
~~ ""'0(--~ 
dialkoxide 
Figure 1.5: Proposed mechanism of action of vitamin K 
1.1.7 GLA FORMATION AND PROTEIN ACTIVATION 
~R ~o-
peroxide 
11 
~'lyR 
~ 
dioxetane 
Upon this post-translational modification of Glu residues the protein is able to 
chelate calcium ions in the geminal carboxylate groups of the newly formed Gla 
residues. In the instance of blood coagUlation, the most studied of processes 
involving Gla containing proteins, this calcium ion may then form ion bridges to the 
phosphate head groups at phospholipid membrane surfaces of blood platelets and 
endothelial cells.25 Introduction of the Gla carboxyl group is also believed to confer 
structural changes upon the protein by calcium ion mediated intrachain Gla-Gla 
interactions (see figure 1.6). 25 
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Figure 1.6: Interaction of Gla residues with a calcium ion 
In most Gla proteins identified, including all the K-dependent clotting factors, all 
the Gla residues fall within a short sequence at the amino terminal of the peptide. 
This area is termed the Gla domain, and with the solving of the X-ray crystal structure 
of the Gla domains of several clotting factors more information on the role of Gla in 
the activation of these proteins has become available.2 It was found that the Gla 
residues point inwards towards calcium ions bound in the interior of the Gla domain. 
Studies have also shown that Gla itself has a poor affinity for calcium ions, and 
groups of Gla residues do not create functional calcium binding sites without correct 
folding of the parent protein? . 
The fact that vitamin K -dependent carboxylase could effect the carboxylation of 
various numbers of Glu residues in different proteins without affecting the rest of the 
protein raised several questions about the specificity and recognition of the 
carboxylase for the vitamin K-dependent protein. Identification of the cDNA 
sequences for the known vitamin K-dependent proteins revealed an homologous 
peptide that is the recognition sequence for the carboxylase.26 In most cases this is a 
propeptide which is cleaved before the release of the peptide into circulation.26,27 
Although the level of carboxylation varies between proteins, a certain amount of 
homology has also been observed in the Gla domain of most of the known vitamin K-
dependent proteins?6 The identification of these recognition sequences has lead to the 
identification of previously unknown vitamin K-dependent proteins in various body 
tissues. 
1.1.8 VITAMIN K AND HDN 
A clinical vitamin K deficiency is rarely observed in adults, unless excessive 
antibiotic treatment or other medical conditions (e.g. liver complaints) accompany this 
diagnosis. However, in neonates, spontaneous bleeding due to vitamin K deficiency 
is a well-known risk. I 1 This condition termed haemorrhagic disease of the newborn 
(HDN), or vitamin K deficient bleeding, was first described in 1894, with a treatment 
of fresh cows milk being prescribed. I All neonates are born deficient in vitamin K, 
but several other factors have been identified as increasing the risk ofHDN. 
There are several factors contributing to the low vitamin K status of newborns. It 
has been shown that vitamin K is not readily transferred across the placenta,I,28 this 
could be partly due to the low lipid concentrations in cord plasma. 13 Hepatic stores of 
menaquinones are also known to be virtually non existent in neonates. I I The 
administration of anticonvulsant drugs during pregnancy, e.g. warfarin, or a stressful 
pregnancy and delivery have been shown to increase the risk of HDN?9 
HDN may be classified into three syndromes: early HDN when bleeding occurs 
within 24 hours of birth, classic HDN when bleeding occurs on days one to seven, and 
late HDN when bleeding occurs after the first week of life. 32 Bleeding in early HDN 
is often intracranial, intrathoracic or intraabdominal, and maternal drugs are a frequent 
cause. 11 In the case of classic HDN bleeding is often gastrointestinal, under the skin 
or nasal and this is mostly an idi'opathic disorder. I I Late onset HDN is often 
identified by intracranial bleeding which may be fatal or cause morbidity, this is also 
often idiopathic and may be the presenting feature of underlying disease eg cystic 
fibrosisll,32 or subclinical liver dysfunction.33 Late onset HDN is almost entirely 
confined to exclusively breast-fed infants who did not receive vitamin K prophylaxis 
at birth.28,34 
Estimating the incidence of HDN in an unprotected population is difficult, and 
there is large intercountry variation, with estimates of incidence of late HDN (per 
100000 births) of 4.4 in UK, 7.2 in Germany, 10.5 in Japan, and 72 in Thailand.ll 
The incidence of bleeding due to vitamin K deficiency has been shown to be 15-20 
fold higher in solely breast-fed infants.3o Purely breast-fed infants are at a higher risk 
for two reasons. Firstly vitamin K levels of breast-milk have been shown to be a lot 
lower then levels in cows milk and infant formulas (which are fortified with vitamin 
K).31 Also the bacteria in breast milk which go on to colonise the intestine of the 
infant are unable to produce menaquinones, unlike the organisms often associated 
with intestinal flora of formula fed infants. I 
Since the observation that HDN is responsive to vitamin K, the generally 
accepted practise has been vitamin K prophylaxis at birth.35 The two main routes of 
administration of vitamin K are oral (by three consecutive doses) or intramuscular 
(via a single injection at birth). There has long been much debate about the most 
effective prophylactic treatment, as well as many investigations into the possibility of 
administering vitamin K to breast-feeding mothers.36 The debate over vitamin K 
prophylaxis was again raised in 1992 when Golding et al published the results of a 
study which suggested a possible link between intramuscular, but not oral, vitamin K 
prophylaxis, and an increased incidence of childhood cancer.37 There were two 
possible reasons for this put forward. Firstly very high levels of vitamin K (5000 
times normal) have been shown to increase sister chromatid exchanges in human 
placental lymphocytes in vitro.37 The site of intramuscular injection is thought to act 
as a store and slowly release the vitamin into circulation possibly setting up this 
increased risk of sister chromatid exchange, however one small study involving six 
infants showed no evidence of this occurring in vivo.37 The second hypothesis is that 
it isn't the vitamin K itself but other ingredients in the preparation that are 
carcinogenic.37 Phenol and vitamin K may provide reactions needed for 
carcinogenesis, and vitamin K has been shown to increase the mutagenicity and 
carcinogenicity of benzopyrene also' found in some K preparations.37 Alternatively 
Golding postulates that rather than the vitamin K being harmful a deficiency state may 
be protective, and protect vulnerable tissue from mutagenesis during this critical stage 
of rapid growth and development. 37 Since this study several other groups have tried 
to confirm or discount the link suggested by Golding. These results are still 
inconclusive. A study in the United States showed no link between intramuscular 
vitamin K and cance~8,39 and more recently four British studies have failed to resolve 
this debate. Two of these studies suggested a increased risk of cancer with 
intramuscular K prophylaxis, although with a risk factor much smaller than that 
reported by Golding, and the remaining two studies found no link between the points 
in question. 
With no risk shown by any group between cancer and oral vitamin K prophylaxis 
this became the preferred route of administration for some time. However, 
independent studies have shown that oral prophylaxis is not as effective against 
classic and late HDN, especially if all three doses are not administered.34 The 
possibility of targeting breast-fed infants by giving vitamin K supplements to breast-
feeding mothers has also been investigated. Supplementation of vitamin K has been 
shown to dramatically increase breast milk and plasma concentrations in the mother, 
but an increased dietary intake of vitamin K showed no appreciable increase in 
vitamin K content in breast milk.35 However, no significant correlation between 
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plasma phylloquinone concentration of the infant and breast milk phylloquinone 
concentration was observed, implying that absorption of the K vitamins may be the 
problem.35 It was also shown that when all infants were given prophylaxis at birth no 
difference in the vitamin K -dependent clotting factors could be demonstrated between 
formula and breast-fed infants, implying almost full protection from HDN.35 
1.1.9 VITAMIN ANDBONEHEALTH 
Following the study of the vitamin K-dependent clotting factors, Gla containing 
proteins were isolated from bone tissue. Three Gla containing proteins have been 
isolated in bone to date: osteocalcin (or Bone Gla protein, BGP), matrix Gla protein 
(MGP) and protein S. It has been demonstrated that adequate vitamin K status is 
important both for early skeletal development and the maintenance of healthy mature 
bone. II Vitamin K antagonists have been shown to be toxic to bone, and the optimum 
vitamin K concentration required to maintain function in bone may be higher than that 
necessary for coagulation. I I Oral anticoagulants inhibit carboxylation of Gla proteins 
which vitamin K administration reverses in the liver, but this process is not reversed 
in the bone. I7 Bone tissue is also a repository for vitamin K and may contain levels as 
high as the liver. I8 Vitamin Kl is the major form in bone tissue but MK-4, 5, 6 and 7 
are also observed in bone lipid, with concentration decreasing with increasing side 
chain length. I9 
The most abundant of the vitamin K-dependent bone proteins is osteocalcin, 
which accounts for up to 15% of the non-collagenous bone.19 Osteocalcin is a protein 
of 49-50 amino acid residues including 3 Gla residues at positions 17,21, and 24,19 
which are essential for calcium binding.40 The spacing of the Gla residues is 
consistent with the spacing of calcium ions in hydroxyapatite to which osteocalcin 
binds tightly. 11 Like all bone Gla proteins osteocalcin is synthesised by osteoblasts, 
but unlike the other Gla containing bone proteins it is also synthesised by 
odontoblasts.17 The precise mechanism of action of osteocalcin is unknown but it 
functions as a negative regulator of bone formation.40 A group of osteocalcin-
deficient mice were shown to be normal at birth, but by six months of age had 
developed long bones of increased thickness and density compared to wild-type 
mice.4o Undercarboxylated oscteocalcin has been shown to be very sensitive to low 
vitamin K intake,17 and is now considered a more sensitive marker of vitamin K status 
than undercarboxylated clotting factors. Circulating undercarboxylated osteocalcin 
has been observed to increase with age, especially in post-menopausal women. These 
levels are also increased in patients with hip-fracture and may be used as an indicator 
of fracture risk,I9,40 These levels of undercarboxylated osteocalcin respond positively 
to vitamin K supplementation. 16 
Matrix Gla protein (MGP) is a 9.6 kDa protein which despite it's high proportion 
of hydrophilic amino acids is virtually insoluble in aqueous solutions. I7 Most 
secreted MGP enters circulation, but it is also abundant in bone and cartilage. I7 MGP 
has been identified to take part earlier in the calcification process than osteocalcin and 
binds to both the organic and mineral components of the bone.4o MGP inhibits 
calcification of arteries and cartilage through it's mineral-ion-binding ability,40 and 
mice without the genes necessary for MGP synthesis displayed increased heart rate, 
decreased stature, osteopenia, fractures and eventually died due to calcification of the 
aorta.40 However, no atherosclerotic plaques were present in these animals, implying 
the fonnation of such plaques is controlled by a gene independent of the MGP genes, 
but MGP may affect calcification once plaques are fonned. 4o The role of MGP in 
inhibition of calcification has been proposed as a mechanism for maintaining the 
organization of chondrocytes necessary for longitudinal bone growth.40 MGP is not 
exclusive to bone tissue, it is also found in cartilage and expressed in a variety of 
other soft tissues. I9 The teratogenic effect of warfarin in causing excessive fetal 
calcification is at least partly due to the inhibition of MGP function by the vitamin K 
antagonist. 19 
The [mal vitamin K-dependent protein isolated from bone tissue is protein S, 
which has already been discussed as an anticoagulant in the blood clotting cascade.19 
Protein S is a single chain molecule containing 11 Gla residues, and is synthesised not 
only by osteoblasts but also by hepatocytes, megal<.aryocytes and endothelial cells. I7 
The study of two patients with well established protein S deficiency showed severe 
osteopenia and reduced bone mineral density.I7 This finding, coupled with isolation 
of protein S from organic bone matrix, suggests that protein S may have an additional 
role in bone metabolism. 17 The exact nature of this role and its mechanism of action 
are still unclear. 
With evidence of vitamin K-dependent proteins being vital to bone metabolism, 
and the indication of poor vitamin K status in many fracture patients, the possibility of 
a link between vitamin K and osteoporosis has been suggested.41 Osteoporosis is a 
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metabolic bone disease characterised by a defect in bone remodelling, and loss of 
normally mineralised bone (see figure 1.7).41 Bone remodelling is the result of the 
opposing actions of two cell types in bone.41 The osteoclasts, attracted to an area of 
damage, will remove a finite amount of bone before undergoing apoptosis.41 
Osteoblasts then synthesise new bone to replace that which has been removed.41 
Osteoporosis results from an imbalance in this process where osteoblasts fail to 
replace removed bone leading to lower bone mineral density.41 There is still debate 
over any role for vitamin K in osteoprosis, as healthy mature bone appears resistant to 
the effects of vitamin K antagonists.42 
Figure 1.7: Healthy bone (left) compared with osteoporotic bone (right)' 
Although epidemiological studies are limited, there is support for the role of 
vitamin K in the retardation of bone loss in the eldedy,41 and in Japan MK-4 is often 
given at 4Smg/day for treatment of post-menopausal osteoporosis. 16 Due to its role in 
tissue mineralisation, it has been proposed that poor vitamin K status may be the 
common denominator in osteoporosis and atherosclerosis. I? 
1.1.10 VITAMIN K AND CELL GROWTH 
In the search for proteins containing Gla residues, the protein encoded by growth-
arrest-specific gene 6 (gas6) was identified as the first Gla containing receptor ligand 
that regulates cell activity.43 This protein (Gas6) is released from growth-arrested 
vascular smooth muscle cells (VSMCs) and potentiates VSMC proliferation induced 
by calcium ion mobilising growth factors.43 Gas6 shows sequence similarity with 
protein S, and is a ligand for the receptor tyrosine kinases Axl and Sky.43 The 
* Image sourced from pepper.uchc.edulbone.jpg 
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interaction of Gas6 with its receptor requires calcium ion binding and Gla deficient 
Gas6 shows poor receptor binding and growth potentiating activity.43 The Gla 
domain of Gas6 is thought to act as a regulatory domain fixing the protein in an 
inactive conformation when uncarboxylated, and activating receptor binding when 
carboxylation occurs. 43 The role of Gas6 in the activity of VSMCs in vitro suggest 
that it contributes to the development and maintenance of the vascular wall, as well as 
the process of vascular disease.43 
As well as it's role in cell proliferation vitamin K has been implied in the 
inhibition of growth of several tumour celllines.44 As early as 1980 it was recognised 
that vitamin K3 inhibited the binding of epidermal growth factor to the membrane 
receptors.44 Vitamin K3 was also found to inhibit the growth of mouse neuro-
blastoma, rat glioma and mouse melanoma cells at micromolar concentrations.44 
Following this, vitamin K3 was shown to have similar properties against a series of 
animal and human tumour cells in vitro and in vivo, including several drug resistant 
cell lines.45 Vitamin K3 was suggested as a possible agent in combination 
chemotherapy, and preliminary studies showed that the concentrations required to 
suppress tumour growth were readily achievable.45 The mechanism by which vitamin 
K3 arrests tumour growth is thought to revolve around the quinone moiety. The 
quinone can undergo one electron reduction resulting in the formation of a 
semiquinone, which in turn may react with molecular oxygen to regenerate the 
quinone and superoxide, similar to that of known anticancer agents diaziquone, 
mitomycin, and doxorubicin.45 Vitamin K3 has been shown to be a potent inducer of 
ssDNA damage in the absence of topoisomerase, which is believed to playa role in 
the mechanisms of other quinone anticancer agents. 45 Other studies have suggested 
that sulfhydryl arylation may be responsible for cell growth inhibitory effects of 
vitamin K3.46 
Following these studies the investigation of several vitamin K analogues found 
that 2-(2-mercaptoethanol)-3-methyl-l,4-naphthoquinone (Cpd 5) was a more potent 
cell growth inhibitor than previously known K vitamins.46 It was predicted that Cpd 5 
was active due to arylation of cellular thiols or thiol dependent proteins, by an 
addition-elimination mechanism.46 It was found that Cpd 5 targeted protein-tyrosine 
phosphotases (PTPases), which playa pivotal role in many cellular functions. 46 
Sulfhydryl arylation of a critical cysteine in the active site of PTPases, and subsequent 
perturbation of protein tyrosine phosphorylation is the suggested mechanism of cell 
growth inhibition of Cpd 5.46 
1.2 COENZYME Q 
Like vitamins, coenzymes are non-protein substances required by proteins for 
biological activity, especially in enzyme catalysed reactions. These compounds are 
not consumed in the course of the reaction, but are found unchanged upon its 
completion. Coenzymes include substances such as nicotinamide-adenine 
dinucleotide (NAD), flavin-adenine dinucleotide (FAD), pyridoxal phosphate and 
coenzymes A and Q. Unlike vitamins however, coenzymes are produced by the body 
and are therefore not a dietary requirement for cellular function. 
Coenzyme Q (CoQ), or Ubiquinone, is found throughout the body in cell 
membranes, especially the mitochondrial membranes of the heart, liver, lungs, 
kidneys, spleen, pancreas and adrenal glands. The total body pool of CoQ is 
estimated to be 500 mg to 1500 mg.47 A deficiency of this cofactor has been 
associated with many varied disease states including heart disease, ageing, cancer, 
diabetes, stroke, Alzheimer's disease, Parkinson's disease, muscular dystrophy, 
atherosclerosis and AIDS. CoQ has been found to have two main biochemical 
functions: as a cofactor in the electron transport chain of the mitochondrial membrane, 
and as an antioxidant. 
The chemical structure of coenzyme Q is closely related to that of the 
menaquinones (see figure 1.8). The 2-methyl-3-polyprenyl-5,6-dimethoxybenzo-
quinone exists with varying numbers of prenyl units, with COQI0 (containing 10 
prenyl units) being the active form in humans. 
o 
MK-n Co~ 
Figure 1.8: Chemical structure of menaquinone-n (MK-n) and coenzyme Q-n (CoQn) 
1.2.1 HISTORY 
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Coenzyme Q 10 was first isolated from beef heart mitochondria in 1957 by Dr 
Fred Crane,48 and the structure was elucidated by Dr Karl Folkers and reported the 
following year.49 It was soon determined that CoQ was found in virtually every cell 
in the body, but it's biological function was still unknown.50 The role of CoQ in the 
energy transfer process in mitochondria was elucidated by Dr Peter Mitchell, who was 
awarded the 1978 Nobel Prize in chemistry for his work in this area.51 
Coenzyme Q first went into clinical trials in patients with congestive heart 
disease in 1965 in Japan, and the first documentation of a CoQ deficiency in heart 
disease patients was published by Littarru and Folkers in 1972.52 At approximately 
the same time a COQlO deficiency was also observed in patients with periodontal 
disease. Clinical trials at this time were difficult due to limited supply of CoQ, but 
with the introduction of a viable commercial fermentation technique to produce CoQ] 0 
in significant quantities, in the mid 1970's the number and size of clinical trials for 
various different human diseases increased dramatically. Although marketed as a drug 
in Japan, coenzyme Q was marketed as a health supplement in the US in order to 
hasten its appearance on the market by removing the need for FDA approval. By the 
1990's CoQ was widely prescribed in Japan for treatment of heart failure, cardiac 
arrhythmias and hypertension, and had become popular on the health food market 
worldwide. 
1.2.2 BIOSYNTHESIS 
The biosynthesis of CoQ takes place in all body tissues, and proceeds from 
chorismate and a polyprenylpyrophosphate. It is a multistep process which requires at 
least 8 vitamins and several trace elements.53 The biosynthesis occurs in three 
sections; the synthesis of the polyprenyl side-chain via the mevalonate pathway in the 
microsome, the synthesis of the precursor ring, chorismate, via the shikimate 
pathway, and the condensation of the two and subsequent functionalisation of the ring 
which takes place in the Go1gi system (see figure 1.9).54 
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Figure 1.9: Simplified scheme of ubi qui no 1 biosynthesis 
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The mevalonate pathway is present in all tissues of higher organisms, and the 
products of this pathway are cholesterol, CoQ, and the cytoplasmic intermediates 
farnesyl pyrophosphate and geranylgeranyl pyrophosphate which are used for the 
isoprenylation of proteins. 54 Geranyl pyrophosphate, which is synthesised in the 
cytosol, is the substrate for an enzyme at the cytosolic surface of the endoplasmic 
reticulum (ER) membranes which synthesise solanesyl pyrophosphate.54 This is then 
transferred to the lumen of the ER and transported to the Golgi system, but it is not 
clear in which part of the Golgi system the polyisoprene is utilised.54 Condensation 
with the precursor ring occurs at the inner membrane of the Golgi system, followed 
by functionalisation of the ring. The fmal product appears at the cytoplasmic surface 
of these membranes. 54 
Many agents have been shown to interfere with the biosynthesis of CoQ, all of 
which act in the early stages of the pathway. Mevinolin, an inhibitor of HMG-CoA 
reductase, has also been shown to affect other enzymes in the mevalonate pathway 
and lowers the CoQ content of several tissues. Any inhibitors which decrease the 
farnesyl pyrophosphate pool also decrease the rate of CoQ synthesis.54 No inhibitors 
of the fmal stages of CoQ synthesis are available, and the only inhibitors used 
clinically are HMG-CoA reductase inhibitors.54 
A commonly encountered family of drugs affecting CoQ biosynthesis are the 
statins. These drugs, e.g. lovastatin, are inhibitors of HMG-CoA reductase, and are 
commonly prescribed for hypercholesterolemia (high cholesterol). The 
transformation of HMG-CoA to mevalonate by HMG-CoA reductase is the rate 
limiting step in the synthesis of cholesterol making these inhibitors particularly 
effective. This step, however, is also crucial to CoQ synthesis, and thus patients 
receiving statin therapy often show significantly lowered plasma CoQ levels. The 
decrease in plasma CoQ levels with statin therapy can be prevented by concomitant 
administration of CoQ. 53 Despite this reduction in CoQ induced by statins, oxidation 
of LDL appears to be inhibited by statins, so no serious adverse effects have been 
observed in relation to CoQ deficiency. 53 
1.2.3 CoQ AND THE ELECTRON TRANSPORT CHAIN 
Coenzyme Q is a coenzyme for at least 3 mitochondrial enzymes (complexes I, II, 
and III), as well as enzymes in other parts of the cell. The role of CoQ in the 
production of energy, in the form of ATP, via oxidative phosphorylation has been 
extensively studied (see figure 1.10).53 
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Figure 1.10: The electron transport chain of mitochondria 
CoQ has a multifaceted function in energy transduction. It's role as a redox 
link between flavoproteins and cytochromes in the mitochondrial respiratory chain 
has been known since the mid 1960's.55 CoQ acts as a traditional coenzyme to each 
dehydrogenase through a CoQ binding site on the enzyme.56 Each binding site has 
individual characteristics and sequence of electron transfer, and one such system 
which has been well studied is that of succinate dehydrogenase. 56 
CoQ is involved in direct proton movement to establish a proton gradient across 
the membrane that can be coupled to A TP production. 56 First it gathers electrons 
from dehydrogenases for substrates oxidised by mitochondrial cristea membranes. 56 
The location of protonation, on the matrix or the inner side of the cristae membranes, 
lays the groundwork for proton transfer across the membrane.56 The hydroquinone is 
reoxidised at specific sites on the quinol dehydrogenase, which transfers electrons 
from the quinone though a series of electron carriers. 56 Orientation of proton release 
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to the outside of the membrane is the fmal step in the chemiosmotic proton gradient 
formation. 56 This process is called the Q cycle (see figure 1.11). 
matnx 2W 
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Figure 1.11: The Q cycle" 
cyt c 
The Q cycle centres on the ability of the quinone moiety of CoQ to donate and 
accept two single electrons in association with its stepwise protonation and 
deprotonation. 54 One of the electrons involved is cycled through the semiquinone 
radical to the heme centre of cyt b566, while the other electron is linearly transferred 
through the iron-sulfur centre of the Rieske protein and cytochrome c), to cytochrome 
oxidase. 57,58 The crucial intermediate in this process is the semiquinone radical (Q-), 
with the electron flux through this intermediate affecting the efficiency of energy gain 
through oxidative phosphorylation.54 Between the primary quinone reduction site and 
subsequent quinol oxidation, the quinol diffuses through the lipid bilayer and back.56 
This implies that the efficiency of the process depends on the affinity and quality of 
quinone binding sites in the proteins, condition of the electron carrier elements and 
the ability of the quinone to move through the membrane. 56 The Q cycle is driven as 
long as electrons from the CoQ pool are transferable to the iron-sulfur protein. 57 If 
the oxidant side ofCoQH2 is fully reduced, semiquinone pools with equilibrate at low 
levels.57 
The concentration of CoQ in the membrane is not saturating for NADH 
dehydrogenase, that is the affinity ofCoQ for the enzymes it interacts with is not high 
enough to saturate them at physiological concentration.59 This implies that the 
velocity of the respiratory chain is strongly dependent on the CoQ concentration, and 
any event giving rise to an increase or decrease in the concentration of CoQ will 
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the flux of electrons through the respiratory chain.55,59 Therefore, the administration 
of exogenous CoQ, which will increase the concentration of CoQ in the mitochondrial 
membrane, will increase the rate of the respiratory chain. 56 This process is limited by 
the low solubility of CoQ in the lipid membrane, making the greatest possible 
increase only 20-30% above the basal rate.56 Any process which leads to a decrease 
in the mitochondrial total CoQ concentration, or excessively oxidising or reducing 
conditions in the mitochondrial CoQ pool, will lead to a skew in the CoQ:CoQHz 
ratio. The corresponding decrease in the concentration of either CoQ or CoQHz may 
inhibit mitochondrial proton movement and ADP phosphorylation, and produce 
serious physiological and medical problems.59 
CoQ is also present in plasma membranes where it's function relates to growth 
control and signal transmission. 56 The plasma membranes of all cells contain ligand-
activated NADH oxidase that can transfer electrons across the membrane to activate 
cell signals and stimulate cell growth. 56 These signals are the same as those activated 
by other mitogenic ligands, such as an increase in internal pH or calcium ion 
concentration, activation of protein kinases and activation of the early 
protooncogenes.56 As electron transfer across the plasma membrane induces proton 
release by the cell in the presence of CoQ, it is postulated that CoQ may be an agent 
for proton transfer in plasma membranes, as it is in mitochondria.60 Most proton 
release activated by electron transfer at the plasma membrane is based on activation of 
the Na+/H+ exchange, which can be inhibited by CoQ analogues,56 but a small amount 
may be based on the redox cycling of CoQ.60 CoQ may also control signalling across 
the plasma membrane as the redox change in lipophilic quinones may modify the 
function of the associated proteins leading to activation of protein ldnases associated 
with the membrane. 60 
The involvement of CoQ in NADH-dependent redox chain also contributes to the 
acidification of the lumen by transfer of protons to the interior of the cristernae, in an 
analogous manner to proton movement in the mitochondria. 57 
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1.2.4 CoQ AS AN ANTIOXIDANT 
The second major role of CoQ is as an antioxidant. It has been shown that CoQ 
can reduce free radicals, which can cause damage to structural lipids or proteins in the 
membrane, not only in mitochondria but in any cellular CoQ containing membranes.56 
The reduced form of CoQ (COQH2) acts as the reducing agent for this removal of free 
radicals or peroxides.56 COQH2 can exert this free radical-scavenging activity and 
inhibit subsequent lipid peroxidation in liposomes, membranes, cells and 
lipoproteins. 57 This process is supported by the dehydrogenases in the membrane 
which can reduce CoQ to COQH2 thereby renewing the cellular supply. 56 Reduced 
CoQ is the only known lipid-soluble antioxidant which can be synthesised de novo in 
animal cells and for which there exists a mechanism of regeneration from the oxidised 
c 57 lorm. 
In addition to quenching free radicals itself, reduced CoQ can reduce the a-
tocopheryl radical to a-tocopherol (the most active form of vitamin E), thereby 
recycling this important cellular antioxidant.57,59 Reduced CoQ has been shown to 
preferentially reduce the a-tocopheryl radicals over peroxyl radicals, supporting this 
important function of CoQ in the regeneration of a-tocopherol.57 Purified human 
NADPH-cytochrome P450 reductase can reduce the a-tocopheryl radical in the 
presence of CoQ in an NADPH-dependent process.57 Also CoQH2 and the a-
tocopheryl radical are likely to occupy the same domain in membranes and collisions 
between the two would be facilitated by changes in the amphipathic character of the 
two lipids. 57 
Similarly, it has been shown that transplasma membrane electron transport, which 
depends on CoQ acts to reduce extracellular ascorbate free radical back to ascorbate, 
another important biological antioxidant.60 Following exposure to a radical source, 
LDL deploys antioxidants which are consumed while opposing oxidative attack. 59 In 
this situation ascorbic acid is the first to intervene followed by COQH2.59 When LDL-
ascorbic acid is exposed to radical attack peroxidation is under control as long as 
some COQH2 is present.59 It is only when the COQH2 is almost entirely oxidised that 
lipid peroxidation occurs, when 95% of the initial vitamin E is still present.59 
The bioenergetic and antioxidant roles of CoQ are not independent. Any 
condition of increased oxidative stress leads to enhanced involvement of CoQ as an 
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antioxidant which may decrease the critical availablility of CoQ for oxidative 
phosphorylation. 59 In many disease states arising from a CoQ deficiency, both these 
roles are important. 59 
1.2.5 PRO OXIDANT ACTIVITY 
Under certain conditions the semIqUInOne radical which is an important 
intermediate in the Q-cycle (see section 1.2.3) may undergo autooxidation by reaction 
with molecular oxygen to produce the highly reactive superoxide radical.57 This 
process, which is not expected during normal respiration, effectively converts CoQ 
from an antioxidant to a pro oxidant supporting lipid peroxidation.57,58 The reaction of 
superoxide radicals with COQH2 is also possible giving the semiquinone radical and 
hydrogen peroxide. 57 
The process of superoxide formation by the semiquinone radical requires the 
availability of protons, and there are two situations when this auto oxidation is 
possible; if protons can penetrate into a disturbed membrane allowing reaction, or if 
the physical state of the membrane remains unchanged while mobility of the redox-
cycling semiquinone is changed so it can come in contact with the aqueous phase of 
the polar headgroup section of the membrane.57,58 Both of these situations may occur 
in response to various toxicological or pathophysiological events ( e.g. ischemia), or 
during ageing.57,58 The mitochondria from heart tissue of aged rats are active 
superoxide generators, and also exhibit decreased membrane fluidity and lower 
respiration control values suggesting increased membrane permeability for protons. 57 
This prooxidant role of CoQ is also utilised by the cell, in the formation of superoxide 
radicals in neutrophiles and lysosomal granules.57 
1.2.6 CoQ AND AGEING 
The antioxidant effect of CoQ is considered important in retarding ageing in view 
of the reported accumulation of free radicals attacking tissues of the elderly. 55 
According to the free radical theory of ageing mitochondria are both the main source 
and target of oxygen free radicals. 55 A decrease in the activity of mitochondrial 
enzymes is suggested to result from somatic DNA mutations induced by oxygen free 
radicals, implying that the level of antioxidants in the cell may be critical to 
preventing or retarding this free radical damage. 55 The incorporation of exogenous 
CoQ in the cell is postulated to limit the propagation of damaging free radicals from 
the cytosol to the mitochondria protecting against free radical damage. 55 
There is also a clear relationship between age and mitochondrial respiratory 
complex deterioration. 59 The age related decline of CoQ is greater than the age 
related decline of many of the other lipids.59 Exercise may minimise the effect of this 
CoQ reduction, and in animal models a regimen of endurance training increased not 
only the concentration of CoQ in heart submitochondrial particles, but also the plasma 
levels of enzymes such as superoxide dismutase which are radical scavengers.59 
1.2.7 CoQ AND DISEASE 
A deficiency of CoQ has been observed in many diseased states, and 
supplementation with exogenous CoQ is suggested to be advantageous for a range of 
disorders from cancer and diabetes to heart disease and neurodegenerative disease. 
The part CoQ may play in these diseases hinges on its antioxidant, and electron carrier 
roles as described above. 
Cardiovascular Disease 
As discussed earlier, m 1972 Littaru and Folkers first documented a CoQ 
deficiency in patients with heart disease. 52 This deficiency could be due to impaired 
biosynthesis of CoQ, or accelerated catabolism, as an increased antioxidant 
commitment of CoQ may lead to accelerated consumption. 59 The basis for the 
therapeutic effects of CoQ may be due to the high levels of aerobic energy production 
in cardiac tissue,56 or action as an antioxidant against the high levels of free radicals 
produced in many forms of cardiovascular disease. 59 In heart disease a deficiency of 
vitamin E leads to peroxidation of many lipids, including CoQ. Supplementation with 
H6COQ4 gave partial replacement of the endogenous pool of CoQ with restoration of 
respiratory chain activity. 59 Disturbance of energy production with consequent energy 
starvation of muscle cells has been proposed as a fmal common pathway in the 
progression of myocardial disease of various etiology. 59 An increase in the LDL:CoQ 
ratio in heart disease patients has been found to be more consistent than the 
corresponding increase in the total cholesterol:HDL cholesterol ratio which is a 
commonly used coronary risk factor. 59 
It was observed as early as 1977 that patients with hypertension exhibited low 
levels of CoQ, and supplementation showed a decrease in blood pressure associated 
with a reduction in peripheral resistance.61 CoQ supplementation has also shown to 
be beneficial to patients suffering from angina53 ,62 or arrhythmias. 
Clinical trials have shown that in patients with congestive heart failure the 
administration of CoQ in conjunction with conventional therapy can reduce the risk of 
hospitalisation by 38%, and reduce the incidence of pulmonary edema by 60%,63 as 
well as improving clinical symptoms in most patients.64 
Cardiomyopathy is a state in which the muscle tissue of the heart has become 
damaged, enlarged or stretched leaving the muscle fibres weakened. This may be 
secondary to nutritional deficiencies, or brought on by longstanding excess alcohol 
consumption or infection, and tends to be associated with a major CoQ deficiency. 53 
Whether CoQ deficiency is the cause or an effect of cardiomyopathy is still unclear. 53 
Again with CoQ supplementation a vast improvement in symptoms, and myocardial 
mitochondrial function was observed in several clinical trials.65,66 
, When pump failure is due to ischemic heart disease, increased radical production 
might exist according to a well studied mechanism linking oxidative damage to 
ischemia-reperfusion,59 Therapeutic uses ofCoQ may also be related to the beneficial 
effects of antioxidants in this clinical syndrome.59 In a rabbit model of ischemia-
reperfusion, pre-treatment with CoQ gave a relative maintenance of tissue ATP and 
ATP generating capacity of the mitochondria together with smaller calcium 
overload.53 ,59 These beneficial effects are similar to those seen with drugs such as 
propanolol (a beta-andrenergic receptor blocking agent) and verapamil (a calcium 
channel blocking drug).53 
There are three sources of free radicals during myocardial ischemia; oxygen, 
neutrophils, and mitochondria. 53 Since skeletal muscle and myocardium are rich in 
myoglobin, the formation of hydrogen peroxide from ischemia-reperfusion may 
trigger myoglobin oxidation leading to ferryl myoglobin and further damage. 59 It has 
been shown that reduced CoQ slows the formation of ferryl myoglobin. 59 Reduced 
CoQ is instrumental in allowing heme to act as a device for removing hydrogen 
peroxide and other peroxides,59 Mitochondria from untreated hearts can be 
transformed into superoxide generating machines via the auto oxidation of 
semiquinone radicals upon exposure to the metabolic conditions of ischemia-
reperfusion.57 CoQ may have the ability to maintain the integrity of myocardial 
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calcium channels and potassium channels during ischemic insults. 53 It may therefore 
activate potassium channels similar to nicorandil, and modulate calcium channels 
resulting in decreased cellular calcium ion concentration and improved cardiac 
integrity during ischemia. 53 CoQ protects ischemic tissue from reperfusion damage 
by antioxidant membrane stabilising properites and free radical scavenging activity. 53 
Periodontal Disease 
Gingival tissue in patients with periodontal disease was shown to have decreased 
CoQ levels. 59 Oral administration of CoQ lead to increased levels of CoQ in affected 
tissues and a decrease in inflammation, while other periodontal assessments also 
showed improvement. 59 
N eurodegenerative Disease 
It is possible that mitochondrial defects play a key role in the pathogenesis of 
neurodegenerative diseases and it has been demonstrated that CoQ administration can 
increase brain mitochondrial concentrations in older animals.67 CoQ is postulated to 
play a neuroprotective role, involving both improved mitochondrial function and 
antioxidant activity, and has efficacy in a number of animal models for 
neurodegenrative diseases.67 In animal studies CoQ can protect against malonate and 
3-nitropropionic acid neurotoxicity, which are models for Huntington's disease, and 
against l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) toxicity which is 
consistent with potential therapeutic effects in Parkinson's patients.67 CoQ has been 
shown to exert a biochemical improvement in Huntington's patients as assessed using 
MRI and is now in clinical trials.67 
Patients with progressive muscular dystrophy also exhibited low CoQ levels and 
clinical trials involving such patients showed improvements in cardiac output in 
addition to increased exercise tolerance, and decreas'ed fatigue.68 
Diabetes 
Diabetes IS a multifactorial disease associated with a number of different 
metabolic abnormalities. As CoQ plays a major role in the electron transport chain, 
which is important in carbohydrate metabolism, a deficiency of CoQ may have an 
adverse effect of glucose tolerance. Mitochondrial dysfunction and oxidative stress 
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have also been shown to participate in the development of diabetic complications, but 
the mechanism of their origin is unclear. 69 
A study involving rats with experimentally induced diabetes showed increased 
levels of lipoperoxidation and decreased mitochondrial levels of CoQ in the heart and 
liver.69 A clinical study involving 39 diabetic patients also showed a consistent fall in 
fasting blood glucose levels and ketone body concentration in those patients receiving 
CoQ when compared with controls.70 
Cancer 
CoQ has been postulated to reduce the cardiotoxicity of certain chemotherapeutic 
drugs. Studies have shown that the cardiac toxicity of doxorubicin (of the 
anthracyclin family of chemotherapeutics), postulated to be due to interference with 
mitochondrial electron transport in heart tissue, is decreased with CoQ 
supplementation in humans.59,7! 
In addition CoQ deficiencies have been noted in patients with varying forms of 
cancer including breast, lung, prostate, pancreatic, and colon cancer.72-74 
Supplementation of a group of breast cancer patients with CoQ plus vitamin C, 
vitamin E, beta carotene, selenium and omega-3 and omega-6 fatty acids in addition 
to chemotherapy showed no increase in metastases, and in 20% of cases partial 
tumour regression.75 
Immune Disorders 
The administration of CoQ or a combination of CoQ and vitamin B6 has been 
shown to boost the immune system and may be useful in the treatment of AIDS and 
other infectious diseases.76 Patients with HN-infection have been shown to have a 
deficiency of CoQ, which became more severe with progression of the disease. 
Exploratory therapy with CoQ showed encouraging, and in some cases striking 
results.77 
1.3 RESEARCH DESCRIBED THIS THESIS 
Due to the varied, and biochemically important, roles of vitamin K a fast and 
efficient method for assaying vitamin K levels in plasma could be applied widely in 
medicine. Several methods for measuring vitamin K by high-performance liquid 
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chromatography (HPLC) have been developed and these will be reviewed in chapter 
2. The methods for the determination of vitamin K in various media published to date 
are labour intensive and used for research purposes only. For this reason the main 
goal of this study was to investigate methods for the precise and efficient assay of 
vitamin K in plasma. Two approaches were taken to this problem, the development of 
a new HPLC based assay for vitamin K (see chapter 2), and early investigations into 
the feasibility of an immunoassay for vitamin K. 
The development of an immunoassay involves the production of monoclonal 
antibodies to a given antigen, in this case vitamin K (see chapter 4). Given that 
vitamin K is lipid soluble, and too small to evoke an immune response in a host 
organism, the first step in this process was attach an analogue of vitamin K to a 
suitable carrier protein (see chapter 3). This in turn required the design and synthesis 
of a series of side-chain functionalised analogues of vitamin K. 
Due to the structural similarities between vitamin K and coenzyme Q, and the 
importance of CoQ in many biological processes, the potential use of an 
immunoassay for CoQ was also identified. Therefore, a series of analogues of 
coenzyme Q were also designed and synthesised (see chapter 5). 
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2.1 INTRODUCTION 
The diverse biochemical roles of vitamin K, and its implication in disease states, has 
led to a large amount of research being devoted to the development of a simple and 
efficient assay for vitamin K in various media including plasma, tissue, foods and mille. 
There are several intrinsic difficulties in the development of such an assay. Vitamin K is 
sensitive to UV light and alkaline conditions, and is present in tissues and plasma at 
levels several-fold lower than the other fat-soluble vitamins. 1 Also measurement and 
isolation of the K vitamins is complicated by coeluting lipophilic material and the 
multiple forms of K that possess biological activity. 1 
Since the mid 1960's many different assay techniques have been applied either to the 
detection of vitamin K directly, or various markers for vitamin K deficiency in biological 
samples. Assays involving biological markers of vitamin K deficiency include; the 
detection of urinary y-carboxyglutamic acid by HPLC, functional blood coagulation 
studies (including prothrombin time), the detection of protein induced by vitamin K 
absence or antagonism (PIVKA-II) - a measure of undercarboxylated prothrombin often 
by immunoassay, and more recently the detection of undercarboxylated osteocalcin as an 
indicator of vitamin K status in bone. 1 
The earliest method used for the determination oflevels of vitamin K activity was the 
chick bioassay developed by Matschiner and Doisy in 1966.2 This was essentially a 
qualitative index which, although used for all early investigations into vitamin K content 
of various foods, lacked precision. 1 As analytical techniques have improved over the last 
35 years so have the methods used for vitamin K determination. Thin-layer 
chromatographl and gas chromatography4 have both been utilised for vitamin K] 
analysis but these methods required large volumes of biological samples and multiple 
chromatographic steps. More recently, a mass spectrometry method combining mass-
selective detection with the benefits of stable isotopes dilution for internal standardisation 
was developed. 5 This method for the quantitative determination of vitamin K1 involves 
the extraction of vitamin K from human plasma and derivatisation to the 
heptafluorobutyryl ester after reduction of one carbonyl group with zinc metal. 5 This 
method allows measurement in small quantities of plasma and has a detection limit of2.0 
pg/ml of plasma (4.4 pM).5 
With the introduction of high performance liquid chromatography (HPLC) a variety 
of different analytical procedures for the determination of vitamin K in various matrices 
have been developed. The fIrst HPLC methods developed in the early 1980's used UV 
detection for the identifIcation and quantitation of vitamin KI.6-9 The fIrst determination 
of vitamin K in human milk: was achieved by Haroon et al in 1982 using a multistep 
chromatographic process.9 Extraction of the sample was followed by adsorption 
chromatography and semi-preparative HPLC to remove the contaminating lipids, before 
analytical HPLC with UV detection.9 Quantitation was achieved by the use of an intemal 
standard, in this case vitamin KI-epoxide.9 This method was successfully used to 
quantify vitamin KI in human milk, cows milk and selected infant formulas, but was 
unable to identify the presence of menaquinones in either human or cows milk.9 
In the same year the fITst report of the use of HPLC for the determination of vitamin 
K levels in human blood was published. 8 Again this was a multidimensional analysis 
involving normal phase chromatography for removal of polar lipids followed by reverse 
phase (RP) analytical HPLC with UV detection.8 This method was able to detect vitamin 
K to levels of 0.5 ng/ml of serum (1.1 nM) with a detection limit of 400-550 pg per 
injection.8 
Another commonly used detection technique for vitamin K assays was electro-
chemical detection, with one of the earliest examples of this being reported by Ikenoya et 
al in 1979. 10 Many early assays using this technique experienced problems with 
increased background currents due to the reduction of interfering compounds such as 
oxygen. I This problem was overcome by Haroon et all I by employing a dual electrode 
system in redox mode, with the quinone being reduced at the fIrst electrode and 
reoxidized at the second 'detector' electrode. This system demonstrated improved 
sensitivity over earlier methods with a detection limit of 100 pg per injection. I I Further 
improvements on this technique, for the determination of sub-normal plasma levels of 
vitamin K in plasma, were later established by Hart et al. 12 This method halved the 
detection limit of previous assays to 50 pg per injection. 
Vitamin Kl itself does not fluoresce but its reduced hydro quinone form is highly 
fluorescent. By exploiting this fact Langenberg and Tjaden13 developed an HPLC system 
using dual electrode reduction for post-column derivatization of vitamin K1, followed by 
fluorescence detection. The sensitivity of this general method was limited by the fact that 
only 40-60% of the quinone injected was reduced to the fluorescent hydro quinone. 14 
During investigations into the use of a zinc packed column as an oxygen scrubber for 
use in the electrofluorimetric system it was observed that zinc metal, in the presence of 
zinc ions, was able to reduce vitamin K to its fluorescent hydro quinone form. 1 With a 
mobile phase of lOmM zinc chloride, sodium acetate, and acetic acid in 2:8 
dichloromethane:methanol, 95% reduction of the injected vitamin K was observed upon 
reaction with metallic zinc. 15 This method had several advantages over previous systems 
as it required only a singe chromatographic step, and utilised smaller volumes of plasma 
(0.5-1 ml).15 Although the lower detection limit for this assay was 50 pg/ml of plasma 
(0.1 nM), the extraction procedure described was complicated, and did not lend itself to 
use in high-throughput routine analysis. This general HPLC system has since been 
adapted for use by many laboratories arid is still used today for the analysis of vitamin Kl 
levels in plasma,IS-17 tissue,16 and food samples,16,18-21 as well as the determination of 
menaquinones17,19 and vitamin K3 (menadione) in various matrices.22 
As well as zinc metal reduction systems, many other methods for the reduction of 
vitamin K to the hydroquinone have been used in conjunction with fluorescence detection 
in assay systems for the K vitamins. Lambert et al developed a method utilising 
temperature-dependent wet-chemical post-column reduction. 23 In this method tetra-
methylammonium octahydridotriborate, present in the mobile phase, reduced vitamin K 
only upon heating in a post-column reaction coil to 80 oC.23 ,24 This process was used to 
measure vitamin Kl levels in serum, and was shown to have a minimum detectable level 
of 50 pg/ml of serum (0.1 nM).23,25 
Photochemical reduction has also been employed for the post-column derivatization 
of vitamin K before fluorescence detection.26 This is a reagent free process in which the 
quinones are photoreduced via hydrogen abstraction from the HPLC mobile phase in a 
post-column photoreactor. 26 Using this method vitamin KI was detected in plant extracts 
without prefractionation.26 
As well as zinc a number of other metal catalysts have been investigated for the 
reduction of vitamin K 'on-line'. M Shino in 1988 published an HPLC assay utilising 
platinum oxide in the presence of hydrogen for the reduction of vitamin K. 27 After an 
investigation of several different possible catalysts MacCrehan et al used 10% platinum 
on alumina, with an alcohol mobile phase, for a similar purpose?8 Finally Usui et al have 
determined vitamin Kl and menaquinone levels in human liver to sUbnanogram levels 
using a platinum black catalyst and alcohol mobile phase, coupled with fluorescence 
detection.29,3o In the methods of MacCrehan and Usui it is the alcohol which, upon 
oxidation by the transition metal catalyst, acts as the reducing agent for the reaction. 
2.2 OXIDATION OF METHANOL BY METAL CATALYSTS 
Based upon the methods of Usui and MacCrehan,28-3o the oxidation of methanol by 
various metal catalysts, under conditions suitable for an HPLC assay, was investigated. 
The oxidation of methanol by a metal catalyst has been extensively studied due to its 
application in combustion engines. Several different metal catalysts have been 
investigated, including platinum, palladium, silver, and metal oxides. 31-37 The kinetics 
and mechanism of this reaction have been studied, usually in the gas phase at raised 
temperatures and pressures.32,33,35,38,39 Oxidation of methanol vapour over platinum has 
been shown to occur via two parallel mechanisms, one inhibited by oxygen and one 
which is not. The uninhibited reaction is thought to involve the breaking of a metal-
oxygen bond as the rate-determining step.32 The dehydrogenation of surface adsorbed 
methanol on pure platinum was shown to be energetically favourable by Ishikawa et ai, 
with the fIrst step in this process being the removal of a hydrogen atom from the methyl 
groUp.40 
In the case of silver all studies have been carried out at high reaction temperatures 
(900 K), and it was found that under these conditions the silver surface is restructured and 
a tightly held oxygen species is formed on the surface. Boa et al showed that it is this 
oxygen species which is subsequently involved in the oxidation of methanol to 
formaldehyde.35 The use of copper oxide catalysts is thought to proceed via a mechanism 
in which the oxidation of adsorbed surface structures, formed upon interaction between 
methanol and the catalyst surface, is the rate-determining step.39 
The combination of methanol and a metal catalyst has also been used as a reduction 
system for the many different compounds including quinones, and nitro derivatives of 
polynuclear aromatic hydrocarbons (nitro-P AH). Tejada et atl used a column of alumina 
coated with platinum and rhodium, in combination with a methanol/water mobile phase 
to reduce nitro-PAR to primary aromatic amines. This process was shown to be catalytic 
with no consumption of the platinum/rhodium surface, and required no modifiers in the 
mobile phase. Usui et al have used a similar system for the reduction of vitamin K. 30 In 
this system the methanol is oxidised by the metal catalyst, at the same time acting as a 
reducing agent for vitamin K. 
2.2.1 EFFECTIVENESS OF METAL CATALYSTS 
The first step of our research involved an investigation of the relative effectiveness of 
various methanol/metal catalyst systems towards the reduction of quinones using vitamin 
K. In total eight different metal catalysts were investigated, including five different 
forms of platinum, silver powder, copper (I) oxide, and palladium black. Each catalyst 
was packed into a 20 mm x 2 mm refillable guard column and flushed with methanol at a 
flow rate of 0.5 ml/min for at least 1 hour. It must be noted that caution is required in the 
packing of the platinum reactors as methanol is readily ignited by air in the presence of 
platinum. A sample of 0.5 11M standard solution of vitamin Kl was injected into a flow 
of 0.1 ml/min methanol. This was passed directly through the metal catalyst packed 
guard column to the fluorescence detector with excitation wavelength of 249 nm and 
emission wavelength of 408 nm. The 'peak' obtained plateaued at maximum 
fluorescence due to the slow flow rate, and this height was used to determine the level of 
reduction of vitamin Kl by each catalyst system. The results of this experiment are given 
in table 2.1. When using fluorescence detection, the exact fluorescent response is an 
arbitrary response individual to a given detector, so it is invalid to compare exact values 
with any literature results. These values may, however, be used to calculate relative 
results for the different metal catalysts, which will be constant between different 
detectors. 
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Reduction Catalyst Fluorescence % Fluorescence 
Platinum black 580 100 
Platinum black (new) 475 82 
Platinum powder (0.27-0.47 micron) 495 85 
Platinum powder (0.5-1.2 micron) 355 61 
Platinum on carbon 0 0 
Platinum on alumina 290 50 
Silver powder 10 2 
Copper (I) oxide 5 1 
Palladium black 15 3 
None 0 0 
Table 2.1: Reduction efficiency of various catalysts, absolute fluorescence observed and relative 
efficiency upon comparison with reference column (platinum black) 
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From these results it can be seen that the platinum compounds had superior reducing 
efficiency when compared to the other metal catalysts tested. The only exception to this 
was platinum on carbon, which showed no reduction activity. In this case it is postulated 
that the vitamin K is adsorbed onto the porous carbon surface. Analysis of 10% 
platinum on carbon by MacCrehan et al. gave the same result in a similar study.28 In 
their study, which compared the reducing efficiencies of 5% platinum on alumina, 5% 
rhodium on alumina, 5% palladium on carbon, 10% platinum on carbon, platinum (IV) 
oxide, and 10% platinum on alumina, MacCrehan found that 10% platinum on alumina 
was the most efficient reduction catalyst.28 We have shown above that both platinum 
black and platinum powder can out-perform 10% platinum on alumina in the reduction of 
vitamin K with methanol. 
Palladium is another transition metal that has been used in the catalysis of methanol 
oxidation, and hence was expected to effect the reduction of vitamin Kl. Upon testing, 
however, palladium black gave a much lower fluorescent response than the platinum 
compounds and was not used in further investigations. It was shown by Ionescu et al that 
the oxidation of methanol on palladium catalysts displays oscillating behaviour possibly 
due to the limited range of methanol concentrations on the catalyst surface leading to a 
critical concentration of active species being obtained.34 This effect may explain the low 
reduction of vitamin K by palladium black/methanol system, if critical concentrations of 
these active species were unable to be attained. 
The failure of silver powder to effect any oxidation of methanol under the conditions 
studied can be explained, as silver catalysts have previously been used for methanol 
oxidation at high temperature, and have not been used for room temperature studies.35 
Similarly, copper oxide catalysts have previously been studied at temperatures of 150~ 
270°C and not at room temperature, explaining the low reduction of vitamin K 
observed. 39 
Although platinum black showed the most efficient reduction of vitamin K to the 
hydroquinone, results were inconsistent for some packings. In one instance the guard 
column had been cleaned with nitric acid, washed with water and methanol, and dried 
prior to packing with platinum black. This column gave consistently low fluorescence 
results and it is postulated that trace amounts of nitrates from the washing may interfere 
with the platinum black surface hindering methanol oxidation. 
As well as giving a high fluorescent response the platinum black system does not lose 
reduction efficiency over time. The zinc metal reduction system used in many 
laboratories requires repacking of the zinc filled catalyst column after approximately four 
hours of use. However, upon exposure to an alcohol mobile phase, the lifetime of the 
platinum black catalyst appears indefinite. 
In a study of platinum black from various different suppliers (Aldrich, Merck and 
Acros), we have shown that consistent results are observed after thorough washing with 
methanol. The absolute fluorescence results obtained varied by only 5%, so catalyst 
source does not appear to be important (see table 2.2). 
• Supplier Fluorescence i 
I Aldrich 500 
! Acros 470 
• 
• Merck 470 
I 
Table 2.2: Comparison of platinum black sourced from different suppliers 
The results of this study confrrm the findings of MacCrehan et aP8 and expand on 
these. It has been shown that platinum catalysts are the most efficient for use in the 
described reduction system, with platinum black and platinum powder both producing 
high levels of fluorescence with vitamin K As platinum black showed the greatest 
reduction of vitamin K this was used in all further investigations. Platinum black sourced 
from three different commercial suppliers showed little variation (5%) in fluorescent 
response, implying that the source of this catalyst is not important. 
2.2.2 EFFICIENCY OF METAL CATALYST COLUMN 
As the efficiency of freshly packed platinum black catalyst columns was found to 
vary on occasion, the efficiency of each catalytic column was tested before use. The first 
platinum black column used, which produced the greatest fluorescent response with 
vitamin K, was used as a reference column for the testing of all other catalytic columns. 
Upon placing another catalytic .column. in series with this reference column, no increase 
in fluorescent response was observed. As this was a consistently reproducible 
observation it was postulated that the reference column was acting at 95-100% reduction 
efficiency. The reduction efficiency of any given catalytic column was tested by either of 
the following methods. 
METHOD 1 
A sample of a 0.5 J-tM standard vitamin Kl solution was injected into a mobile phase of 
100% methanol with a flow rate of 0.5 mllmin. This was passed directly through the 
catalytic column being tested, and onto a RP HPLC column for separation of the resulting 
quinone and hydro quinone. The reference column was positioned between the HPLC 
column and fluorescence detector. The reference catalytic column was necessary to 
afford reduction of any quinone not reduced by the test column. The ratio of peak area of 
the hydroquinone (retention time 6.0 min) to the total peak area of hydroquinone and 
quinone (retention time 21.3 min), was calculated as the reduction efficiency of the 
catalytic column. 
METHOD 2 
Alternatively, a sample of a 0.5 JlM standard vitamin Kl solution was injected directly 
into a RP HPLC column and through the catalytic column of interest, before detection via 
fluorescence. This process was then repeated after exchanging the test catalytic column 
for the reference column. The ratio of the peak areas for these two runs was then used to 
determine the reduction efficiency of the test column. 
Both of these methods were used on any given catalytic column and the results 
compared. An example of the results obtained is outlined below in table 2.3. The 
reduction efficiencies for the test column in this case are 27% by method 1 and 34% by 
method 2. 
Method Column Peak area I 
1 Test 62.4 
Test + Reference 230.0 
2 Test 86.2 
Reference 250.0 
Table 2.3: Results for reduction efficiency of test column by two methods 
When a freshly packed catalytic column was found to have a reduction efficiency of 
less than 80% after thorough washing with methanol, attempts were made to increase the 
catalytic activity. This was done via washing with an ethanolic solution of sodium 
borohydride. A mobile phase of 100% methanol was pumped directly through the 
catalytic column at a flow rate of 0.1 mllmin. Successive injections of 400 JlL of the 
ethanolic sodium borohydride solution were then injected into the mobile phase at 3-
minute intervals. This process was repeated until a total of two to three millilitres of 
sodium borohydride solution had passed through the catalytic column, and was followed 
by thorough washing with 100% methanol. Upon retesting the reduction efficiency of a 
treated column by method 2 (above), increased reduction efficiency was initially 
observed. However, over time, and with continued use, the efficiency of treated catalytic 
columns slowly decreased, until fmally returning to the pre-treatment level. From this 
result it appears that a second reduction mechanism was taking place after treatment, 
which was responsible for the observed transient increase in reduction efficiency. It is 
postulated that an 'activated hydrogen species', originating from the borohydride wash, is 
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co-ordinating to the surface of the platinum black in the catalytic column. It is this 
'activated hydrogen species' that is then responsible for the increased reduction of 
vitamin K to its hydro quinone form. This theory is supported by experiments carried out 
involving acid washing of the treated columns. When a borohydride treated column was 
washed with a 0.5% aqueous solution of trifluoroacetic acid following borohydride 
treatment, no significant increase in reduction efficiency was observed. This could be 
due to the removal of such an 'activated hydrogen species' from the catalytic column 
during the acid wash. A control experiment carried out by washing a catalytic column 
with only trifluoroacetic acid showed that this process itself, when followed by thorough 
washing with methanol, had no effect on the efficiency of reduction. 
Two simple methods to test the efficiency of a specific catalytic column have been 
developed, and shown to give comparable results. Attempts to increase the efficiency of 
platinum reactors that were showing below 80% reduction on comparison with a 
reference column gave only a transient increase. However, conditions leading to possible 
loss of activity, e.g. exposure to nitrates, have been identified. 
2.2.3 GENERALITY OF REDUCTION SYSTEM FOR VARIOUS QUINONES 
This study aimed to establish the range of quinones that were effectively reduced by 
the methanol/platinum black system developed above. The extent of reduction was 
established by the level of increase in fluorescence of a standard quinone solution upon 
treatment with the reducing system, assuming the resulting hydroquinone form is more 
fluorescent than the quinone itself. Standard solutions of each of the quinones for this 
investigation (see figure 2.1), were prepared in ethanol at a concentration of 0.5 11M. 
This was injected into a mobile phase of methanol at 0.1 ml/min. The quinone was then 
passed through a platinum black catalyst column and the fluorescent response recorded 
(c.f. method used for assessment of metal catalysts). During the time period of maximum 
fluorescent response a scan was run over a series of wavelengths in order to determine 
either the optimum excitation or emission wavelength for each quinone (see figure 2.2). 
Once these optimum values were established, each quinone was then retested at these 
optimal wavelengths to determine the level of reduction by the platinum black column. A 
control experiment run in the absence of any catalyst column was carried out for each 
quinone to detect any native fluorescence. Any increase in peak height between the 
optimal wavelength run and the control experiment was interpreted as an indication of the 
level of reduction of each quinone. 
o 
or) 
o 
VitaminK j 
~OH ~ 
o 
l,4-Naphthoquinone 2-Hydroxy-l,4-Naphthoquinone 
0 
¢ 
0 
Benzoquinone 
MeO 
MeO 
OH 
¢ 
OH 
Hydroquinone 
0 
0 
Coenzyme Q-l 0 
6¢0 
o 
1,8-Dihydroxyanthraquinone 
9 
Figure 2.1: Range of quinones investigated in this study 
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Figure 2.2: HPLC trace showing the scan over excitation wavelengths 200-320 nm, performed during 
fluorescence of 2-hydroxy-1 A-naphthoquinone. 
The results obtained from this study are outlined in table 2.4. It can be seen that not 
all of the Quinones tested were reduced by the platinum black/methanol system. The K 
vitamins, 1,4-naphthoquinone and 2-hydroxy-l,4-naphthoquinone were all reduced to a 
more fluorescent form , as shown by the large increase in fluorescence observed in the 
presence of the platinum catalyst. interestingly 5-hydroxy-I ,4-naphthoquinone shows 
only a modest increase in fluorescence, which implies that the position of the hydroxyl 
group can have a significant effect on the reduction potential of these compounds. The 
benzoquinones, 2,3-dimethoxy-5-methylbenzoquinone (CoQ-O) and coenzyme Q-IO, 
showed a slight increase in observed fluorescence in the presence of platinum black, 
although not as large as in the case of the K vitamins. 
The three-ring anthraquinone system showed a similar level of increase in 
fluorescence in the presence of platinum black to the benzoquinones, but 1,8-
dihydroxyanthraquinone exhibited no detectable increase in fluorescence. 9, I 0-
15.0 
Phenanthraquinone was, however, efficiently reduced as shown by the large increase in 
fluorescence observed in the presence of platinum black. This increase was of the same 
order of magnitude as observed for the naphthoquinones. 
Hydroquinone was run as a control experiment, as in this case the quinone is already 
in the reduced form before introduction into the system. The levels of fluorescence in the 
presence and absence of the platinum catalyst were the same, as expected. This control 
experiment is useful in ruling out the possibility that the reduction system produces any 
by-products, which may quench fluorescence. 
Peak height ! Peak height in I Aex 
Quinone without Pt black presence of Pt black (nm) 
(mV) (mV) 
Vitamin Kl 0 426 249 
VitaminK3 17 162 240 
I 
1 A-N aphthoquinone 4 164 242 
2-Hydroxy-l A-Naphthoquinone 9 250 242 
5-Hydroxy-l A-Naphthoquinone 9 27 309 
Benzoquinone 7 11 278 
Hydroquinone 37 39 278 
2,3-Dimethoxy-5-Methyl- 49 63 284 
benzoquinone 
Coenzyme Q-I0 6 21 274 
Anthraquinone 10 34 # 
1,8-Dihydroxyanthraquinone 5 5 * 
9,10-Phenanthraquinone 5 295 253 
Table 2.4: Reduction of quinones to fluorescent hydroquiones with platinum black and methanol. 
* Wavelength data not obtained as no reduction occured. # Wavelength data not obtained. 
This investigation has shown that the methanoVplatinum black reduction system is 
able to reduce a variety of different quinones, including selected benzo-, naphtho-, and 
anthraquinones. The ability of this system to reduce quinones of biochemical 
Aem 
(nm) 
408 
428 
418 
436 
359 
325 
325 
310 
297 
# 
* 
424 
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importance, e.g. vitamin K and coenzyme Q, suggests that it may be used to establish an 
HPLC based assay system for these compounds. 
2.2.4 EFFECT OF SOL VENT ON REDUCTION SYSTEM 
Having established the effectiveness of the platinum black/methanol reduction system 
for an assay of various quinones, the effect of the addition of co-solvents and buffers to 
the mobile phase was investigated. Ideal assay conditions would exhibit a short retention 
time and high fluorescence. In practise, however, a compromise between these factors 
must be reached, while achieving separation of all components of a sample mixture. 
Using a reverse-phase analytical HPLC column and platinum black catalytic column, 
the effect of a variety of different solvents on the reduction system was assessed. Any 
changes in the retention time and peak area of a vitamin K standard were recorded. A 
flow rate of 0.5 ml/min was used throughout this study, and the system was equilibrated 
for at least 30 minutes with each mobile phase before testing. 
It was shown initially that the presence of an alcohol in the mobile phase was 
necessary for reduction to occur, as the absence of an alcohol gave no peak for a vitamin 
K standard solution. A series of different alcohol mobile phases were investigated. The 
order of reducing ability for these alcohols, i.e. how readily they were oxidised by 
platinum black, was methanol>ethanol>isopropyl alcohol>butanol>ethanedioL Taking 
this into account an investigation of various mixed alcohol mobile phases followed. 
By increasing the proportion of ethanol in a methanol mobile phase the retention time 
of vitamin KJ was found to decrease, but the observed peak area also decreased. The 
addition of up to 10% isopropyl alcohol to a methanol mobile phase had the effect of 
decreasing the retention time with no significant effect on the peak area observed (see 
figure 2.3). The addition of greater proportions of isopropyl alcohol showed a further 
decrease in retention time, but also led to an increase in operating pressure of the HPLC 
system. Adding up to 10% heptane to a methanol mobile phase gave an increase in the 
peak area with decreased retention time. However, this is at the limit of miscibility of 
these two solvents, which in some instances led to the development of two phases within 
the HPLC system. 
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Figure 2.3: HPLC traces of standard vitamin K solutions with mobile phase of 100% methanol and 10% 
IPA in methanol 
The inclusion of trace amounts of water (2%) in a methanol mobile phase gave a 
significant increase in retention time, with the vitamin KI peak moving from 2l.0 minutes 
to 38 minutes. The same results were observed with a mobile phase of 2% aqueous 
acetate or citrate buffer (concentration 2mM) in methanol (see figure 2.4). This result 
implied that any change in the retention time and peak area of vitamin KI was due to the 
presence of water and not the buffer ions. This was verified by preparing a 2 mM acetate 
buffer in methanol, so no water was present in the mobile phase (see figure 2.5). The 
HPLC chromatogram obtained in the presence of the electrolytes was identical to that 
observed for a 100% methanol mobile phase showing no advantage in the inclusion of a 
buffer in the mobile phase. 
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Figure 2.4: HPLC traces of a standard vitamin K solution with three mobile phases; 100% methanol, 
2mM aqueous citrate buffer in methanol, and 2mM aqueous acetate buffer in methanol 
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Figure 2.5: HPLC traces of standard vitamin K solution with 100% methanol a 2mM acetate buffer 
prepared in methanol. 
Addition of some solvents to the mobile phase led to a decrease in the efficiency of 
the platinum black column. The study of an acetonitrile/methanol mobile phase showed 
that retention time increased with the amount of acetonitrile added and the peak area was 
at a maximum with a 50% acetonitrile/methanol solution. It was observed, however, that 
acetonitrile slowly poisoned the platinum black catalyst, although this could be reversed 
with thorough washing with 100% methanol. The investigation of a 
tetrahydrofuranlmethanol mobile phase gave decreased retention time and peak area with 
an increasing proportion of THF. Again a slow poisoning of the platinum black catalyst 
was observed in the presence of THF, and this poisoning was reversible with extensive 
washing with 100% methanol. The poisoning effects of acetonitrile and THF have 
previously been documented by MacCrehan et at in their investigation of a catalytic 
reduction system using 10% platinum on alumina, however in this case presence of these 
solvents was also shown to completely prevent reduction.28 When dichloromethane was 
added to the mobile phase the platinum black column was irreversibly poisoned. It is 
postulated that the dichloromethane altered the surface of the platinum black, no longer 
allowing methanol oxidation to occur. 
The most efficient solvent for reduction of quinones, as observed in this study, was 
100% methanol, with the use of mixed alcohol mobile phases available to alter the 
retention time of the quinone on the RP HPLC column. The addition of water, or an 
aqueous buffer, to the mobile phase gave a vast increase in retention time, while adding 
acetonitrile, THF or dichloromethane was found to have a detrimental effect on the 
catalytic column. Given these results, 100% methanol was used as the mobile phase in 
all further investigations. 
4.2.5 LINEARITY OF FLUORESCENCE 
In order to quantify vitamin K levels in any gIVen sample, the behaviour of 
fluorescence over a given concentration range must be known. A series of standard 
solutions of vitamin Kl were prepared in ethanol to give the following concentrations; 
0.25 I-LM, 0.5 I-LM, 0.75 I-LM, and I I-LM. A sample of each standard solution was injected 
into a mobile phase of 100% methanol at a flow rate of 0.5 mllmin. This was passed 
through a RP analytical column and reduced by the platinum black/methanol system 
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before detection via fluorescence. The peak area observed for each standard solution was 
recorded. Each of the four standard solutions were prepared and tested on four separate 
occasions to assess the reproducibility of the data obtained. Figure 2.6 summarises the 
results obtained, and shows that the relationship between concentration and peak area is 
linear over the concentration range used. Therefore, the addition of standard 
concentrations to each assay run would allow the establishment of a calibration curve for 
that run, and quantitation of vitamin K levels in test samples from measured peak areas. 
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Figure 2.6: Calibration curve of standard solutions of vitamin K 
2.3 DEVELOPMENT OF ANHPLC ASSAY FOR VITAMIN 
Having investigated many aspects of the methanol/platinum black reduction system, 
this knowledge was then used for assay development. The focus of this study was the 
development of an HPLC assay for vitamin K levels in plasma, but this could also be 
applied to other biologically important quinones e.g. coenzyme Q. It was shown earlier 
(see 4.2.3) that coenzyme Q was reduced by the platinum black/methanol system, 
although the increase in fluorescence was not as great as that seen for the K vitamins. It 
must be noted, however, that coenzyme Q is present in plasma at levels of approximately 
I ""M, which is several fold greater than the corresponding concentrations of vitamin K 
(0.4-1.5 nM). Due to the higher intrinsic levels of coenzyme Q in plasma, less sensitivity 
is required for accurate determination and quantitation. 
The HPLC system used for the development of vitamin K assay consisted of a RP 
column, platinum black catalytic column and fluorescence detector (see figure 2.7). The 
mobile phase used was 100% methanol and the wavelengths for detection were excitation 
249 nm and emission 408 nm. The sample extraction used for initial investigations was a 
standard procedure used for the extraction of other fat-soluble vitamins. This consisted 
of taking a plasma sample and adding an equal volume of ethanol to precipitate the 
proteins. To this hexane was added and the sample vortexed to extract the vitamin K into 
the organic phase. The hexane phase was removed, dried under a stream of nitrogen, and 
reconstituted into methanol. A sample of 50""L of this preparation was injected into the 
HPLC system described above and the chromatogram observed is shown in figure 2.8. 
Two major peaks were observed one with a retention time of 11.7 minutes and the 
expected peak corresponding to vitamin KI at a retention time of 21 minutes. It may be 
noted that these retention times may be decreased if necessary by the addition of 
isopropyl alcohol to the mobile phase. 
Upon testing of other plasma samples the peak at 11.7 minutes was always observed, 
and the identity of this peak was of interest as it was well separated from contaminating 
lipids. A standard solution ofMK-4 was prepared in ethanol at a concentration of 11 nM 
and run through the HPLC system. This was shown to have a retention time 
corresponding to the unknown peak: observed in plasma preparations. This is of 
importance as this assay once validated may be used to simultaneously measure vitamin 
KI and MK-4levels in plasma samples. Several groups have noted the presence ofMK-4 
in plasma samples, but as yet the biological function of this vitamer is unknown. 
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Figure 2.7: Schematic of HPLC system used for assay development. 
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Figure 2.8: HPLC chromatograms of a vitamin Kl st,mdard (red), a solution of K2 and vitamin K, 
(green), and a pooled plasma sample (blue) . 
2.3.1 RECOVERIES 
A series of spiked plasma samples were prepared by the addition of vitamin KJ to 
pooled plasma, to give final concentrations of 5 nM, 10 nM, 20 nM, and 50 nM. Using 
the sample preparation described above the unspiked and 20 nM spiked plasma samples 
were prepared in duplicate. The results obtained from this experiment showed the 
presence of vitamin KJ in the unspiked plasma, and a strong fluorescence at 21 minutes in 
the 20 nM spiked plasma. To obtain a calibration curve and calculate the recovery of 
vitamin K from these spilced plasma samples this process was repeated with the five 
plasma samples each extracted in quadruplicate. Also run were standard solutions of 
vitamin K in methanol at concentrations of 10 nM and 50 nM. Results from this study 
were inconclusive. The peale areas obtained for the 20 nM spiked plasma were much 
smaller in this case, and no vitamin Kl was detectable in the unspilced plasma. Variation 
was also obtained across the duplicate runs of each plasma concentration. To determine 
whether the plasma samples had deteriorated or the sample preparation varied, the 20 nM 
spiked plasma sample was reextracted and tested. The results obtained were comparable 
with the original fmdings, which implied the sample preparation was the cause of these 
inconsistencies. There are several possible reasons for this including variation in the 
extraction of vitamin K into the hexane phase and incomplete reconstitution of the 
vitamin K into methanol before injection. The reconstitution step is problematic as 
vitamin K is only slightly soluble in methanol, but other solvents are not compatible with 
the HPLC mobile phase. Possible solutions to this may include the addition of a small 
amount of a detergent to the reconstitution mixture or sonication to ensure all vitamin K 
is dissolved. The systematic development of a new sample preparation is an involved 
process, which falls beyond the scope of this project. 
This study has investigated several aspects of the methanol/metal catalyst reduction 
system, as it may be applied to an HPLC assay system for several different quinones. 
This included an investigation of several different metal catalysts, and the effects of 
various mobile phases on the reduction process. For the purpose of this thesis we were 
particularly interested in the development of an assay for vitamin K and this was further 
studied. An assay system for the K vitamins, using post-column reduction with platinum 
black and methanol has been developed. This method has several advantages over the 
commonly used zinc metal reduction HPLC assay for vitamin K. The platinum black 
reactor lasts indefmitely removing the need for repacking of the catalyst column between 
each assay run, and the simple solvent system developed removes the need for zinc ions 
in the mobile phase, which can precipitate out within the HPLC system. The methanol 
mobile phase has been shown to effectively separate vitamin K from contaminating lipids 
in plasma samples. Studies have shown that the addition of isopropyl alcohol to the 
mobile phase could be used to slightly reduce the retention times of components, thereby 
shortening the run time of the experiment. The HPLC assay method presented here is 
similar to that described by Usui et apo but the need for semi-preparative chromatography 
of plasma samples prior to analysis, to remove lipophilic contaminants has been removed. 
Upon the establishment of a consistent sample preparation method, this assay will be 
validated for routine use on patient samples. 
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CHAPTER THREE 
SYNTHESIS OF VITAMIN K 
ANALOGUES 
3.1 INTRODUCTION 
In addition to the development of a new HPLC assay for vitamin K, we were 
interested in investigating the feasibility of an immunoassay for vitamin K. The 
production of an enzyme-linked immunosorbent assay (ELISA) hinges on the 
successful preparation of monoclonal antibodies to the antigen of interest, in our case 
vitamin K (see chapter 4 for details). The first step in the production of antibodies is 
the inoculation of a host animal with a suitable analogue of vitamin K to act as an 
antigen (i.e. a foreign body which will evoke an immune response in the host). There 
are several factors that increase the chance of a strong immunogenic response in the 
test animal, and these include greater phyllogenetic distance between the antigen and 
recipient, increased size of the antigen, repeating units within the molecule or 
aggregates of a molecule, and the use of adjuvents. 1 As vitamin K itself is a small 
molecule, which is naturally occurring in all mammals it cannot be used directly as 
the antigen for inoculation. Instead it is necessary to conjugate vitamin K to a carrier 
protein which will increase it's size, immunogenicity, and solubility in aqueous 
media. 
H2N protein 
Analogue j Carrier protein 
o 
protein 
Analogue-protein conjugate (Antigen) 
Figure 3.1: Schematic of conjugation of vitamin K analo gue to carrier protein 
To conjugate vitamin K to a carrier protein several analogues were designed, 
which contained a carboxylic acid moiety at the terminus of the isoprene side chain, 
while leaving the naphthoquinone head group unaltered. This approach was taken as 
the naphthoquinone ring is present in all forms of the vitamin and therefore, is the best 
point for antibody recognition. A carboxylic acid functionality was chosen to allow 
conjugation to the carrier protein via an amide bond to the amino group of the side 
chain of lysine residues on the surface of the carrier protein (see figure 3.1). It is 
common, when conjugating a small molecule to a large protein, to use a 'linker' 
moiety between the small molecule and protein. This acts both as a spacer between 
the two components, so the small molecule protrudes from the surface of the protein 
and, as a convenient way of introducing the functionality required for conjugation. 
There are two possible approaches to the preparation of side-chain functionalised 
vitamin K analogues, the coupling of a core molecule to a functionalised side chain, 
or the synthesis of a polyprenyl K analogue followed by side chain functionalisation. 
This second approach calls for the investigation not only of previous syntheses of 
side-chain functionalised vitamin K analogues, but also of the synthesis of polyprenyl 
quinones in general. Discussed below are the previous synthetic approaches to 
vitamin K and side-chain functionalised vitamin K analogues. This is followed by a 
discussion of the synthesis of the target analogues shown in figure 3.2. 
o 
o 
O~OH 
o 
Figure 3.2: Target vitamin K analogues (n=l or 3) 
3.2 SYNTHESIS OF VITAMIN K 
o 
O~OH 
o 
The first reported syntheses of vitamin Kl came independently from the 
laboratories of Fieser2, Binkley et aP and Almquist and Klose4 in 1939 by condensing 
2-methyl-l,4-naphthohydroquinone or menadione (vitamin K3) and natural phytol in 
the presence of oxalic acid, and zinc dust in acetic acid, respectively (scheme 3.1). 
o 
~ 
o 
3.2 
Scheme 3.1 
HO 
3.3 
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Although this gave the desired compound, yields were low and product purification 
was difficult. The major problems with this approach were chromanol formation 
(cyclic isomers of the corresponding hydroquinones), and the lack of control over the 
stereochemistry at the /12 position of the polyprenyl side-chain, with the production of 
both the cis and trans isomers. 
Since the early 1970 's there has been increased interest in novel and efficient 
syntheses of vitamin K and related compounds, as the varied biological roles of the 
vitamins became apparent (see chapter 1). Most of these syntheses consist of the 
preparation of a protected core followed by the coupling of the desired side chain, and 
deprotection. There have been several syntheses of the varying protected core 
molecules for vitamin K with the choice mainly influenced by the deprotection 
procedure and the chemistry involved in the remainder of the synthetic pathway. 
Some of the more popular choices are 1,4-dimethoxynaphthalene, 1,4-
diacetoxynaphthalene and quinone bisketals which can be deprotected by oxidation, 
or exposure to basic and acidic conditions respectively. 
The key step in the synthesis of polyprenyl vitamin K analogues is the coupling 
of the isoprene side chain to the quinone nucleus. In early reports2-4 this was carried 
out via Friedel-Crafts alkylation where the stereochemistry of the /12 position of the 
side chain was of great interest. The desired product was that which possessed the all-
trans configuration as this was shown to have higher physiological activity than the 
corresponding cis isomer. Under conventional Friedel-Crafts conditions the coupling 
of natural trans-phytol yielded, after oxidation, a quinone mixture containing 
approximately 90% trans-phylloquinone. An improvement on this method by 
Lindlar5 using menadiol I-benzoate as a starting material and BF 3 etherate as the 
catalyst gave complete retention of stereochemistry of the side chain. This process 
avoids chromanol cyclization, and has been optimised to avoid 2-alkylation, but 
remains limited by the inherent instability of the allylic alcohol to the acidic 
conditions used.6 
The coupling procedures used have advanced greatly since the introduction of 
transition metals into organic chemistry. The first reported use of transition metals in 
the synthesis of vitamin K was that of Sato et az7 in 1973 who utilised allyl nickel 
complexes. The treatment of a trans-phytylnickel complex (3.5) with 2-bromo-3-
methyl-I,4-diacetoxynaphthalene (3.4) afforded 3.6, which after deprotection and 
silica chromatography, gave a mixture of the cis- and trans- vitamin KJ (scheme 3.2). 
The ratio of these products was found to vary greatly with the solvent used and the 
best results were obtained when the reaction was carried out in N-methylpyrrolidone 
where vitamin KJ was synthesised in 75% yield with a cis:trans ratio of 20:80. The 
synthesis of vitamin K2 via an analogous route gave an 85% yield and 30:70 cis:trans 
ratio. The proportion of all-trans product was increased by low temperature 
recrystallisation but still only a 13:87 mixture was obtained. 
~+ VYBr 
OAc 
OAc 
3.4 3.5 3.6 
Scheme 3.2 
Just a year later Snyder and Rappaport reported the synthesis of a series of 
menaquinones via the formation ofa 2-metallo-3-methyl-l,4-dimethoxynaphthalene 
and reaction of this with a suitable aldehyde or alkyl halide. 8 This approach varies 
from all earlier reports in that it is the naphthalene portion that is activated as a 
nuc1eophile in relation to the functionalised side chain. A series of different 
metallonaphthalenes (see figure 3.3), and coupling conditions, were investigated with 
Gringard coupling conditions proving the most reliable and giving good retention of 
trans stereochemistry (98-99%). Gringard coupling with allylic halides followed by 
oxidative deprotection to the quinone gave an 80% yield of MK-2 from geranyl 
bromide, and 73% overall yield of MK-9 from solanesyl bromide, with 2-bromo-3-
methyl-l,4-dimethoxynaphthalene as a contaminating by-product. 
c¢c.-...:::: ~e M =Li ~ ~ M (CuLih/2 
MgBr 
OMe cu 
Figure 3.3: Metallonaphthalenes utilised by Snyder and Rappaport in the synthesis ofMK's 
In 1976 Evans and Hoffman published a method for regiospecific isoprenylation 
of benzo- and naphthoquinones (scheme 3.3).9 Cyanide-catalysed addition of 
trimethylsilyl cyanide (TMSCN) to 2-methoxy-l,4-naphthoquinone gave the 
protected quinone 3.7. In situ Gringard addition of prenyl bromide to the protected 
quinone afforded the protected product 3.9, via 1,2-carbonyl addition followed by 
Cope rearrangement. Deprotection of the quinone with AgF gave MK-l (3.10) in 
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71 % overall yield. 
~TMSO C.N ~ OMe I I + A Me 
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Scheme 3.3 
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Various other conditions have also been used in the preparation of short side-
chain K analogues including the use of ~-cyclodextrin catalysis by Tabushi et al. 10 in 
1979. This procedure was carried out in phosphate buffer containing 30% methanol, 
in the dark under an argon or nitrogen atmosphere, and was found to be very oxygen 
sensitive. After 9 hour reaction time yields ranged from 40·60%, with cyclodextrin 
thought to act as a ligase and/or oxygenase, i.e. a 'vitamin K synthase', in the reaction. 
Chenard et al. 11 in 1980 again opted for activation of the quinone core in their 
report of a synthesis of the menaquinones and phylloquinone. Reaction of lithium 
organocuprates of quinone bisketals with allyl halides gave good stereo selectivity at 
2 
the t:. position and yields in the order of 90-95% based on halide. The cuprate 
fOlmed in this reaction took the form R2 CuLi, and its reactivity towards coupling was 
found to be dependant on the nature of coupling substrate. This cuprate addition was 
found to be very versatile in the synthesis of this type of compound. 11 More than one 
R group was transferred when reaction was carried out with allyl bromide, while with 
benzoyl chloride and cyclohexylcarboxylic acid chloride one R group was transferred 
efficiently. Benzyl bromide was found to give good yields of the coupled product 
with one R group transferred, while methylbromoacetate afforded only low yields of a 
product which was difficult to purify. I I 
The same cuprate chemistry was also employed by Syper et al. who synthesised 
MK-I and MK-2 from the reaction of 2-bromo-3-methyl-1 ,4-dimethoxynaphthalene 
with prenyl bromide and geranyl bromide respectively.12 These coupling reactions 
proceeded in 68% and 78% yields, and were followed by oxidative deprotection ofthe 
quinone to give the K vitamins. 
Maruyama et al. J3 in 1989 utilised allylstannanes to produce a series of benzo-
and naphthoquinones photochemically. The reaction of menadione with 
allyltributylstannane in benzene or acetonitrile, with 315 nm light for 3 hours gave a 
mixture of products including 2-allyl-3-methyl-I,4-naphthoquinone in 15-40% yield. 
Purification was achieved by recrystallisation where possible. One advantage over 
earlier syntheses was that no Lewis acid was required, as this was a thermal allylation. 
The use of lead bromide/aluminium powder as a catalyst for the prenylation of 
quinones has also been reported. 14 The advantage of this process over other known 
reagents is that it can be carried out at room temperature and gives only 
monoprenylated products. Also strictly anhydrous conditions are not required. Using 
this technique MK-1 was synthesised from 2-methyl-1,4-naphthoquinone in 50% 
yield. 14 
Another approach to the synthesis of the K vitamins is stepwise elongation of a 
short side chain analogue. Schmid et ailS in 1990 published a synthesis of the 4 
stereoisomers of phylloquinone using this strategy (scheme 3.4). Reaction of 2-
bromo-3-methyl-1,4-dimethoxynaphthalene with isoprene epoxide via a Gringard 
reaction gave 3.13. Side chain extension was then achieved by activation of the 
resulting alcohol as an ester (3.14), followed by reaction with an appropriate alkyl 
magnesium bromide (3.15) to give the three unnatural isomers of vitamin Kl with 
complete stereochemical retention. The natural isomer of phylloquinone was 
prepared by a novel synthesis involving a-alkylation of menadiol mono acetate with 
phytylchloride. A mild Lewis-acid catalysed rearrangement and deprotection of the 
quinone gave the desired phylloquinone. This is an improvement on earlier Lewis-
acid based methods as it takes place in milder conditions with less catalyst required. 
~ ~~ ~e ____ 3._12 __ ~ h h Br 
OMe 
3.11 
Scheme 3.4 
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OMe 
3.13 R=H 
3.14 R= COCH3 
BrMg~H 
3.15 
OR [0] 
o 
Another novel approach reported by Liebeskind 16 was the synthesis of 
stannylquinones from alkynylcyciobutenones, and subsequent prenylation (scheme 
3.5). Synthesis of2-methyl-3-(tri-n-butylstannyl)-1,4-naphthoquinone (3.18) from the 
corresponding benzocyclobutenedione (3.16) proceeded in 49% yield over two steps. 
Subsequent palladium-catalysed cross coupling of this stannylquinone with prenyl 
bromide afforded MK-l (3.10) in 90%.16 
3.16 
Scheme 3.5 
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3.17 
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Until the early 1990's a series of different allylmetallated compounds had been 
used in the synthesis of K vitamins and short chain analogues of these compounds. 
The use of Gringard or oragnolithium reagents required protection of the quinone to 
suppress quinone reduction, but allylzinc and n;-allylnickel(II) reagents could be used 
for direct allylation without protection of the quinone nucleus.17 Allylsilanes and 
allylstannanes had also been used for direct allylation of unprotected quinones in this 
way, but Lewis-acid catalysts were required owing to their low nuc1eophilicity. In 
1991 Araki et aZl7 utilised allylindium sesquihalides R3In2X3 (R=allyl). In the 
synthesis of simple menaquinones only two of the three allyl groups were found to be 
transferred. Reaction of 2-bromo-3-methyl-1,4-naphthoquinones with prenylindium 
species gave rise to MK-1 in 67% yield. 17 In many cases studied, allylation occurred 
at a point of substitution on the quinone ring, but in this case reaction is thought to 
proceed via y-prenylation at the least hindered carbonyl followed by [3,3] sigmatropic 
rearrangement to give exclusively MK -1. 
Garcias et al18 in 1994 produced menaquinone-4 by coupling 2-bromo-3-methyl-
1,4-dimethoxynaphthalene with allylic aldehydes and nBuLi to give an alcohol 
product. Birch hydrogenolysis was then shown to proceed with complete retention of 
/:l2 stereochemistry and when followed by oxidative deprotection of the quinone, gave 
MK-l and MK-3 in 35 and 30% yield respectively. 
In 1995 Hagiwara et aZl9 reported a synthesis of menaquinone-l (MK-l) by the 
allylation of 2-bromo-3-methyl-l,4-naphthoquinone (3.19) with (3-methyl-2-
butenyl)trifluorosilane (3.20) in formamide at 80°C. This reaction occurred 
selectively at the carbon bearing the bromine (scheme 3.6). In contrast the same 
reaction conditions using 2-methyl-1,4-naphthoquinone as the starting material saw 
reaction at the methylated 2-position. This was rationalised by the initial 1 ,2 addition 
of the silane taking place at the sterically less crowded carbonyl group and subsequent 
[3,3]-sigmatropic rearrangement to the observed products. This reaction was found 
to take place with high regioselectivity and MK-l was formed in 54% yield after 68 
hours reaction time.19 
~, +F,Si~ 
o 
3.19 3.20 
Scheme 3.6 
o 
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In 1995 Tso et apo published a one-flask synthesis of the K vitamins (scheme 
3.7). This involved an anionic [4+2J cyc1oaddition of 3-substituted isobenzo-
furanones (3.22) to alkenylsulfones (3.21). The sulfones were prepared in one flask 
from allyl phenyl sulfone, used as initial Michael acceptors and, after cyclizaton the 
sulfonyl group was eliminated in situ under the reaction conditions. This produced 
phylloquinone in 61% yield and MK-I, 2 and 9 in 60, 63 and 64% yield 
respectively,z° 
~ 
3.22 0 
NaHMDS 
Scheme 3.7 
o 
-_. ax 
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3.24 
More recently, Lipshutz utilised Ni(O) catalysis in the synthesis of phylloquinone 
and menaquinones (scheme 3.8),z1 A chloromethylated quinone core (3.25) was 
prepared either by direct chloromethylation of the quinone, or from oxidation of 
corresponding benzylic chlorides. This core was reacted with a trimethylaluminium 
functionalised side-chain (3.26 or 3.27), prepared by carbo-alumination of the 
corresponding terminal akyne, in the presence of 0.5 mol% Ni(O) catalyst to give 
racemic phylloquinone in 88% yield and MK-3 in 93% yield.21 
0 
Me2Al~ Ii> 0 
C<:CC1 3.26 0 0 
3.25 Me2Al~ Ii> 
3.27 
Scheme 3.8 
3.3 PREVIOUS WORK ON FUNCTIONALISED ANALOGUES 
OF VITAMIN K 
As well as there being significant interest in the efficient and stereoselective 
synthesis of vitamin K, over the same period there has also been interest in the 
synthesis of functionalised analogues of the K vitamins. These compounds have been 
synthesised for a variety of reasons from the production of inhibitors of vitamin K 
dependant carboxylase and vitamin K epoxide reductase,22,23 to an investigation of 
metabolites of the K vitamins. A wide variety of analogues have been synthesised 
including substituted vitamin K epoxides,22,23 methylated naphthoquinones24 and side-
chain functionalised vitamin K analogues. It is the side-chain functionalised 
analogues which are of particular interest in this work and these will form the focus of 
this thesis. ill the last three decades there have been several attempts to synthesise 
such compounds.25-32 
From 1974 Okamoto and Watanabe published a series of papers looking at the 
synthesis of metabolites of phylloquinone, Ubiquinone and a-tocopherol, in order to 
study the structure activity relationships of these compounds.26 The isolation of 
urinary metabolites of these quinones and the possibility that these metabolites may 
be the active forms in vivo lead to this work. 
The earliest compounds published were 3.29 and 3.32 in 1974.27 Reaction of 2-
methyl-l,4-naphthoquinone (3.2) with y,y'-dimethoxycarbonylvaleryl peroxide (3.28) 
in acetic acid, followed by ester hydrolysis gave 3.29 in 50% yield from the peroxide 
side chain. However, this peroxide side chain was prepared via a three step synthesis 
in only 5% yield, making this approach less attractive. Condensation of 1-acetoxy-4-
hydroxy-2-methylnaphthalene (3.30) with methyl 6-hydroxy-4-methylhex-4-enoate 
H 
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(3.31) gave a 3:1 mixture of cis: trans isomers of 3.32. An attempt to synthesis purely 
the trans isomer of 3.32 by using the trans-allylic alcohol was unsuccessful as 
cis/trans isomerisation occurred during condensation.27 Compound 3.32 is a possible 
target for our study but there are several problems with this synthesis. As above, the 
side chain used (3.31) must be synthesised via a multi-step synthesis wtih only 
modemte yield. Also cis/trans isomerisation occurs during the coupling step, which 
means the overall yield of the desired trans isomer for the coupling is less than 20%, 
and requires rigorous purification via recrystallisation. 
o ~C02H 
o 
3.29 
c¢r:c ~ I ~ 0 HO,~~)l 
OR ~ "I - OMe 
3.30 
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Scheme 3.9 
In 1978 the synthesis of a series of carboxylated analogues was reported,z8 The 
condensation of 1-acetoxy-4-hydroxy-2-methyl-naphthalene (3.30) with trans-diethyl-
4-acetoxy-2-methyl-2-butenylmalonate (3.33) gave intennediate 3.34 which was 
hydrolysed and oxidised to the diacid 3.35 (see scheme 3.10). Although the BF3-
etherate coupling used in the synthesis of 3.34 proceeded in 66% yield, the side chain 
moiety (3.33) is not readily available, and must be synthesised in four steps from 
isoprene. Intennediate 3.34 was also hydrolysed, de carboxylated and oxidised to give 
the acid 3.32 in 33% yield. This is an alternative synthesis of 3.32, to that described 
earlier by Watanabe et al,27 but it still requires use of a side chain moiety which is 
only available via a multi-step synthesis. Catalytic hydrogenation of 3.34 followed by 
hydrolysis, decarboxylation and oxidation to the quinone yielded the 2',3'-dihydro 
derivative 3.37. 
OAc 
3.34 
C02Et 
OR C02Et 
3.36 
Scheme 3.10 
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Finally, in 1982 the synthesis of a series of vitamin K analogues bearing an 
alcohol functionality was published (scheme 3.11)?6 Condensation of 2-methyl-1,4-
naphthaquinol (3.1) with cinnamoyl alcohol (3.38) followed by oxidation with ferric 
chloride afforded phenylpropenylqmnone 3.39. Reductive acetylation gave the acetyl 
protected quinone 3.40 and cleavage of the alkene with osmium tetroxide and sodium 
periodate gave the corresponding aldehyde (3.41). The Wittig reaction was used to 
extend the side chain giving ester 3.42. Reaction with base and oxidation with ferric 
chloride afforded the acid functionalised analogue 3.44, and a secondary alcohol side-
product 3.45. Reduction of the ester 3.42 with lithium aluminium hydride afforded 
the desired alcohol 3.43. Both the alcohol (3.43) and the acid (3.44) presented here 
are possible targets for our study. Although the side-chain moiety in this procedure is 
the readily available cinnamoyl alcohol (3.38), the BF3-etherate coupling proceeds in 
only 28% yield. This, together with a yield of only 24% for the fmal 
deprotection/oxidation step, gives an overall yield of 3.44 of only 4%. Similarly, the 
reduction of 3.42, and subsequent oxidation to give the alcohol (3.44) proceeds in 
62% yield, to give an overall yield of 10%.26 
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Scheme 3.11 
In a related sequence the Friedel-Crafts reaction of protected side chain 3.46 with 
2-methyl-1,4-naphthaquinol (3.1) and subsequent oxidation with ferric chloride 
afforded a cis/trans mixture of alcohol 3.47 in 29% yield (scheme 3.12). The mixture 
of isomers is introduced here by the use of a cis/trans mixture of 3.46. As the target 
for our study is the production of a pure sample of the corresponding trans isomer, 
this route was not considered further. Alkyl alcohol analogues (3.48) were also 
obtained by the reaction of 2-methyl-1,4-naphthoquinone (3.1) with diacylperoxides, 
followed by hydrolysis of the ester group with base. 
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An efficient synthesis of sulfone functionalised analogues of vitamin K with a 
protected quinone core was published by Fujita et at (scheme 3.13).29 This was 
achieved via the Gringard coupling of 2-bromo-3-methyl-1 ,4-dimethoxynaphthalene 
(3.11) with trans-4-chloro-2-methyl-l-phenylsulfonly-2-butene (3.49), which was 
conveniently obtained from the reaction of isoprene with benzenesulfonyl chloride in 
the presence of copper chloride/TEA hydrochloride as catalyst. This reaction 
proceeded cleanly to give the desired product (3.50) in 82% yield. 
OMe OMe 
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Scheme 3.13 
In 1982 Terao et apo published the synthesis of a series of quinone derivatives 
with modified polyprenyl side chains (scheme 3.14) and investigated the inhibitory 
effects of these compounds on the slow reacting substance of anaphylaxis (SRS-A). 
The regio-specific modification of the terminal prenyl group of the ubiquinone, 
menaquinone or tocoquinone side chain gave a convenient synthesis of quinone acids, 
quinone ami des, quinone alcohols and quinone methylketones. These compounds 
were arrived at via side chain functional group interconversions of parent quinones 
with various polyprenyl side chains, leading to a library of related compounds for 
assay purposes. The two routes used to obtain these compounds rely on the Claisen 
rearrangement and the Carrol reaction. The carboxylic acid (3.56) synthesised here is 
an attractive target for our study. In this synthesis isomerisation of the epoxide (3.52) 
to the allylic alcohol (3.53) and Claisen rearrangement to the ester (3.54), was 
followed by deprotection and oxidation to give the acid (3.56). This series of steps 
increases the length of the side-chain moiety by two carbon units as well as 
introducing the carboxylic acid functionality. As the yields for many of these 
reactions are not reported it is impossible to assess the overall efficiency of this 
synthesis. As the overall length of the side-chain is not important for our study, it was 
recognised that the epoxide could be directly cleaved to the corresponding aldehyde~ 
removing a step from the synthesis described here. This aldehyde may then be 
reduced to the alcohol to allow addition of a 'linker~ (scheme 3.26)~ or oxidised to the 
carboxylic acid (see section 3.4). 
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In an investigation of the alkylation of qumones by carbanions, and the 
mechanism of this reaction, Aldersley et al published a synthesis of a series of side-
chain esters of 1,4 naphthoquinones.31 The reaction ofpyridinium salts with 2-methyl-
1 A-naphthoquinone in the presence of triethylamine, or the reaction of the pyridinium 
salt and 2-methyl-1A-naphthoquinone with potassium carbonate and a catalytic 
amount of 18-crown-6 ether were the approaches taken. Yields of products varied 
with the method and pyridinium salt used between 55 and 85%.31 
In 1990 Barton et al were investigating the synthesis of hindered quinones via 
OR 
OR 
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radical reactions.32 Among the series of compounds produced were several vitamin K 
based compounds with varying side chains> including phenyl and isopropyl 
substituted side chains~ and a carboxylated side chain. The carboxylic acid analogue 
was prepared in 65% yield from the unprotected quinone nucleus.32 
As discussed in the above section, syntheses to potential target compounds for 
our study (e.g. 3.32 and 3.56) have been previously reported. Initially we identified 
key aspects that any potential target must contain. These included functionality at the 
side-chain terminus, an intact and appropriately substituted naphthoquinone core> and 
a trans alkene at the /).2 position of the side-chain. Three vitamin K analogues were 
designed and synthesised for this study. The initial target compound (3.59» was 
synthesised via the coupling of a functionalised side-chain to a protected naphthalene 
core, while later analogues were synthesised via side-chain functionalisation of a 
polyisoprenoid naphthoquinone. 
3.4 SYNTHESIS OF VITAMIN K ANALOGUES 
The initial target analogue designed in this work was 3.59 (figure 3.4)~ which can 
be synthesised via the coupling of a functionalised side chain (3.60) with 2-bromo-3-
methyl-l,4-dimethoxynaphthalene (3.11). This analogue maintains the important k 
double bond, but is lacking the methyl substitution at the 3 position of the side-chain. 
The p-methoxybenzyl group was chosen for protection of the alcohol as it is removed 
under similar oxidative conditions to those used in the deprotection of the quinone 
core. 
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Figu.re 3.4: Retrosynthetic analysis for target analogue 3.59 
This synthesis was split into three sections, the synthesis of the naphthoquinone core 
(3.11)~ synthesis of the functionalised side chain (3.60) and fmally the coupling and 
deprotection to give analogue 3.59, which may then have a 'linker' moiety attached. 
3.4.1 SYNTHESIS OF NAPHTHALENE CORE 
Of the many different quinones or protected quinones used in the synthesis of 
vitamin K molecules it was decided to use 2-bromo-3-methyl-1,4-naphthalene (3.11) 
for this study. This particular compound was chosen as it was stable to all chemical 
conditions used in the preparation of vitamin K analogues, but could be readily 
deprotected to reveal the corresponding quinone under oxidative conditions. The 
method chosen for the synthesis of 3.11 was that reported by Adams et aP3 outlined in 
scheme 3.15. 
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The bromination of menadione (3.2) was achieved by reaction with bromine in 
the presence of glacial acetic acid and anhydrous sodium acetate with protection from 
light, and yielded 2-bromo-3-methyl-1,4-naphthoquinone (3.19) in 71% yield after 
recrystallisation. Reduction of quinone 3.19 to the hydroquinone 3.61 was achieved 
in 93% yield via reaction with stannous chloride in conc. hydrochloric acid. Although 
this hydroquinone (3.61) could be stored at -4°C for some time, it was found to 
undergo a slow reoxidation to the quinone 3.19 even at low temperature. However, 
portionwise addition of an aqueous solution of potassium hydroxide to a suspension 
of 2-bromo-3-methyl-1,4-dihydroxynaphthalene (3.61) in dimethyl sulfate (DMS), 
followed by ether extraction afforded the stable 2-bromo-3-methyl-l,4-
dimethoxynaphthalene (3.11) as pale orange crystals, with melting point of 83-84 °c, 
in 64% yield. 
Using the method of Adams et al,33 2-bromo-3-methyl-1,4-dimethoxynaphthalene 
(3.11) was successfully synthesised from vitamin K3 (3.2) in 42% yield over all steps. 
3.4.2 SYNTHESIS OF FUNCTIONALISED SIDE-CHAIN 
The synthesis of the required functionalised side-chain (3.60) was achieved from 
the readily available l,4-butanediol (scheme 3.16). Monoprotection of l,4-butanediol 
with p-methoxybenzyl bromide34 gave 3.63 in 48% yield, following column 
chromatography. Swem oxidation of the alcohol 3.63 to the aldehyde 3.64 proceeded 
in 83% yield. 
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Scheme 3.16 
The /12 double bond was introduced by reacting aldehyde 3.64 with [(ethyl-
carbonyl)methylene ]triphenylphosphorane in dichloromethane to give the allylic ester 
3.65 in 80% yield (scheme 3.17). Reejuction of ester 3.65 with diisobutyl-aluminium 
hydride afforded the allylic alcohol 3.66 as a yellow oil in 80% yield. The 
portionwise addition of triphenylphosphine to a solution of allylic alcohol 3.66 and 
carbon tetrabromide gave the allylic bromide 3.60 in 77% yield, after radial 
chromatography. 
Ph3P=CHC02Et ~OMe DiBALH ~OMe 
3.64 II ~ I /ilR~O ~I 
Et02C 0 ~ 
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Scheme 3.17 
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A new synthetic route to the allylic bromide 3.60 is presented. The synthesis of 
the aldehyde 3.64 has been previously reported by Onoda et al/4 and we have used 
this as a precursor for the Wittig reaction to produce the allylic ester 3.65. Reduction 
and bromination of this afforded the desired allylic bromide 3.60. This allylic 
bromide has been previously reported by Hayashi et al,35 where synthesis proceeded 
from the allylic alcohol 3.66, which in turn was produced via reduction of the 
corresponding alkyne. 
Chapter 3 77 
3.4.3 COUPLING REACTION 
Although there have been many different methods used for the coupling of an 
allylic halide to an aryl core the one chosen for this work was a copper mediated 
coupling. Syper et al. 12 had successfully used this method in the synthesis of similar 
compounds (see section 3.2) without observation of any isomerisation of the side 
chain. As the side chain (3.60) was produced via a multi-step synthesis a model 
system, geranyl bromide and 2-bromo-3-methyl-1,4-dimethoxynaphthalene, which 
has previously been reported, was attempted initially (scheme 3.18).12 This reaction 
was found to proceed smoothly providing all solvents were freshly distilled and every 
precaution was taken to exclude water from the system. 
c¢:1 :" ~ h Br 
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Scheme 3.18 
Reaction of 3.11 with nBuLi at 0 °C for 30 minutes was followed by cuprate 
formation via the addition of copper bromide dimethyl sulfide complex. Addition of 
geranyl bromide to the reaction, followed by stirring for five hours and quenching 
with HCl afforded a crude product mixture. Purification by radial chromatography 
afforded three fractions, which upon 1H NMR analysis were shown to contain 2-
methyl-1,4-dimethoxynaphthalene, unreacted geranyl bromide, and the desired 
geranyl naphthalene (3.67) in 80% yield. This yield compares favourably with that of 
78% reported by Syper et al. for the same reaction.12 No isomerisation of the /12 
double bond was evident by 1H NMR spectroscopy, but trace amounts of the 
corresponding terminal alleene, produced by attack at the 3-position of the allylic 
bromide, were observed. Distinctive multiplets at 4.92 and 6.35 ppm in the 1H NMR 
spectrum, corresponding to the allylic protons, identified this terminal alkene. 
This reaction is thought to proceed via a diaryl cuprate, or Gilman's cuprate, 
which is prepared by the reaction of an organolithium with CuX (X= I, Cl, Br). Use 
of CuBr in its uncomplexed state is rare, and often leads to the formation of by-
products due to the presence of Cu(II).36 As the dimethyl sulfide complex, however, it 
is an excellent cuprate precursor, as it is ether soluble and readily prepared free of 
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CU(II).37 Copper bromide dimethyl sulfide complex must, however, be used fresh or 
purified by recrystallisation and stored under argon, as it readily losses 
dimethyl sulfide which disrupts the stoichiometry of the reaction.37 It is also important 
to lmow precisely the concentration of the organolithium used by titrating the nBuLi 
before use. Once formed the Gilman's cuprate can be reacted with almost any 
electrophile, with the most efficient being primary centres bearing iodide, bromide or 
tosylate.37 
It is usual for one of the aryl groups of the Gilman's cuprate to be transferred 
during reaction with the substrate, and for this reason often two equivalents of the 
cuprate are reacted with one equivalent of substrate. 11 However, in the case of some 
substrates more than one aryl group is observed to be transferred. An investigation of 
the effect of substrate on the transfer of the aryl group by Chenard et al showed that 
a1lylic bromide gave greater than one R group transferred while benzoyl chloride and 
cyc1ohexylcarboxylic acid showed the transfer of only one R group. I I Benzyl 
bromide gave moderate yields with less than one group transferred while 
methylbromoacetate gave very low yields and lead to a crude product mixture which 
proved difficult to purify.ll The results observed from our model system are 
consistent with these [mdings, with geranyl bromide giving a yield of 80% of the 
coupled product with respect to the quinone core, showing more than one R group per 
Gilman's cuprate was transferred. 
With the coupling process established the coupling of the prepared functionalised 
side chain (3.60) with 2-bromo-3-methyl-l,4-diemthoxynaphthalene under the same 
conditions was undertaken (scheme 3.19). Work-up and purification by radial 
chromatography afforded three fractions. Analysis of these fractions identified the 
desired product (3.68) in fraction three, which still contained a mixture of compounds. 
The desired product (3.68) was identified by the presence of several distinctive proton 
NMR resonances. A doublet at 3.55 ppm is characteristic of the benzylic proton 
resonance and is the most diagnostic signal to determine that coupling has occurred. 
Also present in the spectra are two multiplets at 5.35 and 5.61 ppm which were 
assigned to the allylic protons of 3.68, and appear as two distinct signals in contrast to 
the corresponding proton resonances in 3.60 which occur as a single multiplet at 5.67 
ppm. Another compound in the product mixture was the corresponding terminal 
alkene (3.69), which arises through attack of 3.60 at the C-3 rather than the C-l 
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position. The characteristic splitting patterns of the IH NMR signals at 5.02 and 6.23 
ppm support the presence of a terminal alkene as part of the product mixture. All 
efforts to separate these compounds proved unsuccessful, so the product mixture was 
used in subsequent synthetic steps without further purification. 
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Scheme 3.19 
Oxidative deprotection of the quinone core using cerric ammonium nitrate (CAN) 
was expected to also remove the p-methoxybenzyl protecting group of the side chain 
affording the alcohol (3.59) (scheme 3.20). Addition of a solution of CAN to the 
product mixture containing 3.68 afforded a crude product, which lH NMR analysis 
showed to be a complex mixture of compounds. Purification by radial 
chromatography afforded two fractions, which were analysed by lH NMR. Although 
a molecular ion at 270.12 was observed in fraction 1, which is consistent with the 
desired product (3.59), by IH NMR analysis this fraction still contained several 
compounds. Due to a series of repeating signals, i.e. two doublets appearing at 3.35 
and 3.44 ppm and two triplets appearing at 3.61 and 3.70 ppm, it was postulated that 
the isolated fraction may contain a mixture of the cis and trans isomers of 3.59, 
although no evidence of a mixture of isomers was observed at earlier stages of the 
synthesis. It is impossible to establish any differences in the allylic protons of these 
compounds as a single broad multiplet is observed at 5.50 ppm for all the present 
allylic protons. This fraction also showed traces of p-methoxy benzyl alcohol and p-
methoxy benzaldehyde by IH NMR analysis. 
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Scheme 3.20 
In summary, the known cuprate coupling reaction of 3.11 with geranyl bromide, 
was used as a model system for the coupling of the functionalised side chain. Using 
the reaction conditions described by Syper et aZ. 12 both of these reactions were 
successfully completed. In each case the crude product contained a mixture of 2-
methyl-l,4-dimethoxynaphthalene, the desired product and the corresponding 
terminal alkene, which were separable by radial chromatography. Due to difficulties 
in the separation. of the product mixture obtained from the oxidative deprotection of 
3.68, it was decided to pursue a different approach to the synthesis of functionaUsed 
analogues of vitamin K. 
3.5 ANALOGUE SYNTHESIS VIA SIDE CHAIN 
FUNCTIONALISATION 
Due to the problems encountered during the [mal stages of the synthesis of 
analogue 3.59 it was decided to revisit the model coupling described above, and 
utilise the product (3.67) to obtain an appropriate analogue of vitamin K. This was 
achieved via functionalisation of the L16position of the side chain of 3.67. There were 
certain advantages to this approach as it maintains the trans stereochemistry at the L12 
position, and the methyl substitution at the 3 position of the side chain. This approach 
is similar to that taken by Terao et aZ,30 and led to the design of a new target analogue 
(3.70) (figure 3.5), which incorporates a succinic acid linker moiety for conjugation of 
the analogue to a carrier protein. 
o 
3.70 
Figure 3.5: Structure of target analogue 3.70 
o 
O~OH 
o 
The initial functionalisation of the L16 double bond of 3.67 is possible Via 
dihydroxylation or epoxidation of this alkene. In the synthesis of juvenile hormone 
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III Crispino and Sharpless showed that the osmIUm cata1ysed asymmetric 
dihydroxylation of methyl famesoate in the presence of the phthalazine ligand 
(DHQD)2-PHAL, gave a 20:1 ratio of products with dihydroxylation occurring at the 
i110 to i16 positions respectively.38 This selectivity for the terminal, least hindered 
alkene is analogous to that required in the functionalisation of the geranyl side chain 
of 3.67 (scheme 3.21). Accordingly, the method developed by Crispino et al was 
applied to 3.67.38 Reaction of 3.67 and a solution containing (DHQD)2PHAL, 
potassium ferricyanide, potassium carbonate, methane sulfonamide and osmium 
tetroxide in t-butanol:water for 24 hours at 4 °C was followed by dichloromethane 
extraction. IH NMR analysis showed only starting material (3.67) was present in the 
reaction mixture. It is possible that the phthaliazine ligand is hindering this reaction 
by co-ordinating to the naphthalene ring of 3.67. 
OMe OMe 
OR 
OR 
OMe OMe 
3.67 3.71 
Scheme 3.21 
As the stereochemistry of the dihydroxylation will be lost during cleavage to the 
corresponding aldehyde, and therefore asymmetric dihydroxylation is not required, 
other methods for dihydroxylation of an alkene were investigated. One common 
method for dihydroxylation is reaction with N-methylmorpholine-N-oxide in the 
presence of osmium tetroxide or potassium osmate.39 A solution of 3.67 in acetone 
was added to a solution containing potassium osmate and N-methylmorpholine-N-
oxide in a combined acetone:t-butano1:water solvent. After 24 hours the reaction was 
quenched and crude product isolated. This was purified by radial chromatography to 
give four fractions, which were analysed by IH NMR spectroscopy. Fraction one was 
found to contain 2-methyl-l,4-dimethoxynaphthalene, while fraction two contained 
only a mixture of minor by-products. The desired diol (3.71) was isolated in fraction 
three, and obtained in 30% yield, while fraction 4 was tentatively assigned as 
contained the corresponding tetraol (3.72) in 20% yield (see figure 3.6). The IH NMR 
spectrum of the tetraol (3.72) showed complex splitting, indicative of the presence of 
a mixture of diastereoisomers. 
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Figure 3.6: Structure oftetraol by~product from dihydroxylation of3.67 
As the yield of diol 3.71 was low and purification difficult, epoxidation of the 
alkene was investigated as another possible route to the introduction of functionality 
into the isoprenoid side-chain of 3.67. Reaction of 3.67 with m-chloroperbenzoic acid 
in dichloromethane for 2 hours at 0 °C showed the absence of starting material by 
TLC analysis. Excess m-chloroperbenzoic acid was removed by the addition of 
sodium meta bisulfite and a crude reaction product isolated. Purification by radial 
chromatography afforded two fractions. The first of these fractions contained 
predominantly starting material, while the second, although showing a triplet at 2.67 
ppm, consistent with H-6 of the desired product (3.73), showed no resonance for the 
allylic proton at 5.17 ppm. As neither of these fractions contained the desired epoxide 
(3.73), this method was not further investigated. 
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Scheme 3.22 
Given the problems encountered with the above epoxidation process it was 
decided to attempt reaction of 3.67 with sodium acetate and peracetic acid at -10°C. 
All literature procedures require the use of 40% peracetic acid, but only 20% peracetic 
acid was available. The crude product obtained from this reaction was analysed by IH 
NMR and, although some of the desired product (3.73) was present, purification by 
silica chromatography afforded 3.73 in less than 5% yield. 
During work towards the total synthesis of trident oquin one (3.74) in 1995, Brown 
and Robinson successfully functionalised a farnesyl intermediate (3.75) selectively at 
the terminal alkene (figure 3.7).40 This synthesis involved bromohydrin formation 
followed by cyclisation to an epoxide and subsequent cleavage to the corresponding 
aldehyde. This method provides an alternative route to the desired regioselective 
formation of an epoxide at the terminal alkene of a polyisoprene chain, thereby 
overcoming problems encountered with earlier epoxidation procedures. It should be 
noted that although this process increases the number of steps in the overall synthesis 
of the target analogues the efficiency of the synthesis is increased. The synthetic 
pathway devised for the preparation of target analogues 3.70 and 3.80 (see section 
3.6) encompassed this approach. 
3.74 
3.75 
Figure 3.7: Structures of tridentoquinone (3.74) and a synthetic farnesyl intermediate (3.75) 
The formation of the bromohydrin of 3.67 (scheme 3.23) was achieved by 
reaction with recrystallised N-bromosuccinimide, which afforded a 'crude' mixture of 
reaction products. Purification by radial chromatography afforded the desired 
bromohydrin 3.76 in 59% yield. The orientation of bromohydrin formation is 
determined by the substitution pattern of the alkene. The bromonium ion intermediate 
formed upon reaction of Bt with the alkene is unsymmetrical, carrying more positive 
charge on the tertiary carbon centre than the secondary carbon centre. This promotes 
attack of the OH- at the tertiary carbon centre giving the bromohydrin shown in 
scheme 3.23. 
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Scheme 3.23 
Conversion of the bromohydrin (3.76) to the corresponding epoxide (3.73) 
(scheme 3.24) was achieved in 91% yield by reaction with potassium carbonate at 
room temperature for 18 hours. Upon work up this gave 3.73 which was pure by IH 
NMR (c.f. scheme 3.22), and used without further purification. 
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Scheme 3.24 
Cleavage of the epoxide (3.73) with periodic acid in ether then afforded the 
corresponding aldehyde (3.77) in 60% yield without need for purification (scheme 
3.25). 
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The synthesis of target analogue 3.70 from the aldehyde intermediate (3.77) was 
then achieved in three steps (!?cheme 3.26). The reduction of aldehyde 3.77 to the 
corresponding alcohol (3.78) proceeded in 60% yield, without need for purification. 
The addition of a linker to the alcohol to act as a spacer between the analogue and 
carrier protein is the next step in this synthesis. Although there are countless possible 
linkers available it was decided to use a succinyl based group as this was readily 
available and provided the required acid functionality for protein conjugation. The 
choice of base used for the coupling of succinic anhydride and the alcohol (3.78) 
proved important when considering both yield and ease of purification of this 
reaction. The use of pyridine as a base on reaction of 3.78 and succinic anhydride 
gave only 25% yield of the succinyl ester (3.79) and rigorous purification was 
required, but triethylamine has also been used in similar reactions and this proved 
more successful. Reaction of a solution of succinic anhydride, triethylamine and 
dimethylaminopyridine (DMAP) with the alcohol (3.78) for 18 hours, afforded the 
desired succinyl ester (3.79) in 60% yield with no purification required. Subsequent 
oxidative deprotection with CAN afforded the desired analogue 3.70 in 72% yield. 
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Scheme 3.26 
The synthetic route outlined above has several advantages over literature 
procedures to similar compounds. Unlike the syntheses described by Watanabe et 
az26-28 (see section 3.3), this route does not require the coupling of a functionalised 
side-chain moiety which is produced via a multi-step synthesis. Instead the coupling 
reaction uses geranyl bromide, and functionality is introduced by manipulation of the 
terminal alkene of the coupled product (3.67). A similar approach was taken by Terao 
et al.30 The synthetic route they established involved elongation of the side chain 
moiety by two carbon units during functionalisation. Although it is difficult to make a 
direct comparison between the two methods, as no data was given for yields in the 
literature, we believe that by removing the need for elongation of the side chain, and 
therefore reducing the number of synthetic steps, we have designed a more efficient 
synthesis of the target compounds. It may be noted that the same products can be 
arrived at via either route by using a starting material with one extra isoprene unit 
when proceeding via the synthetic method outlined above. 
3.6 VITAMIN K2 BASED ANALOGUES 
Having established the synthetic route described above it was decided to use this 
in an attempt to produce analogues from vitamin K2• The target analogue (3.80) is 
shown in figure 3.8 and this was synthesised by an analogous route to that developed 
for the synthesis of3.70. 
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Figure 3.8: Structure of vitamin K2 based analogue (3.80) 
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Initially this synthesis was attempted on vitamin K2 itself, without protection of 
the quinone core. Reaction of vitamin K2 (3.81) with N-bromosuccinimide afforded a 
mixture of products, which upon purification by radial chromatography afforded three 
fractions. By IH NMR analysis these were shown to contain recovered starting 
material (30 % yield), the desired bromohydrin (3.82) (47% yield) and the 
corresponding dibromohydrin product (3.83) (7% yield) (scheme 3.27). The signals 
of interest in the IH NMR spectrum of 3.82, are those corresponding to the terminal 
methyl groups and the proton adjacent to the bromine functionality. The presence of a 
doublet at 3.97 ppm was attributed. to the proton adjacent to the bromine, on 
comparison with the corresponding proton (at 3.93 ppm) in 3.76 (scheme 3.23). The 
position of the terminal dimethyl group signals have shifted upfield from 1.57 and 
1.58 ppm for vitamin K2 to 1.32 and 1.33 ppm in 3.82 due to the presence of the 
adjacent hydroxyl group. The IH NMR spectrum of 3.83 was tentatively assigned by 
comparison, and showed a decrease in the integral of the allylic proton resonances at 
4.91 and 5.17 ppm, and the two protons adjacent to the bromine groups are observed 
as a multiplet at 3.97 ppm. Regions of this spectrum were busy indicating the 
presence of a mixture of diastereoisomers. 
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Oxidation of the bromohydrin (3.82) to the epoxide, with potassium carbonate, 
gave a crude product, which by lH NMR analysis was inconsistent with the desired 
epoxide (scheme 3.28). The proton resonance of the benzylic protons at 3.35 ppm in 
the corresponding bromohydrin (3.82), was absent in the isolated product, and the 
number of allylic protons had increased from three to four by integration. From these 
fmdings it was postulated that the basic reaction conditions may have removed one of 
the acidic benzylic protons, leading to isomerisation of the A? double bond into 
conjugation with the aromatic ring (3.84). As this destroys the isoprenoid nature of 
the side chain it was decided not to proceed via this synthetic route and this was not 
purified further. This problem can be overcome by protection of the quinone nucleus. 
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Scheme 3.28 
Refluxing vitamin K2 (3.81) in acetic anhydride in the presence of zinc powder 
followed by extraction into ethyl acetate afforded diacetoxyvitamin K2 (3.85) in 95% 
yield (scheme 3.29). Reaction of this with N-bromosuccinimide afforded the 
corresponding bromohydrin (3.86) in 15% yield. The reason for this low yield of 
bromohydrin is unknown, but similar results were not observed with any other 
substrate. Epoxidation ofbromohydrin 3.86 with potassium carbonate again lead to a 
mixture of products. Upon comparison of the lH NMR spectrum of the reaction 
mixture with the bromohydrin starting material (3.86), it was observed that the signal 
corresponding to the benzylic protons at 3,43 ppm in 3.86 was again absent, as 
observed in the case of unprotected vitamin K2. In addition the two singlets at 2,46 
and 2,48 ppm in the bromohydrin (3.86), corresponding to the acetyl protecting 
groups, were also absent in the isolated product. From this evidence it was postulated 
that the acetyl protecting groups had been cleaved in the basic reaction conditions and 
the 8 2 double bond had again moved into conjugation with the aromatic ring. As 
isomerisation of the double bond lead to a compound which could not be utilised, this 
synthetic route was not further investigated. 
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As the methoxy ether protecting group had been shown in earlier work to 
withstand the reaction conditions of the epoxidation, and subsequent steps of this 
synthetic approach, it was decided to use this protecting group for vitamin K2. 
Initially the same method as used in the preparation of the naphthoquinone core 
compound 3.11 (see section 3.4.1) was attempted. The reduction of vitamin K2 with 
stannous chloride and concentrated hydrochloric acid afforded only starting material 
upon work up. The reduction of vitamin K2 (3.81) with sodium dithionite under a 
nitrogen atmosphere in degassed solvents was then attempted. This also led to the 
isolation of vitamin K2 upon work-up and IH NMR analysis. This reaction was 
repeated and followed by IH NMR analysis in order to establish if any dihydrovitamin 
K2 (3.88) could be detected (scheme 3.30). After a reaction time of 30 minutes, an 
aliquot was removed from the reaction vessel, dried under reduced pressure and 
analysed by IH NMR. At this point the ratio of dihydrovitamin K2 to vitamin K2 was 
75:25, by integration of the benzylic proton resonances which appear as two doublets 
at 3.36 ppm for the quinone and 3.53 ppm for the hydroquinone. Analysis of aliquots 
in this same manner after reaction time of 60, 90, 150 and 210 minutes gave variable 
results, with the hydroquinone:quinone ratio ranging from 60:40 at 90 minutes, back 
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to 75:25 at 150 minutes. From these results it appeared that exposure to air may be 
responsible for the observed variation in hydroquinone:quinone ratio. At 210 minutes 
two aliquots were taken, with one being exposed to air for longer before IH NMR 
analysis. The hydroquinone:quino~e ratios in this case were 70:30 for the control 
experiment, and only 45:55 for the sample exposed to air. This supported the earlier 
hypothesis of reoxidation of dihydrovitamin K2 to vitamin K2 upon exposure to the 
atmosphere. From this finding all further attempts to synthesise dimethoxyvitamin K2 
(3.89) were carried out without isolation of the hydro quinone intermediate. If the 
hydro quinone was immediately transferred via cannular to dimethylsulfate and 
reacted with potassium hydroxide, a mixture of dimethoxyvitamin K2 (3.89) and 
vitamin K2 (3.81) was isolated. These could be separated by radial chromatography to 
yield dimethoxy-vitamin K2 in 33% yield, with 15% recovery of vitamin K2. It has 
been shown by Kraus and On Man41 that the use of phase transfer catalysts can 
increase the yield of the reductive methylation of quinones. This process removes the 
need for the transfer of the highly air sensitive dihydrovitamin K2 by having the 
reduction and methylation occurring in one flask. A solution of sodium dithionite was 
added to a solution containing vitamin K2 and, tetrabutylammoniumiodide.· The 
addition of potassium hydroxide followed by dimethyl sulfate and reaction for 18 
hours, afforded after purification, the desired dimethyoxyvitamin K2 (3.89) in 63% 
yield (scheme 3.30). 
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Having successfully prepared dimethoxyvitamin K2 (3.89) the target analogue 
3.80 could now be synthesised by the same route used previously (scheme 3.31). 
Reaction of dimethoxyvitamin K2 (3.89) with N-bromosuccinimide afforded the 
bromohydrin 3.90 in 50% yield after purification by radial chromatography. 
Epoxidation with potassium carbonate yielded the corresponding epoxide (3.91) in 
80% yield with no purification required. The presence of a doublet corresponding to 
the benzylic proton resonance, at 3.57 ppm in the IH NMR spectrum of 3.91 implied 
that no isomerisation of the /::,,2 double bond had occurred in this case. Cleavage of the 
epoxide (3.91) with periodic acid yielded the corresponding aldehyde (3.92) in 95% 
yield. 
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Reduction of the aldehyde of vitamin K2 (3.92) with sodium borohydride to give 
the alcohol (3.93) (scheme 3.32) proceeded cleanly in 74% yield. The addition of the 
succinyl linker with succinic anhydride, dimethylaminopyridine and triethylamine 
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afforded 3.94 in 60% yield with no purification. Deprotection of the quinone core 
with CAN gave the target analogue 3.80 in 60% yield. 
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In summary, attempts to synthesise 3.80 from vitamin K2 or diacetoxyvitamin K2 
were unsuccessful due to isomerisation of the 1::J,,z double bond being observed in the 
basic reaction conditions. However, the preparation of dimethoxyvitamin K2 (3.89) 
via reductive methylation using a phase transfer catalyst overcame this problem, 
leading to the successful completion of this synthesis via the route established for the 
preparation of 3.70. 
This study resulted In the synthesis of two novel side chain functionalised 
analogues of vitamin K (3.70 and 3.80), suitable for conjugation to a protein for 
immunological studies. We found that side chain functionalisation of a polyisoprene 
naphthalene was the most efficient route to these compounds, as attempts to couple a 
functionalised side chain to the naphthalene core lead to isolation difficulties of the 
final product. 
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Both of the vitamin K analogues synthesised (3.70 and 3.80) were then used at 
Canterbury Health Laboratories for initial studies into the production of monoclonal 
antibodies, for use in the development of an immunoassay for vitamin K in blood and 
breast milk. 
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IMMUNOLOGICAL STUDIES 
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4.1 IMMUNOASSAYS 
Immunoassays are recognised as a quick and efficient method for screening large 
numbers of biological samples. Due to the decreased preparation time of samples and 
high-throughput capability an immunoassay for vitamin K levlesin blood is an attractive 
target. There are many different types of immunoassays, including radioimmunoassays 
and enzyme-linked immunosorbent assays (ELISAs). Both of these assay types utilise 
the same basic principles, while differing in the detecting methods for quantitation. In 
both cases an antibody is produced which recognises the antigen of interest, in this case 
vitamin K. This antibody is added to a blood sample where it binds the reI event antigen. 
A second antibody is then introduced which will bind to the first antibody. If this second 
antibody is radiolabelled, the assay is termed a radioimmunoassay, and the amount of 
radiolabel bound by the sample gives a measure of the amount of antigen in the original 
sample. In the case of an ELISA, the second antibody is labelled with an enzyme. 
Introduction of the enzyme substrate produces a coloured product which, when detected 
spectrophotometric ally gives a measure of the antigen concentration in the sample. For 
the purposes of our study the ELISA was the target assay. 
The first antibody introduced in the ELISA, which binds to the antigen (vitamin K), is 
a monoclonal antibody. This is an antibody that is designed and produced to recognise a 
specific antigen. Therefore, in order to develop a functional ELISA it is first necessary to 
produce monoclonal antibodies which will bind vitamin K. 
4.1.1 MONOCLONAL ANTIBODY PRODUCTION 
Monoclonal antibodies do not differ structurally from naturally occurring antibodies. 1 
What makes monoclonal antibodies (MCAs) unique is that all antibodies produced in any 
single preparation are identical. 1 In general, when the body is exposed to a foreign 
molecule (or antigen) an immune response is triggered. 1 Our study requires an antibody 
to recognise vitamin K as the antigen. However, vitamin K itself is unable to evoke an 
immune response for several reasons. Most importantly the K vitamins are naturally 
occurring compounds, and therefore will not be recognised as a foreign particle. Vitamin 
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K is also a small molecule which is not readily soluble in aqueous environments, again 
affecting its immunogenicity. The conjugation of vitamin K to a carrier protein will 
increase both the particle size and aqueous solubility. The carrier protein is chosen to be 
recognised as a foreign body by the host, thereby evoking an immune response. This 
immune response involves the production of specific proteins called antibodies, which 
link to the antigen by a series of non-covalent bonds.! Antibodies are produced by B-
lymphocytes, with each B-Iymphocyte producing only one specific type of antibody, as 
stated in the 'one-cell, one-antibody' axiom of Burnet's clonal selection theory.2 Any 
single antigen will usually elicit a polyc1onal response with different antibodies directed 
to different antigenic determinants (or epitopes), or even different combining sites of the 
same epitope*.2 ill the case of the vitamin K-carrier protein 'antigen', this implies 
antibodies will be produced to various surface features of the carrier protein, and 
hopefully to the vitamin K core attached to the protein surface. 
ill the production of MCAs the aim is to produce an immortal cell line producing an 
antibody which recognises the epitope of choice for a given antigen, i.e. the vitamin K 
naphthoquinone core. The overall process for MCA production is outlined in figure 4.1. 
A mouse is inoculated with the vitamin K-carrier protein conjugate and after some time 
the B-Iymphocytes are harvested by isolation from the spleen. As B-lymphocytes cannot 
be grown in culture conditions, they are then fused with myeloma cells which are lackIDg 
either hypoxanthine phosphoribosyl transferase (HPRT) or thymidine kinase.2 Myeloma 
cells are a strain of rapidly dividing cells that may be readily grown in culture conditions. 
Both HPRT and thymidine kIDase are essential for the salvage pathway of DNA 
synthesis, and this is important in the selection of fused hybrid cells. The cell culture, 
after fusion, will contain fused and unfused myeloma cells, as all unfused B-lymphocytes 
will not survive culture conditions. 
* An epitope is a site on a large molecule against which an antibody will be produced and to 
which it will bind. 
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Figure 4.1: Schematic representation of the process for MeA production 
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This cell culture is grown in a medium containing hypoxanthine, aminopterin and 
thymidine (HAT).! Aminopterin blocks the main pathway for purine and pyrimidine 
biosynthesis and cells which possess HPRT can utilise hypoxanthine to synthesise 
purines and thymidine to synthesise pyrimidines via a salvage pathway. As the myeloma 
cells are HPRT negative they will die under these culture conditions, and only cells which 
have successfully undergone fusion, and therefore are HPRT positive, will survive.! This 
fusion will result in a cell which can grow in culture and produce antibodies to an epitope 
of the vitamin K -carrier protein conjugate. 
The successfully fused cells are then diluted, separated to single cells, and grown 
in culture to give a series of cell cultures each producing a single antibody (MCA).! Each 
culture is screened for antibodies which recognise vitamin K, and the required cell line 
can be cultured for further antibody production. These antibodies may then be used in an 
ELISA for the determination of vitamin K levels in blood. 
4.1.2 ENZYME-LINKED IMMVNOSORBENT ASSAY 
The principles of an ELISA are quite simple (see figure 4.2). The general 
procedure for an ELISA initially involves a sample containing the antigen, vitamin K, 
being placed in a microtitre plate. The MCA is introduced to the well and any unbound 
MCA is washed out. 3 A second MCA is introduced which will bind to the first antibody, 
and is coupled to an enzyme. 3 The introduction of the substrate of this enzyme will lead 
to the production of a coloured product which may be detected spectrophotometrically.3 
Although the ELISA is less sensitive than some alternative techniques, including 
radioimmunoassay, it boasts simpler sample handling and faster measurement, especially 
in automated systems.2 Once developed an ELISA could potentially be used to 
spectrophotometric ally determine the vitamin K content of serum samples, reading a 96 
well microtitre plate in minutes, as opposed to current HPLC methods which require 
extensive sample preparation and have an analysis time of approximately 30 minutes per 
sample. 
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4.2 INITIAL IMMUNOLOGY FINDINGS 
Following the successful synthesis of analogues 3.70 and 3.80 (see chapter 3), these 
were taken to Dr Peter Elder of the Steroid Laboratory at Canterbury Health Laboratories 
for immunology studies. These compounds were coupled to bovine serum albumin 
(BSA) and bovine thyroglobulin (Tg). BSA was used as the carrier protein for 
inoculation and the Tg conjugate was used in the antibody screening process. The 
coupling procedure used in this instance was a mixed anhydride method. A sample of 3 
mg of the analogue was treated with I 0 ~ of tributylamine and 4 JlL of isobutyl 
chloroformate, before addition to 10 mg ofBSA or Tg. Upon completion of this reaction 
it was noted that some yellow oil remained unreacted and adhered to the reaction vessel. 
This observation led to model peptide coupling studies to investigate the effectiveness of 
the conjugation of a vitamin K analogue (3.70 or 3.80) and a protein (see section 4.3). 
The crude analogue-BSA conjugates were then used for inoculation of mice, as purity of 
the antigen is not important for antibody production.2 An initial tail bleed of these mice 
at 6 weeks showed that antibodies were being produced and after 8 weeks the spleen cells 
were harvested. The antibodies produced after inoculation with the analogue-BSA 
conjugate will recognise sites on both BSA and the vitamin K analogue. The antibodies 
harvested were screened for activity towards vitamin K. To acheive this a sample of 
mouse blood was placed in a microtitre plate containing the analogue-Tg conjugate. Any 
antibodies recognising the analogue, which are present in the blood, will bind to the 
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analogue-Tg conjugate and may be visualised by the addition of antimouse HRP 
antibodies. These antimouse HRP antibodies will bind to the antibodies in mouse blood, 
and upon addition of 3,3' ,5,5' -tetramethylbenzidine produce a blue colour. Testing via 
this method eliminates the possibility of detecting antibodies specific to the carrier 
protein BSA, as there is no BSA present in the test medium. Although tests showed that 
some analogue specific antibodies had been produced, all efforts to bind these antibodies 
with vitamin K (e.g. menadione) proved unsuccessful. From these results it was 
postulated that the 'bridge effect' must have been occurring. This involves antibodies 
recognising both the vitamin K analogue and the chemical bridge used for conjugation to 
BSA, in this case the isoprene side chain and linker moiety, as opposed to the 
naphthoquinone core. With this in mind further analogues of vitamin K were designed 
which did not possess the long isoprenoid side chain (see section 4.4). 
4.3 MODEL COUPLING STUDIES 
Following observations by Dr Peter Elder during the conjugation studies, that some 
organic residue remained after coupling, model studies to investigate this coupling 
process were undertaken. The vitamin K analogues synthesised (3.70 and 3.80) possess a 
carboxylic acid functionality to allow coupling to a protein via peptide bond formation 
with the amine group of the lysine side chain. The model studies must, therefore, be 
carried out using lysine or short lysine containing peptides. For this reason the 
commercially available N-a-acetyl-Iysine and N-acetyl-glycine-Iysine methyl ester were 
used. The use of amino acids protected at the a amine was essential to block reaction of 
the vitamin K analogue at this site. 
Initially the peptide coupling method chosen for these studies was the mixed 
anhydride method, as this had been used for protein conjugation. However, reaction of 
3.70 and N-a-acetyl-Iysine methyl ester via the mixed anhydride method was hampered 
by solubility problems. The preparation of a solution of N-a-acetyl-Iysine methyl ester 
and triethylamine in DMF proved difficult, with some solid remaining after gentle 
heating and sonication. This would suggest that this method is not ideal for the protein 
conjugation studies. After addition of this to a solution containing the analogue (3.70), 
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N-methyl morpho line, and isobutyl chloroformate at 5°C, the reaction was allowed to 
warm slowly to room temperature. Subsequent work-up and analysis of the crude 
product by 1 H NMR analysis showed no indication of a successful coupling. The 1 H 
NMR spectrum showed only the resonances of 3.70, with no resonances corresponding to 
the amino acid moiety of the coupled product. As the mixed anhydride coupling had 
proved unsuccessful, EDCI was used in all further studies. 
4.3.1 COUPLING TO PROTECTED LYSINE 
The peptide coupling method used for these studies utilised the coupling reagent 1-
(3-dimethyl-aminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) see scheme 4.1.4 
The first EDCI coupling was attempted using an N-a-protected lysine residue (4.1), as it 
is the side chain amino group of lysine, and not the a amine, that is the target point for 
conjugation to the carrier protein. The coupling reaction consisted of the addition of 
EDeI, I-hydroxybenzotriazole hydrate, and diisopropylethylamine to a solution of the 
analogue (3.70) and N-a-acetyl-lysine methyl ester (4.1) in dichloromethane. After 
reaction for 18 hours the crude product was isolated and purified by radial 
chromatography. The desired product (4.2) was isolated in 55% yield and analysed by 
IH, 13e and two-dimensional NMR spectroscopy. 
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. Analysis of 4.2 by IH and BC NMR indicated that conjugation of 3.70 and lysine had 
been successful. The upfield shift of the C-9 methylene proton resonance from 2.63 ppm 
in 3.70, to 2.43 ppm in 4.2 is consistent with a change in functionality from an acid to an 
amide adjacent to this position. The presence of IH resonances for the lysine residue was 
also apparent. The IH NMR spectrum of 4.2 (see figure 4.3), showed a series of 
multiplets corresponding to the methylene proton resonances of the lysine side chain at 
1.35, 1.51, 1.71, 1.82, 3.20 and 3.26 ppm. The a proton resonance of lysine was 
observed as a multiplet at 4.56 ppm, while the methyl ester protons appeared as a singlet 
at 3.74 ppm. The acetyl-protecting group of the lysine appeared as a singlet at 2.04 ppm, 
and fmally the two NH protons were present at 5.94 and 6.37 ppm. Observation of a 
molecular ion (MHl at 569.2871 was also consistent with the desired product 4.2. 
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Figure 4.3: lH NMR spectrum of 4.2 
4.3.2 COUPLING TO GL Y -L YS DIPEPTIDE 
Having successfully coupled analogue 3.70 to a protected lysine residue, coupling to 
a dipeptide containing lysine was undertaken. The glycine-lysine dipeptide was chosen 
as it was commercially available, and did not contain a free a-amine group which would 
give more than one possbile reaction site. The same methodology as described above 
was used in the coupling of analogue 3.70 to N-acetyl-glycine-Iysine methyl ester (4.3) 
(scheme 4.2). Upon work up and purification by radial chromatography, conjugate 4.4 
was isolated in 50% yield and subsequently analysed by NMR spectroscopy and mass 
spectrometry. 
o 
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Scheme 4.2 
Analysis of the isolated product by lR NMR spectroscopy showed several signals 
consistent with the desired conjugate 4.4. The methylene resonances of the succinyl ester 
shifted from 2.58 and 2.63 ppm in the. 3.70, to 2.44 and 2.62 ppm in the conjugated 
product. The shift in C-9 proton resonance is consistent with its change in environment 
due to the adjacent functionality being converted from an ester to an amide. The three 
resonances at 6.25, 6.74 and 7.04 ppm were consistent with the presence of three amide 
protons in 4.4. The methylene resonance of glycine is observed as a multiplet at 3.95 
ppm, while the C-ll proton resonances of the lysine side chain appear as a pair of 
multiplets at 3.18 and 3.26 ppm. The remaining proton resonances of the lysine side 
chain are observed upfield as multiplets at 1.32 (2R), 1.49 (2R), 1.70 (lR) and 1.85 (lR) 
ppm. Finally the lysine a proton resonance is a multiplet at 4.53 ppm. 
Modelling of the coupling reaction of a vitamin K analogue (3.70) with simple amino 
acids or dipeptides has shown that the mixed anhydride peptide coupling method is not 
suited to this reaction. Model couplings of 3.70 and N-acetyl-Iysine methyl ester via the 
mixed anhydride method showed no coupled product, whereas the same reaction using 
EDCI coupling conditions proceeded to give the coupled product 4.2 in 55% yield. 
4.4 DESIGN AND SYNTHESIS OF FURTHER VITAMIN K 
ANALOGUES 
The results of initial immunology studies (see section 4.2) suggested that attempts 
to raise antibodies to recognise the quinone moiety of vitamin K may have been 
hampered by the 'bridge effect'. This means that antibodies produced by the host 
recognise a linker between the desired antigenic moiety (in this case the quinone core of 
vitamin K analogues 3.70 or 3.80) and the carrier protein (BSA). In an attempt to 
overcome this problem three further vitamin K analogues were designed which did not 
possess the natural long isoprene side chain of vitamin K. The three analogues designed 
(see figure 4.4) did, however, retain the carboxylic acid functionality to allow conjugation 
to a carrier protein for immunological studies, and the 2-methyl-1 A-naphthoquinone core. 
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Figure 4.4 Structures of short chain target analogues 
Analogue 4.5 has previously been synthesised by Masaki et al. 5 via hydrolysis of the 
corresponding methyl ester, which was prepared from an allylic sulfide by sulfur-
contractive anionic [2,3]-sigmatropic rearrangement. This synthesis had proceeded in 
15% yield, and afforded a mixture of the cis and trans isomers. It was recognised, 
however, that this analogue could be synthesised in two steps (scheme 4.3) from 3.77, an 
intermediate in the synthesis of 3.70 discussed in chapter 3~ The aldehyde (3.77) was 
directly oxidised to the corresponding carboxylic acid (4.8) in 50% yield, using silver 
nitrate and sodium hydroxide. This carboxylic acid was then deprotected with CAN to 
afford 4.5 in 60% yield after purification by radial chromatography. 
OMe OMe 
0 NaOR 0 
R OR 
OMe OMe 
3.77 4.8 
0 
) CAN 
0 
(OR 
0 
4.5 
Scheme 4.3 
The synthesis of analogues 4.6 and 4.7 began with the same brominated core compound 
(3.11) used in the earlier synthesis of analogues 3.70. This protected quinone (3.11) was 
coupled to ethylbromoacetate using a cuprate coupling (see section 3.4.3) to give 4.9 
(scheme 4.4). The yield from this coupling reaction, after purification by radial 
chromatography, was found to be 35%, which is much lower than the 80% yield observed 
using analogous reaction conditions with geranyl bromide. A similar lowering in yield 
for the cuprate coupling reaction was observed by Chenard et al when comparing the 
coupling of methylbromoacetate to a quinone core, with the analogous reaction using 
allylic bromides.6 Reduction of 4.9 with lithium aluminium hydride afforded the 
corresponding alcohol (4.10) in 90% yield as a white solid after radial chromatography. 
This was then reacted with succinic anhydride in the presence of N,N-
dimethylaminopyridine and triethylamine to give the succinyl ester (4.11) in 55% yield. 
Oxidative deprotection of the quinone with CAN and radial chromatography, afforded 
analogue 4.7 in 75% yield. 
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The synthesis of analogue 4.6 proceeded in two steps (scheme 4.5) from the ester 4.9 
used in the synthesis of analogue 4.7. Hydrolysis of the ethyl ester with potassium 
carbonate in refluxing methanol afforded the corresponding carboxylic acid (4.12) in 
73% yield. The oxidative deprotection of 4.12 using CAN, although attempted several 
times, always gave a complex mixture of products. All attempts to purify this mixture by 
radial chromatography or recrystallisation proved unsuccessfuL Due to time constraints 
further investigation of this step were not possible. 
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Following the successful synthesis of analogues 4.5 and 4.7, these were used in 
model coupling reactions with N-acetyl-Iysine and N-acetyl-glycine-Iysine methyl ester. 
These reactions were used to establish that peptide coupling between the carboxylic acid 
functionality of analogues 4.5 and 4.7, and the amine group of a lysine residue was 
possible. Analogue 4.5 was coupled to N-a-acetyl-lysine methyl ester, while both 4.5 
and 4.7 were coupled to the dipeptide N-acetyl-glycine-Iysine methyl ester (scheme 4.6) 
using the EDCI coupling method outlined earlier (see section 4.3.1). Following 
extraction and purification by radial chromatography coupled products 4.13, 4.14, and 
4.15 were isolated in 51 %, 31 % and 85% yield respectively. These products were 
analysed by NMR spectroscopy and mass spectrometry. 
4.5 
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N-a-acetyl-Iysine methyl ester 
4.5 
+ 
N-acetyl-glycine-Iysine methyl ester 
4.7 
+ 
N-acetyl-glycine-lysine methyl ester 
Scheme 4.6 
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Analysis of 4.13 by IH NMR spectroscopy showed several resonances indicative of 
successful coupling. The resonances for protons at C-4 and C-5, which are observed at 
2.29 and 2.41 ppm respectively in 4.5, overlap in the conjugated compound to give a 
multiplet at 2.29 ppm. This is due to the change in chemical environment of the protons 
at C-5 following the conversion of the adjacent acid functionality in 4.5, to an amide in 
4.13. The presence of two amide resonances at 5.72 and 6.32 ppm, and the resonance of 
the a-proton of lysine at 4.54 ppm are also indicative of the presence of the desired 
product 4.13. The terminal methylene resonance of the lysine side chain was observed as 
a multiplet at 3.17 ppm, while the other lysine side chain resonances were observed at 
1.28, 1.46, 1.68 and 1.80 ppm. A molecular ion (M+H) observed at 483.25 by mass 
spectrometry, is also consistent with 4.13. 
Similar results were observed in the IH NMR analysis of conjugate 4.14. The 
resonances for the protons at C-4 and C-5 at 2.29 and 2.41 ppm respectively in 4.5, are 
seen as a single multiplet at 2.29 ppm in 4.14. The tenninal methylene resonance of the 
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lysine side chain is observed as a broad multiplet at 3.12 ppm, which is consistent with 
results from the analogue-lysine conjugate (4.13). Differences observed in this spectrum, 
when compared with that of 4.13, include a multiplet at 3.92 ppm for the methylene of 
glycine, and the presence of three amide proton resonances at 6.17, 6.80 and 7.10 ppm. 
The coupling of analogue 4.7 to the protected glycine-lysine dipeptide also proceeded 
smoothly. The IH NMR of the conjugated product (see figure 4.5) showed a downfield 
shift of proton resonances of C-4 and C-5 to 2.61 ppm from 2.55 ppm in 4.7. The 
methylene adjacent to the side chain amine of lysine is observed as two distinct multiplets 
at 3.14 and 3.24 ppm. The methylene protons of glycine are observed as a multiplet 
at 3.95 ppm, and the a-proton resonance of lysine is seen as a mUltiplet at 4.54 ppm. 
Finally the three amide proton resonances are observed at 6.41,6.86, and 7.16 ppm. The 
observation of a molecular ion (M+H) at 558.25 is consistent with the coupled product 
4.15 (C2sH36N309)' 
I 
Ii 
o 
~ 0 Me02C 0 ~oNN~N~tfIrMe 
I 
S 
o 0 H H 0 
4.15 
Figure 4.5: IH NMR spectrum of conjugate 4.15 
Two further analogues of vitamin K have been successfully synthesised for use in 
further immunological studies. A new synthetic route to 4.5 has been developed which is 
higher yielding than the reported synthesis,s and produces purely the desired trans 
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isomer. Analogue 4.7 is a new compound prepared via a simple three step synthesis from 
a protected quinone core 3.11 and ethylbromoacetate. These two analogues have 
successfully been coupled to N-acetyl-lysine and N-acetyl-glycine-lysine methyl ester in 
model studies for their conjugation to carrier proteins during immunology studies. 
4.5 FURTHER IMMUNOLOGY STUDIES 
The second series of vitamin K analogues (4.5 and 4.7) were also forwarded to Dr 
Peter Elder for immunology studies. The coupling of 4.5 and 4.7 to BSA and Tg via a 
mixed anhydride coupling encountered similar solubility problems to those observed 
during the coupling of 3.70 and 3.80. However, the crude products from the conjugation 
of these analogues with BSA were used for the inoculation of mice. After 6 weeks a 
blood sample was obtained from these mice via a tail bleed. Upon testing against the 
analogue-Tg conjugates, as described in section 4.2, antibodies specific to the analogue 
moiety of the conjugates were detected. Attempts to competitively bind these antibodies 
with vitamin K3 were unsuccessful, implying the quinone moiety was not being 
recognised by the antibody. It was postulated that the 'bridge effect' must again be 
interfering with the production of antibodies suitable for MCA production. 
The analysis of analogue-protein conjugates was attempted by mass spectrometry, 
however problems with detection of the large molecular ions by electrospray mass 
spectrometry meant no further information was obtained. Cleavage of the analogue-
protein conjugates with a protease and the use of LC-MS is a possible route to 
overcoming detection problems and thereby obtaining information on the number of 
analogue molecules attached to each protein, as well as the sites of conjugation. 
However, time constraints meant this was not possible. 
Initial immunological studies using the vitamin K analogues 3.70 and 3.80 
encountered problems with differing solubiliy profiles of the analogues and the proteins. 
This led to model studies of the peptide coupling process, which suggested that the EDCI 
coupling was a more effective method than the mixed anhydride coupling for this system. 
Use of the crude analogue-protein conjugates to inoculate mice led to the isolation of 
antibodies that recognised the analogue moiety of the conjugate. These antibodies would 
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not however, competitively bind vitamin K3 suggesting the quinone core of vitamin K 
was not being recognised. The design and synthesis of two further analogues of vitamin 
K (4.5 and 4.7), which do not possess the natural isoprene side chain, was carried out in 
further attempts to produce an analogue capable of raising monoclonal antibodies towards 
the quinone core of vitamin K. However, the inoculation of mice with conjugates of 4.5 
or 4.6 with BSA failed to produce antibodies suitable for MCA production. 
Should MCAs which recognise vitamin K be raised it is recognised that assay 
development will still be a difficult process due to the lipophilicity of vitamin K and 
hydrophilicity of antibodies. During the course of an assay the antibody and antigen 
(vitamin K) must be present in the same phase to allow binding. One possible solution to 
this problem would be the synthesis of artificial organic soluble antibodies via molecular 
imprinting. 
Molecular imprinting is a technique that involves the production of synthetic 
examples of molecular recognition. 7 This technique involves the production of an 
imprinted polymer capable of combining the advantages of synthetic plastics, such as low 
cost, durability and robustness, with the recognition properties of natural receptors, e.g, 
antibodies.7 This is achieved by using elements of the target molecule to create it's own 
recognition site, by forming a highly cross-linked polymeric matrix around a template, 
which can be the target molecule itself or a close structural analogue.7 Non-covalent 
imprinting has successfully been applied to many compounds of biological importance 
including amino acid derivatives and peptides,8 ~-blockers,9 and diazepam. JO A full 
investigation of this technique falls beyond the scope of this thesis, but this poses a 
potential solution to the solubility problems encountered, and therefore a route to a 
synthetic 'immunoassay' for vitamin K. 
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CHAPTERF 
SYNT ESIS OF CoQ AN OGUES 
5.1 INTRODUCTION 
Although structurally related to the K vitamins, coenzyme Q (or ubiquinone) 
plays a vastly different role in biological systems. Ubiquinones have been shown to 
function as mobile mediators for electron transfer and proton translocation between 
redox enzymes in the electron transport chain of mitochondria and bacterial 
respiratory systems (see chapter 1). Coenzyme Q (CoQ) is required for at least three 
of the mitochondrial enzymes (complexes I, II and III) as well as enzymes in other 
parts of the celL It has been implicated that coenzyme Q-lO (CoQ-lO) 
supplementation is advantageous to a number of disease states including cardio-
vascular disease, cancer and gum disease, as well as boosting energy and brain power. 
Due to the remarkable physiological and clinical activity of CoQ-1 0 there has been 
much interest in the development of an efficient synthesis of the ubiquinones and 
analogues of these compounds. 
Due to the chemical similarities between the K vitamins and CoQ, it was 
recognised that analogues of CoQ could be synthesised by a route analogous to that 
devised for vitamin K (see chapters 3 and 4). Outlined below is a review of current 
literature procedures for the synthesis of CoQ and its analogues. This is followed by a 
discussion of the synthesis undertaken towards four side-chain functionalised 
analogues of CoQ suitable for immunological studies towards the production of an 
assay for CoQ. Model coupling reactions of one of these analogues to protected 
amino acids is also discussed. 
PREVIOUS WORK ON SYNTHESIS OF COENZYME Q 
In 1959 Shunk et all coupled s01anesol, believed to contain 10 isoprene units, to 
2,3-dimethoxy-5-methylhydroquinone to give a compound which was found to differ 
in physical properties from isolated CoQ-10, but was indistinguishable from CoQ-9. 
From this work solanesol was identified as only containing 9 isoprene units. Shortly 
thereafter CoQ-10 was successfully synthesised by Ruegg et al from decaprenol and 
2-methyl-5,6-dimethoxyhydroquinone.2 Since this time many researchers have 
endeavoured to increase the efficiency and control of stereochemistry in the synthesis 
of this important class of compounds. 
The use of n-allylnickel halide complexes in the carbon-carbon bond forming 
step of this synthesis was first studied by Sato et al in 1972.3 The condensation of 6-
bromo-2,3-dimethoxy-5-methylhydroquinone bis(methoxymethyl) ether (5.1) and 1,1-
dimethyl-n-allylnickel bromide (5.2) in HMPA, followed by hydrolysis of the ether 
and oxidation, gave CoQ-l (5.4) in 40% yield (scheme 5.1). A similar approach was 
5.2 
OCH20Me 0 Meo~ .......... Me Meo~e 
------- ..... ----- I I 
MeO ~ '-'::: MeO '-'::: 
OCH20Me 0 
OCH20Me 
MeO*Me I + 
~ MeO Br 
OCH20Me 
5.1 5.3 5.4 
Scheme 5.1 
utilised by Hegedus et at who synthesised CoQ-1 in one step via the condensation of 
2,3-dimethoxy-5-methyl-benzoquinone and 1,1-dimethylallylnickel bromide. This 
reaction used a 4: 1 ratio of quinone:Ni complex and proceeded in 30% yield with 
respect to consumed quinone,. after purification by preparative layer chromatography. 
This n-allylnickel chemistry was again used by Inoue in 1974 to synthesise CoQ-9 
and CoQ-1O.5 Reaction of 1,4-diacetoxy-2-bromo-5,6-dimethoxy-3-methylbenzene 
(5.5) with rc-solanesylnickel bromide (5.6) (scheme 5.2), followed by removal of the 
acetate groups and oxidation to the corresponding quinone (5.8) gave CoQ-9 in 48% 
yield. This product was isolated as a mixture with a cis:trans ratio of 26:74, which 
were separable by silica chromatography. Similarly CoQ-lO (n=lO) was produced in 
28% yield, also as a mixture of cis and trans isomers.5 The stereo selectivity of this 
reaction was investigated in various solvents with the highest trans:cis ratio occuring 
with the use of MN-dimethylacetamide, giving 75% trans selectivity. Hegedus and 
Evans studied the mechanism of the reaction of n-allylnickel bromides with quinones, 
or quinone synthons.6 
OAc 
MeO*Me I + o MeO Br 
OAc 
OAc 0 
H _->-... Meo~,-,::: Me _ MeoDMe < 
MeO ~ '-'::: H MeO~H 
OAc nOn 
5.5 5.6 5~ 5~ 
Scheme 
Maruyama and Naruta in 1978, reported an improved synthesis of CoQ-l using 
allyltin reagents.7 Dimethylallyltributyltin (5.10) was reacted with 2,3-dimethoxy-5-
methylbenzoquinone (5.9) to give, after chromatography, CoQ-1 (5.4) in 75% yield 
(scheme 5.3). This method had several advantages over earlier syntheses as allyation 
occurred only at the non-substituted site of the quinone ring, the prenyl group was 
introduced without isomerisation, and the prodecure was shown to be applicable to a 
range of quinones in good yields (60-90%).7 
a 
MeaqMe I I + 
Mea 
a 
5.9 
Scheme 5.3 
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In 1980 Syper et al8 synthesised CoQ-2 using cup rate chemistry. The formation 
of the diaryl cuprate of 1-methyl-2,3,4,5-tetramethoxybenzene using CuBr, followed 
by reaction with geranyl bromide afforded CoQ-2 in 66% yield after oxidative 
deprotection of the quinone. 
Due to the high expense and limited availability of the decaprenyl unit for the 
synthesis of CoQ-IO, many researchers elected to build the polyprenyl chain from 
simpler monomer units which were more readily available. The reaction of an allyl 
halide with a p-tolylsulfonate was a popular approach. The first synthesis of CoQ 
using this approach was reported by Terao et at in 1978, where side-chain elongation 
was used to convert CoQ-7 to CoQ-10 (scheme 504). Through a series of functional 
group interconversions the terminal double bond of the prenyl side chain of CoQ-7 
(5.11) was converted to an allyl chloride (5.12). This could then be reacted with 
trans, trans p-tolylsulfonylfamesene (5.13) to give a protected CoQ-IO analogue 
(5.14) with complete retention of stereochemistry. Deprotection and oxidation gave 
CoQ-IO in 33% yield overall. 
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A year later Terao et at utilised the same chemistry to synthesise CoQ-lO from 
COQ_O.10 In this case however, the benzylic core was functionalised with a single 
isoprene unit bearing a phenyl sulfonate group (5.16), and reacted with solanesyl 
bromide (scheme 5.5). When followed by removal of the benzyl and phenyl sulfonyl 
groups, and oxidation of the resulting hydroquinone this gave CoQ-10 in 49% yield. lO 
~-MeoY 
o 
::8 --_~lIIP"" :::& ~ . SO,Ph 
OBz ~
5.9 
Meo~o 
I I 
MeO ~ H 
o 10 
Scheme 5.5 
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Since this work several groups have reported modifications to this chemistry in 
an attempt to increase yields, and make these reactions more amenable to larger scale 
syntheses. In 1982 Fujita et alll presented an improved synthesis of the sulfone 
functionalised benzene intermediate (5.16) in only two steps from 2,3-dimethoxy-5-
methylhydroquinone. The same year Sato et al12 proposed a slightly different 
approach to CoQ-10 using the same chemistry outlined above. Coupling of the 
Gringard reagent of a protected quinone core with isoprene epoxide in the presence of 
CuClafforded the corresponding trans allylic alcohol in 77% yield. This alcohol was 
then converted to the bromide and coupled with solanesyl p-tolyl sulfone. After 
removal of the sulfone groups and deprotection of the quinone this afforded CoQ-lO. 
ill 1986 Mohri et al13 presented an investigation of the desulfonylation reaction in 
an effort to overcome the production of a small amount of the /).3 alkene product. By 
choosing a synthon which placed the sulfone at the 5-position of the side chain, 
instead of the 4-position, complete stereo selectivity for the /).2 alkene was observed, 
but 5% ofthe cis isomer at the /).6 position was isolated. 
Naruta14 in 1980, synthesised an all-trans decaprenyl side chain from simpler 
prenyl units using a similar approach (scheme 5.5). A phenylsulfonylprenyl unit 
(5.15) was reacted with an allyl chloride prenyl unit (5.16) to effect chain elongation. 
Once the desired chain length was achieved, this was converted to the corresponding 
trimethylpolyprenylstannane, which was coupled to a quinone core using 3 
equivalents of BF
3
,OEt
2
• This method was used to synthesise CoQ-3 to CoQ-9 in 
yields of 40 to 90% with a trans:cis ratio of 98:2. CoQ-10 was also synthesised in 
this way, in 51% yield with a trans:cis ratio of 86:14. The reason for the lower 
stereo selectivity in this case is not disclJssed,14 
5.15 5.16 
Scheme 5.5 
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This strategy of systematically building the polyprenyl side chain from simpler 
units was also employed by Eren et al (scheme 5.6),15 They designed an 
oligomerisation approach utilising monoterpene monomers derived from geraniol, and 
Pd(O) coupling techniques. Once a chain of the desired length had been synthesised 
the substituents remaining from the coupling process were removed collectively. The 
methyl carbonate groups were removed initially with p-aminothiophenol and cesium 
carbonate, followed by removal of the sulfonyl groups with Pd( dppp )Ch and lithium 
triethylborohydride. Final deprotection of the quinone with CAN afforded CoQ-4 in 
60% yield from 5.19 and CoQ-IO in 20% yield from 5.19,15 
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Another approach used in the synthesis of ubiquinones is based on Diels-Alder 
chemistry (scheme 5.7).16 In this strategy the quinone moiety is synthesised via a 
Diels-Alder reaction between 1,1 ,2-trichloroethene (5.26) and 2,5-
bis[(trimethylsilyl)oxy]-3-methylfuran (5.27). Methanolysis of the Diels-Alder 
adduct (5.28) to give 5.29 was followed by reaction with cyclopentadiene and 
substitution of the chloride groups for methoxy groups to give a diketone intermediate 
(5.31). This intermediate is readily alkylated with the desired polyprenol (5.32) using 
a strong base to give 5.33. Finally a retro-Diels-Alder reaction reveals the 
corresonding CoQ in a yield of 26% for both CoQ-5 and CoQ-9 from 5.29.16 
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The coupling reaction of a polyprenyl side chain and protected core has more 
recently been investigated by Lisphutz et at.17 The core compound used in this case is 
a benzylic halide (5.34) which is reacted with vinylalane 5.35 in the presence of 0.5 
mol % Ni(O) catalyst at room temperature for 15 minutes (scheme 5.8), to afford 5.36 
in 87% yield. This is an improvement over the previously used methods of copper 
catalysed Grignard coupling, which didn't give complete retention of 
stereochemistry,18 and Pd(O) based couplings which are more expensive, employ 
harsh reaction conditions and require longer reaction times, while proceeding in lower 
yeilds. 15 
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A small amount of work has also gone into producing various analogues of 
coenzyme Q including fluorescently19 and isotopically labelled analogues?O The 
study of protein-coenzyme Q analogue interactions by He et at.21 ,22 has also led to the 
synthesis of many analogues of CoQ, including compounds alkylated at the 
position21 and ethoxy- derivatives of the 2- and 3- positions.22 Analogues with side 
chains containing various levels of unsaturation have also been synthesised in an 
effort to establish the role of the isoprene chain in the interaction between respiratory 
enzymes and COQ.23 
Of more interest for our work are the limited reports of the synthesis of side-chain 
functionalised analogues of CoQ. In 1978 Terao et al produced a series of such 
analogues in the process of functionalising CoQ-7 for chain elongation.9 These 
included such functionalities as bromohydrins, epoxides, ruols, aldehydes, allyl 
acetates and allyl alcohols. Some years later the same group prepared a series of 
quinone acid, amide, alcohol and methylketone derivatives.24 These compounds were 
synthesised via a series of functional group interconversions of CoQ compounds with 
varying chain length. The synthetic route used is the same as that described 
previously (scheme 3.14) for the corresponding synthesis of vitamin K analogues. 
The synthetic route outlined below, to the production of side-chain fenctionalised 
analogues of CoQ (5.37 and 5.38) is similar to that used by Terao et ap4. However, 
as was the case with vitamin K2, the scheme has been shortened to remove 
unnecessary chain elongation steps. As the chemistry of vitamin K and CoQ are so 
closely related the same synthetic route was applied to the production of analogues of 
CoQ as outlined in sections 3.5 and 4.4 for the synthesis of vitamin K analogues. 
5.3 SYNTHESIS OF COENZYME Q ANALOGUES 
As discussed for the case of vitamin K earlier in this thesis, the synthesis of 
analogues of CoQ was undertaken with emphasis on the production of an analogue 
suitable for conjugation to a carrier protein (see section 3.1). For this reason a 
carboxylic acid functionality at the side chain terminus of the target analogue was 
chosen to allow amide bond formation with the amine group of a lysine side chain on 
the surface of a potential carrier protein. Upon successful synthesis of such an 
analogue, and conjugation to a carrier protein, this may be used to inoculate mice, 
stimulating the production of antibodies for use in the preparation of monoclonal 
antibodies (see chapter 4 for details). The synthetic route adopted is a parallel 
synthesis to that described earlier for the synthesis for vitamin K analogues. The 
initial target compounds designed are shown in figure 5.1. 
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Figure 5.1: Structures of desired coenzyme Q analogues 
The retrosynthetic analysis of these target analogues is shown in figure 5.2. All 
of these compounds arise from the coupling of a protected quinone core (5.42) and a 
side chain moiety (5.43 or 5.45). The first step therefore, in the synthesis of these 
analogues, is the·· production of l-bromo-2-methyl-3,4,5,6-tetramethoxybenzene 
(5.42), the protected benzoquinone core. 
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Figure 5.2: Retrosynthetic analysis of CoQ analogues 
5.3.1 SYNTHESIS OF PROTECTED CORE MOEITY 
The protected quinone core (5.42) is readily synthesised via bromination of 1-
methyl-2,3,4,5.tetramethoxybenzene (5.48). Upon reviewing the literature, it was 
found that many groups had synthesised 5.48 via complicated multistep procedures 
from highly functionalised aromatic starting materials such as vanilline,25 and 
pyrogalloL8 However, Keinan and Eren26 published a convenient two step synthesis 
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of 1-methyl-2,3,4,5-tetramethoxybenzene (5.48) from the readily available starting 
material p-cresol (5.56) (scheme 5.9), reporting an overall yield of 71 %. 
Br OMe 
iY )[7 M~* 10 Ih 10 HO h HO MeO h 
5.46 Br OMe 
5.47 5.48 
Scheme 5.9 
Tribromination of p-cresol (5.46) with bromine in chloroform afforded 2,3,6-
tribromo-4-methylphenol (5.47) as white needles in 61% yield after recrystallisation 
from petroleum ether. The second step in the synthesis, copper-catalysed 
methoxylation of 5.47, followed by methylation with dimethyl sulfate to yield 5.48 is 
a one-pot process.26 Following the literature procedure this yielded a crude product, 
which was purified using radial chromatography, into three fractions. Identification 
of these fractions proved difficult by lH NMR analysis as all protons in the various 
products were in similar chemical environments. For this reason all characterisation 
was carried out by mass spectrometry. The frrst fraction contained a product which 
still possessed two bromine atoms, the second fraction was a mixture of 5.48 and a 
monobrominated product, and the third fraction contained a mixture of minor by-
products which were not identified. Despite this reaction being attempted several 
times, yields of the desired product were poor and isolation by chromatography 
proved difficult, even though a 94% yield without need for purification was reported 
in the literature?6 Due to the problems encountered, a new synthetic route to 5.48 
was developed (scheme 5.10). This synthesis involved the protection of 2,3-
dimethoxy-5-methyl-1,4-benzoquinone (CoQ-O) (5.9) in a process analogous to that 
used in the protection of vitamin K3 (see section 3.4.1). 
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Scheme 5.10 
Reaction of 5.9 with stannous chloride and concentrated hydrochloric acid, 
followed by extraction into ethyl acetate afforded an off white solid identified as 5.49 
by lH NMR analysis. This isolated product was directly methylated to 5.48 in order 
order to minimise any reoxidation to the quinone. The hydroquinone mixture was 
suspended in dimethylsulfate and potassium hydroxide was added portionwise. 
Reaction at 80°C for one hour followed by extraction, yielded 5.48 as a pale yellow 
oil (85% yield over two steps). 
The final step in the preparation of a core compound suitable for analogue 
production is the bromination of l-methyl-2,3,4,S-tetramethoxybenzene (5.48). This 
was carried out following the procedure of Syper et al. 8 Reaction of 5.48 with 
bromine for 10 minutes afforded I-bromo-2-methyl-3,4,S,6-tetramethoxybenzene 
(5.42) as a yellow oil in 84% yield. The isolated product was found to be clean by IH 
and l3C NMR spectroscopy, and could be identified by the loss of any proton 
resonance at 6.44 ppm corresponding to the aromatic proton of 5.48. The singlet of 
the methyl ether protons also shifted downfield from 2.22 ppm for 5.48 to 2.30 ppm 
for 5.42. This isolated compound was used in the synthesis of coenzyme Q analogues 
without further purification. 
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A new and efficient synthesis of 1-methyl-2,3,4,5-tetramethoxybenzene (5.42) 
from 2-methyl-5,6-dimethoxy-l,4-benzoquinone (5.9) was developed. This involved 
the reduction of CoQ-O (5.9) with staunous chloride and concentrated hydrochloric 
acid to give the corresponding hydro quinone (5.49). This hydroquinone was directly 
methylated with dimethylsulfate and KOH to afford 5.48. Using the method of Syper 
et al,8 5.48 was brominated to give the desired protected benzoquinone core 5.42, for 
use in the synthesis of coenzyme Q analogues. 
5.3.2 SYNTHESIS OF COENZYME Q ANALOGUES 
The synthetic route described below for the preparation of coenzyme Q analogues 
is analogous to that used in the preparation of vitamin K analogues (see sections 3.5 
and 4.4). The target analogues (see figure 5.1), were designed based upon the second 
series of vitamin K analogues produced (4.5 and 4.7) (see section 4.4). 
Analogues 5.37 and 5.38 were both synthesised from the common intermediate 6-
(2-methyl-3,4,5,6-tetramethoxyphenyl)-4-methylhex-4-enal (5.50) (see figure 5.3). 
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Figure 5.3: Intennediate aldehyde (5.50), used for the synthesis of 5.37 and 5.38 
The first step in the synthesis of 5.50 is the coupling of I-bromo-2-methyl-
3,4,5,6-tetramethoxybenzene (5.42) with geranyl bromide.8 The diaryl cuprate of 
5.42 was formed via treatment with nJ:3uLi and copper bromide dimethylsulfide, and 
this was then reacted with geranyl bromide. Purification of the crude product by 
radial chromatography gave 5.41 as a yellow oil in 50% yield. This yield was lower 
than expected based on the preparation of 3.67 (see section 3.4.3), and literature 
results of 76% yield.8 This may be due to the need for recrystallisation of the copper 
bromide dimethylsulfide complex, which loses dimethyl sulfide over time leading to 
incorrect stoichiometry of the reaction. Analysis of the isolated product (5.41) by III 
NMR spectroscopy showed evidence of the presence of trace amounts of the terminal 
alkene, arising from attack at the 3 position of the alkyl bromide. This was suggested 
by the presence of two small multiplets at 4.88 and 6.27 ppm, indicative of the proton 
resonances of a terminal alkene. 
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Treatment of 5.41 with N-bromosuccinimide, followed by work up and 
purification by radial chromatography afforded the bromohydrin (5.51) as a yellow oil 
in 65% yield (scheme 5.13). Upon analysis by III NMR spectroscopy the two C-4 
proton resonances were multiplets at 1.79 and 1.98 ppm, while the C-5 proton 
resonances were two multiplets at 2.09 and 2.35 ppm. Each ofthese four protons is in 
a unique chemical environment, and hence have a different chemical shift, due to the 
presence of a stereo genic centre at C-3, which makes the protons at C-4 and C-5 
diastereotopic. 
Reaction of the bromohydrin (5.51) with potassium carbonate gave the 
corresponding epoxide (5.52) in 78% yield (scheme 5.13). Analysis of the isolated 
product by IH NMR spectroscopy showed the absence of a doublet at 3.95 ppm 
corresponding to the C-6 proton of 5.51, and the presence of the corresponding proton 
resonance of the epoxide as a triplet at 2.67 ppm. This product was clean by both IH 
and J3C NMR analysis, and was used without further purification. 
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Reaction ofthe epoxide (5.52) with periodic acid yielded, after work up, a yellow 
oil (85%), which was identified by IH NMR analysis to be aldehyde 5.50 (scheme 
5.13). This was confrrmed by the presence of a singlet in the IH NMR spectrum at 
9.74 ppm, and a peak in the I3C NMR spectrum at 202.47 ppm, both corresponding to 
the aldehyde functionality of 5.50. This aldehyde (5.50) was used in the synthesis of 
5.37 and 5.38 without further purification. 
Target analogue 5.37 was synthesised from the aldehyde (5.50) in two steps 
(scheme 5.14). The oxidation of 5.50 to the carboxylic acid 5.53 was achieved with 
silver nitrate and sodium hydroxide in ethanol, and afforded after work up, 5.53 as a 
yellow oil in 78% yield. NMR spectroscopy of the carboxylic acid showed few 
differences from the spectra obtained for 5.50. The IH NMR spectrum of 5.53 no 
longer possessed a peak at 9.74 ppm, and showed an up field shift from 2.52 to 2.45 
ppm for the C-2 methylene proton resonance. In the BC NMR spectrum of 5.53 the 
aldehyde signal at 202.47 ppm, was replaced with a peak at 178.47 ppm 
corresponding to the carbon of the carboxylic acid functionality. This carboxylic acid 
(5.53) was used without any further purification. Deprotection of the quinone core 
with CAN proceeded in 55% yield to give target analogue 5.37 as a yellow oil after 
purification by radial chromatography. The disappearance of the methyl ether 
resonances at 3.77 and 3.78 ppm in the proton NMR spectrum of 5.37, together with 
the appearance of two peaks at 183.79 and 184.60 ppm in the corresponding l3C NMR 
spectrum characteristic of the quinone, confinned that deprotection to the 1,4-
benzoquinone had occurred. 
OMe OMe 
0 
lOB 
2 
MeO A NO MeO g 3 .. 
NaOH 
MeO MeO 
OMe 
5.50 5.53 
0 
jeAN 
MeO 0 
MeO lOB 
0 
5.37 
Scheme 5.14 
The synthesis of target analogue 5.38 from aldehyde 5.50 is shown in scheme 
5.15. Reduction of the aldehyde (5.50) with sodium borohydride afforded the 
corresponding alcohol (5.54) as a pale yellow oil in 74% yield. Analysis by ill NMR 
spectroscopy showed no resonance corresponding to the aldehyde proton at 9.74 ppm, 
and the presence of the C-1 methylene proton resonance at 3.59 ppm, confinning that 
reduction to the alcohol had occurred. This alcohol was reacted with succinic 
anhydride in the presence of triethylamine and ~N-dimethy1aminopyridine for 18 
hours. Following work up, the crude product was purified by radial chromatography 
to give the succinic ester (5.55) as a pale yellow oil (82% yield). The downfield shift 
of the C-1 methylene resonance from 3.59 ppm for 5.54 to 4.05 ppm for IS 
explained by the conversion of the adjacent functionality from an alcohol to an ester. 
The presence of two mulitplets in the ill NMR spectrum of 5.55 at 2.59 and 2.65 
ppm, and 13C NMR signals at 172.22 and 176.96 ppm corresponding to the succinyl 
ester moiety, also confinned that esterification had occurred. 
Deprotection with CAN proceeded in 80% yield to afford target analogue 5.38 as 
an orange oil after purification by radial chromatography. As with 5.37, the 
disappearance of the methyl ether proton resonances at 3.78 and 3.79 ppm in the IH 
NMR spectrum, and the appearance of 13C NMR signals at 183.93 and 184.74 ppm, 
confirmed oxidation to the 1 ,4-benzoquinone was successful. 
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The retrosynthetic analysis for target analogue 5.39 was shown in figure 5.2. 
The first step in the synthesis of this analogue is the coupling of the I-bromo-2-
methyl-3,4,5,6-tetramethoxybenzene core (5.42) and ethyl bromo acetate (scheme 
5.16). 
Reaction of 5.42 and ethyl bromoacetate under standard cuprate coupling 
conditions8 gave a crude reaction mixture which was purified by radial 
chromatography to give three fractions. Analysis by IH NMR spectroscopy of these 
fractions showed fraction one contained a complex mixture of minor by-products, 
fraction two contained I-methyl-2,3,4,5-tetramethoxybenzene, and the desired 
product was isolated in the third fraction as a yellow oil in only 7% yield. IH NMR 
analysis of this product showed an upfield shift of the aromatic methyl resonance 
from 2.31 ppm for 5.42 to 2.09 ppm for 5.44. The other IH NMR signal indicative of 
reaction was the methylene resonance at 3.85 ppm in ethyl bromoacetate, and 3.51 
ppm in the coupled product 5.44. Although this reaction was repeated several times 
no increase in this yield was observed. A low yield when using methyl bromoacetate 
in cuprate coupling reactions, in comparison with alkyl bromides, has been previously 
documented. 27 A drop in yield from the coupling reactionof 3.11 with geranyl 
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bromide to that of 3.11 with ethyl bromoacetate was also observed in the synthesis of 
vitamin K analogues as discussed earlier (see chapter 4). 
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One alternative synthetic route to target 5.39 is outlined in scheme 5.17. This 
approach eliminates the low yielding cuprate coupling with ethyl bromo acetate, and 
replaces it with the use of allyl bromide for this coupling reaction, which has been 
documented to proceed in high yield.27 Oxidation and subsequent deprotection of the 
coupled product 5.56, would give the desired analogue 5.39. Due to lack of time this 
approach was not attempted, but this is a good starting point for future work in this 
area. Many other transition metal based coupling procedures have also been reported 
for the synthesis of coenzyme Q and related compounds, and these could also be 
investigated. 
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As the synthesis of analogue 5.40 also requires intermediate 5.44 (scheme 5.16), 
synthesis of 5.40 was not completed due to time constraints. Analogue 5.40, 
however, could be synthesised from 5.44 via the synthetic route outlined in scheme 
5.18. This chemistry has been investigated for the synthesis of vitamin K analogues, 
and it is expected to proceed smoothly. 
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Synthesis of the aldehyde inteInlediate (5.50), for use in the preparation of CoQ 
analogues 5.37 and 5.38 proceeded via functionalisation of the teIminal alkene of 
5.41. Although the method used for the bromohydrin fOInlation and epoxidation is 
reported in the literature,24 data on the bromohydrin (5.51) was not reported. The 
cleavage of epoxide 5.52 gave rise to the aldehyde 5.50, which has not previously 
been reported. 
A new synthesis to analogue 5.37 has been developed which is shorter and more 
efficient than that previously presented by Terao et aZ,z4 By oxidation of the 
inteInlediate aldehyde 5.50, and subsequent oxidative deprotection to the analogue 
5.37, rather than c1aisen rearrangement of a corresponding allylic alcohol we have 
reduces the number of steps and amount of purification required for this synthesis. 
The synthesis of analogue 5.38 has not previously been reported. This analogue 
was prepared in three steps from the inteInlediate aldehyde 5.50. Reduction of the 
aldehyde (5.50) to the corresponding alcohol, followed by esterification with succinic 
anhydride and oxidative deprotection afforded 5.38 which was fully characterised by 
one and two-dimensional NMR analysis and mass spectrometry. 
Due to the low yields observed in the cuprate coupling reaction of 5.49 with ethyl 
bromoacetate, synthesis analogues 5.39 and 5.40 was not achieved. Another route to 
analogue 5.39 utilising the cuprate coupling of 5.42 with allylic bromide, which has 
been previously studied, has been presented. The use of other transition metals could 
also be investigated to effect the coupling of 5.42 and ethyl bromoacetate. Although 
time constraints meant these alternatives could not be investigated there is a good 
basis for future synthetic studies in this area. 
5.4 COUPLING OF ANALOGUES TO DIPEPTIDES 
Having successfully completed the synthesis of two analogues of coenzyme Q 
(5.37 and 5.38), 5.37 was used in model peptide coupling reactions. The conjugation 
of analogues to a carrier protein for immunological study, will occur via the reaction 
of amino group of the side chain of lysine residues on the peptide with the carboxylic 
acid functionality of the analogue. For this reason, in model studies, protected lysine 
and a protected lysine-glycine dipeptide were used. 
The peptide coupling method chosen for the reaction of 5.37 with N-a-acteyl-
lysine methyl ester and N-acetyl-glycine-Iysine methyl ester was that mediated by 
EDCI. This coupling procedure was chosen over the other possible coupling methods 
in light of solubility and purification problems observed in the analogous couplings 
with vitamin K analogues (see chapter 4). The products synthesised in this manner 
are shown in figure 5.4. 
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Figure 5.4: Structures ofCoQ analogue-amino acid conjugates 
The coupled products were analysed and characterised by IH, BC, and two-
dimensional NMR techniques, as well as by mass spectroscopy. Upon analysis of the 
IH NMR spectrum of conjugate 5.58 several features confinned the presence of the 
desired product (see figure 5.5). The presence of the amide resonances at 5.77 and 
6.40 ppm in the IH NMR spectrum, and a mUltiplet at 4.55 ppm corresponding to the . 
a-proton of the lysine residue confinned successful conjugation. The side chain 
methylene proton resonances of lysine were observed as a series of multiplets at 1.35 
(2H) , 1.50 (2H) , 1.69 (lH), 1.82 (IH), and 3.21 (2H) ppm. The upfield shift of the 
methylene protons at C-2, from 2.43 ppm in 5.37 to 2.29 ppm in the conjugate, 
indicates the change in functionality from an acid to an amide adjacent to this site. 
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Similarly, analysis of conjugate ,5.42 by IH NMR spectroscopy gave similar 
1 . 
results. The H NMR spectrum of 5.42 contained three resonances at 6.03, 6.74, and 
7.08 ppm indicating the presence of three amide protons. The a proton resonance of 
lysine was observed as a multiplet at 4.53 ppm, while the side chain methylene proton 
resonances of the lysine residue were observed as a series of multiplets at 1.34, 1.46, 
1.71, 1.85, and 3.23 ppm. The a proton resonance of the glycine residue was 
observed as two doublet of doublets at 3.91 and 4.01 ppm. In this conjugate the 
methylene protons of C-2 and C-3 are no longer observed as two signals, but a single 
multiplet at 2.28 ppm. 
During this study two analogues of CoQ were successfully synthesised. A 
shorter more efficient route to the previously known analogue 5.37 is presented, while 
5.38 has been synthesised as a novel compound via a route analogous to that 
described for the synthesis of vitamin K analogues is chapter 3. Synthesis of 
analogues 5.39 and 5.40 were not completed due to time constraints and low yields of 
the cuprate coupling reaction between 5.42 and ethyl bromoacetate. Further study 
into the presented alternative routes to these analogues is required. 
The analogues of coenzyme Q synthesised in this study are suitable for use in 
studies towards the feasibility of an immunoassay for coenzyme Q levels in biological 
tissues. As such an assay is not currently available, and coenzyme Q has been shown 
to be important in many diseased states, this could be important for use in research 
and routine assessment in medical areas. 
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6.1 GENERAL PROCEDlJRES 
Nuclear Magnetic Resonance 
Proton detected NMR spectra were obtained on either a Varian Unity 300 
spectrometer operating at 300 MHz, or an Inova 500 spectrometer operating at 500 
MHz. Carbon detected NMR spectra were obtained on a Varian XL300 spectrometer 
or a Varian Unity 300 spectrometer both operating at 75MHz. All spectra were 
obtained at 23°C. Other two-dimensional NMR experiments used include HSQC, 
HMBC and CIGAR experiments, which were all obtained on the Inova 500 
spectrometer at 500 MHz. Chemical shifts are reported in parts per million (ppm), on 
the {} scale, and are referenced to the appropriate solvent peaks: CDCh referenced to 
(CH3)4Si at {} 0 ppm for IH spectra, and CDCh at {} 77.0 ppm for BC spectra. AU13C 
NMR spectra were obtained with a delay (D1) of 1 s. NMR spectra were assigned 
by.comparison, with all assignments verified by 2-D NMR experiments. 
Mass Spectrometry 
Mass spectrometry was performed by Electron Impact (EI) at 4 kV using a Kratos 
MS80 Mass Spectrometer. Where softer ionisation was required the technique of Fast 
Atom Bombardment (FAB) was used. All amino acid conjugates were analysed by . 
electrospray mass spectrometry using a Micromass LCT spectrometer. 
IR Spectroscopy 
IR spectra were obtained using a Shimadzu 8201PC series FTIR. All oils were 
analysed neat on KBr disks, and solids were pressed into a KBr disk for analysis. 
Melting Points 
Melting points were taken on an electrothermal apparatus and are uncorrected. 
Reagents and Solvents 
Unless otherwise stated all reactions were carried out in oven-dried, or flame-
dried glassware. Analytical thin layer chromatography (TLC) was conducted on 
plastic-backed Merck Keiselgel KG60F254 silica plates, and visualised using short 
wavelength ultraviolet light or potassium permanganate solution. Radial 
chromatography was carried out on Imm, 2mm or 4mm plates of Merck Silica Gel 60 
PF254 containing gypsum, and visualised with short-wavelength ultraviolet light. 
Flash column chromatography was carried out under a positive pressure of nitrogen 
using Merck silica gel 60 (230 to 400 mesh). All reagents were purified by 
established techniques. 1 Petroleum ether and dichloromethane were distilled over 
calcium hydride, and ethyl acetate was distilled from phosphorous pentoxide before 
use. Petroleum ether here refers to the fraction collected between 60 and 80°C. 
Diethyl ether and tetrahydrofuran were used freshly distilled from sodium 
benzophenone ketal, under a nitrogen atmosphere. Pyridine and triethylamine were 
distilled over calcium hydride, and pyridine was then stored over 4 A molecular 
sieves. Dimethylformamide was dried by placing over activated 4 A molecular 
sieves and standing for 24 h. This process was repeated four tim~s before the dry 
DMF was stored over 4 A molecular sieves under a nitrogen atmosphere. All other 
solvents were used as received from the supplier. Menadione, vitamin K2 and 
coenzyme Q-O were obtained· from Sigma Chemical Co. Geranyl bromide was 
obtained from Aldrich Chemical Co. Butyllithium was used fresh or titrated before 
use with sec-butanol and 1,10 phenanthroline to determine exact concentration.2 All 
other reagents were obtained from commercial sources. 
6.1.2 GENERAL METHODS 
General Method A: Cuprate COUpling3 
A solution of the aryl bromide (typically 1.8-2.5 mmol) in ether (to give a 0.6 M 
solution) was cooled to 0 °C under an argon atmosphere, and nBuLi (1.15 equiv) was 
added slowly. During this addition the reaction went green then dark red and after 
stirring at 0 °C for 30 min a pale precipitate formed. To this solution copper bromide 
dimethyl sulfide complex (0.7 equiv) was added, and stirring continued for 2.5 h 
during which time the solution turned dark purple. To this the alkyl bromide (1.1 
equiv) in ether (to give a I M solution) was slowly added and the reaction stirred at 0 
°C for 2 h and room temperature for 3 h. The reaction was quenched via the addition 
of 10% aqueous HC! and the ether layer separated. The aqueous phase was extracted 
with ether (x3), and the combined organic fractions were washed with saturated 
aqueous NaHC03, water, dried (MgS04) and solvent removed to give the crude 
product. 
General Method B: Bromohydrin Formation4 
A solution of alkene (typically 0.1 to 1.6 mmol) in THF (to give a 0.03 M 
solution) was cooled in an ice bath and water was added slowly to the reaction until it 
remained turbid. THF was then added dropwise until the reaction just cleared. N-
Bromosuccinimide (1.15 equiv) was added and the reaction stirred at room 
temperature for 3 h. The reaction was then extracted with ether (x3), dried (MgS04) 
and solvent removed to give the crude product. 
General Method C: Epoxidation of Bromohydrin4 
To a stirred solution ofbromohydrin (typically 0.05 to 0.9 mmol) in methanol (to 
give a 0.01 M solution) was added potassium carbonate (70 equiv) and the reaction 
was stirred at room temperature for 16 h. The reaction was filtered and solvent 
removed. Water was added and the resulting solution was extracted with 
dichloromethane, dried (MgS04) and solvent removed under reduced pressure. 
General Method D: Epoxide Cleavage with Periodic Acid4 
To a stirred solution of epoxide (typically 0.05 to 0.9 mmol) in ether (to give a 
0.02 M solution), was added a solution of periodic acid (1 equiv) in THF (to give a 
0.04 M solution). This was stirred at room temperature for 1.5 h during which time a 
fme precipitate formed. The reaction was quenched via the addition of water, the 
ether layer was separated and the aqueous phase extracted with ether (x2). Combined 
organic fractions were dried (MgS04) and solvent removed under reduced pressure. 
General Method E: Reduction of Aldehyde with Sodium Borohydride 
To a stirred solution of sodium borohydride (1 equiv) in methanol (to give a 0.5 
M solution) at 0 °C, was added a solution of aldehyde (typically 0.05 to 0.3 mmol) in 
methanol (to give a 0.25 M solution). The reaction was stirred and allowed to warm 
to room temperature. After 20 min saturated aqueous NH4Cl was added to quench the 
reaction, and methanol was removed under reduced pressure. The resulting aqueous 
phase was extracted with dichloromethane (x2), and the combined organic fractions 
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washed with saturated aqueous NaCl, water, dried (MgS04) and solvent removed 
under reduced pressure. 
General Method F: Esterification with Succinic Anhydride5 
A solution of succinic anhydride (2.1 equiv), dimethylaminopyridine (0.05 equiv) 
and triethylamine (1.5 equiv) in dichloromethane (to give a 0.6 M solution), was 
added slowly to a solution of alcohol (typically 0.03 to 0.20 mmol) in 
dichloromethane (to give a 0.1 M solution). This was stirred at room temperature 
under an Ar atmosphere for 16 h. The reaction was diluted with dichloromethane and 
washed with 2N aqueous HCI, water, saturated aqueous NaHC03, water, dried 
(MgS04) and the solvent removed under reduced pressure. 
General Method G: Oxidative Deprotection with CAN3 
To a solution of analogue (typically 0.04 to 0.7 mmol) in a 2: 1 acetonitrile:water 
mixture (to give a 0.25 M solution) was added a cooled solution of cerric ammonium 
nitrate (CAN) (2.5 equiv) in a 1:1 acetonitrile:water mixture (to give a 0.5 M 
solution), over a 10 min period. The resulting solution was stirred at 0 °C for 20 min 
and room temperature for 10 min before quenching via the addition of water. The 
resulting reaction mixture was extracted with dichloromethane (x2) and the combined 
organic fractions washed with water, dried (MgS04) and the solvent removed under 
reduced pressure. 
General Method H: Peptide Coupling using EDCI6 
To a solution of substrate (typically 0.02 to 0.04 mmol) and peptide (1.1 equiv) in 
dichloromethane (typically 0.3 mL) stirring under an Ar atmosphere, was added 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide. HCI (EDCI) (1.3 equiv), I-hydroxy-
benzotriazole hydrate (1.5 equiv) and diisopropylethylamine (1.1 equiv). The 
resulting solution was stirred at room temperature for 16 h. The reaction was 
quenched via the addition of 3M aqueous NaCI solution and the layers separated. The 
aqueous phase was extracted with dichloromethane (x2), and combined organic 
fractions were dried (MgS04), and the solvent removed under reduced pressure. 
6.2 EXPERIMENTAL WORK DESCRIBED IN CHAPTER 2 
The high-performance liquid chromatography work described in this chapter was 
carried out using a system made up of the following components; Shimadzu SCL-IOA 
system controller, Shimadzu SIL-lOAXL auto injector, Shimadzu LC-lOAT liquid 
chromatograph pump, Shimadzu DGU-14A membrane degasser and Shimadzu RF-
551 spectrofluorimetric detector. Unless otherwise stated the fluorescence detector 
was set at 'low' sensitivity. The arrangement of these components for each section of 
work is described below. The HPLC system was interfaced through Delta 5.0 
Chromatography for data collection. All solvents used were HPLC grade, and used as 
received from the supplier. Where stated the analytical column used in this study was 
a 15 cm reverse-phase Merck Supersphere 100 RP-18 endcapped column. 
Investigation of Metal Catalysts 
All metal catalysts were used as received from the supplier. A standard 0.5 IlM 
solution of vitamin Kl in ethanol was used throughout this study. Before testing each 
catalyst was packed into an Alltech refillable guard column (20 rnm x 2 rnm) and 
flushed thoroughly with methanol at a flow rate of 0.5 mLimin for at least 1 h. A 400 
ilL sample of vitamin K standard was injected into a degassed mobile phase of 100% 
MeOH and passed directly through the test catalytic column at a flow rate of 0.1 
mL/min. This then passed through the fluorescence detector (excitation wavelength 
249 nm and emission wavelength 408 nm), and the chromatogram was recorded. The 
total run time for this experiment was 15 min. 
Efficiency of Catalytic Reduction Column 
A 0.5 !lM ethanolic solution of vitamin Kl was used for this study. The mobile 
phase was 100% methanol, with an injection volume of 20 ilL and flow rate of 0.5 
mLimin. The run time for these experiments was 25 minutes. The reference column 
used in this study was a platinum black catalytic column which consistently showed 
high activity, and which when placed in series with a second catalytic column showed 
no increase in peak area for a standard vitamin K injection. Two methods were used 
in this investigation. 
METHOD 1 
The HPLC system was set up with the analytical RP column placed between the test 
catalytic column and the reference column. The vitamin K solution therefore, passed 
through the test column before separation of the quinone and hydro quinone on the RP 
column. This then passed through a second reference catalytic column and into the 
fluorescence detector. The recorded chromatogram showed two peaks at retention 
time 6.0 min for the hydroquinone and 21.3 min for the quinone. The area of the 
hydro quinone peak divided by the total area of the two peaks gave a measure of the 
reduction efficiency of the test column. 
METHOD 2 
Alternatively, two HPLC runs were used for each test column. Initially the HPLC 
system was set up with the test column following the analytical RP column, and no 
catalytic column before the analytical RP column, and the peak area for vitamin Kl 
was recorded. This process was then repeated replacing the test column with the 
reference column, and the peak area was again recorded. The ratio of the peak areas 
from these two chromatograms gave a measure of the reduction efficiency of the test 
column. 
Generality of Reduction System for Various Quinones 
All quinones used were commercially available, and were used without 
purification. A 0.5 JlM solution of each quinone was prepared in HPLC grade 
ethanoL For this investigation the mobile phase was 100% methanol and a flow rate 
of 0.1 mLimin was used throughout. The HPLC system was set up to consist of the 
degasser, pump, autosampler, platinum black catalytic reduction column and 
fluorescence detector. The run time for this experiment was 15 min. A 400 ~ 
sample of each quinone was injected into the HPLC system. The fluorescence 
detector was set to run a time programme scanning over a range of excitation or 
emission wavelengths. 
The following time programme used was: 
Zero 
Mark 
Scan 
End 
0.05 minutes 
3.99 minutes 
4.00 minutes 
15.00 minutes 
- to zero the detector 
- to mark the scan start 
- scan over set wavelengths 
- end run 
Typical scanning wavelengths were 220-340 nm for excitation scans, and 350-470 nm 
for emission scans. As the scan speed, start time, and wavelength range were known 
for each experiment, the wavelength of A.max for each scan could be calculated from 
the chromatogram obtained. As the fluorescence detector stored a scan after each 
experiment, the results obtained by calculation from the Delta chromatogram were 
compared with those obtained from the fluorescence detector in each case. 
Once the excitation and emission maxima were obtained each quinone was rerun 
without the time programme, to obtain a measure of optimum fluorescence. As a 
control experiment each quinone was also tested in the absence of the platinum black 
catalyst to check for levels of native fluorescence of the oxidized form. 
Effect of Solvent on Reduction System 
All experiments in this study were run using a 0.5 IlM ethanolic solution of 
vitamin K1• The RP column was fitted to the HPLC system described above for this 
study. The injection volume was 20 ilL, with a flow rate of 0.5 mL/min and 
excitation and emission wavelengths set at 249 nm and 408 nm respectively. Each 
solvent system was prepared and the HPLC thoroughly washed for 15 minutes and 
allowed to equilibrate. The peak area and retention time for vitamin Kl were then 
recorded for each mobile phase investigated. 
Linearity of Fluorescence 
A series of four concentrations of vitamin Kl were prepared by dilution from the 
stock solution of vitamin K1• The fmal concentrations used in this study were 0.25, 
0.5, 0.75 and 1.0 J.lM. These experiments were run using the same HPLC set-up 
described above, with a mobile phase of 100% methanol and, excitation and emission 
wavelengths of 249 nm and 408 nm respectively. The run time for each injection was 
25 minutes. Each standard solution was run in duplicate, and the experiment was 
repeated four times, using freshly prepared vitamin Kl standards in each case. The 
peak areas from each chromatogram were recorded and used in the preparation of a 
calibration curve for vitamin Kl through the given concentration range. 
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Application to Biological Samples 
For the detection of vitamin K in plasma samples, the sensitivity of the 
fluorescence detector was increased to 'high'. The injection volume was also 
increased from 20 ilL to 50 ilL. The HPLC set-up was the same as described above 
with a platinum black catalytic column used for the reduction of vitamin K, and a 
solvent system of 100% methanol. The sample extraction procedure used was a 
standard method used for other fat-soluble vitamins. This consisted of taking 400 j.lL 
of plasma and adding 400 j.lL of ethanol to precipitate the proteins. To this 400 j.lL of 
hexane was added and the sample was vortexed to extract the vitamin K into the 
organic phase. The sample was centrifuged cold at 3000 rpm for 10 min, and 350 ilL 
of the hexane phase was removed and dried down under a stream of nitrogen. The 
resulting solid was reconstituted into 200 ilL of methanol for injection into the HPLC 
The standard solution of MK-4 used was prepared in ethanol from commercially 
available vitamin K2, at a concentration of 11 nM. A 50 j.lL sample of this was 
injected into the HPLC as described above, and the resulting retention time and peak 
area recorded. 
Vitamin K Recoveries 
A series of spiked plasma samples were prepared by diluting a stock solution of 
vitamin K1 in ethanol to the required concentrations with pooled plasma. The [mal 
concentrations of these solutions were 5 nM, 10 nM, 20 nM and 50 nM. A sample of 
the unspiked plasma was also retained as a control. The preparation of these plasma 
samples before analysis by HPLC was carried out as describe above. 
Analysis was carried out using the RP HPLC column, platinum black reactor 
column and fluorescence detection with Ex 249 and Em 408. The injection volume 
was 100 j.lL, with the fluorescence detector set at 'high' sensitivity and a flow rate of 
0.5 mLimin. Chromatograms were recorded, and results calculated, using Delta 
chromatography. 
6.3 EXPERIMENTAL WORK DESCRIBED IN CHAPTER 3 
2-Bromo-3-mcthyl-l,4-naphthaquinonc (3.19)7 
o 
~ VYBr 
o 
2-Methylnaphthaquinone (5.50g, 0.032 mol, 1 equiv) and anhydrous sodium acetate 
(11.00 g, 0.14 mol, 4.2 equiv) were dissolved in glacial acetic acid (50 mL) with 
heating to give a clear brown solution. This was cooled in ice and bromine (2.0 mL, 
0.04 mol, 1.2 equiv) was added dropwise. The flask was then sealed, encased in foil 
and stored in the dark for 3 d, during which time yellow crystals formed. The entire 
contents of the flask was transferred to 300 mL of water and filtered. The resulting 
crude product was recrystallised from hot methanol to afford 3.19 as yellow needle-
like crystals (5.69g, 71 %); mp 149-150 °C (lit. mp 151-152 oC)7 
IH NMR (CDCh) 0 2.40 (s, 3H, CH3), 7.75 (m, 2H, ArH), 8.15 (m, 2H, ArB) 
13C NMR (CDCb) 0 17.82,127.06,127.45,131.14,131.50,133.85,134.06,139.00, 
148.44, 177.45, 181.89 
HRMS Found 249.9629 (Calcd for CllH70279Br 249.9633) 
2-Bromo-3-mcthyl-l,4-naphthaquinol (3.61)7 
2-Bromo-3-methyl-1,4-naphthaquinone (3.19) (4.00g, 0.02 mol, 1 equiv) was 
dissolved in ethanol (55 mL) with heating. After cooling in ice to give a paste, was 
added a solution of stannous chloride (l4.38g, 0.06 mol, 4 equiv) in conc. HCI (14.5 
mL) was added. To this, water (45 mL) was added causing precipitation of the 
desired quinol, and the appearance of a strong purple colour. Upon heating the quinol 
redissolved and the solution cleared. Cooling gave 3.61 as pale pink crystals 
(3.347g). Concentration of the mother liquor and subsequent cooling gave a second 
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crop of pink crystals (386 mg, overall yield 93%); mp 101-102 DC (decomp.) 
1 
H NMR (CDCh) 82.50 (s, 3H, CH3), 4.81 (s, 1H, OH-1), 5.75 (s, 1H, OH-4), 7.54 
(m, 2H, ArH), 8.04 (d, J=8.0 Hz, 1H, ArH), 8.20 (d, J=8.2 Hz, 1H, ArH) 
13C NMR (CDCh) 8 16.28, 107.96, 120.92, 122.44, 122.80, 125.70, 126.43, 127.09, 
127.48, 133.87, 134.09 
2-Bromo-3-methyl-l,4-dimethoxynaphthalene (3.11)7 
'*I~' ~ ~ Br OMe 
A solution of dihydroxynaphthalene (3.61) (3.73g, 0.02 mol, 1 equiv) in dimethyl-
sulfate (20 mL) was stirred vigorously under a nitrogen atmosphere. To this a 
solution of potassium hydroxide (33.1g, 0.59 mol, 40 equiv) in water (66 mL) was 
added portionwise with a dark colour appearing upon each addition. The addition was 
kept at a rate that avoided reflux of the reaction mixture. Upon completion of this 
addition the solution had turned orange and a precipitate had formed. The reaction 
was heated at 80 DC for 1 h and then allowed to cool slowly to room temperature, 
before dilution to 600 mL with water. The resulting solution was extracted with ether 
(3x) and the combined organic fraction washed with 5% aqueous NaOH, water, dried 
(MgS04) and solvent removed to give orange crystals. Recrystallisaton from hot 
methanol gave 3.11 as pale orange crystals (2.68g, 64%); mp 83-84 DC (lit. mp 84-85 
DC/ 
IH NMR (CDCh) 8 2.54 (s, 3H, CH3), 3.88 (s, 3H, OCH3), 3.98 (s, 3H, OCH3), 7.52 
(m, 2H, ArH), 8.06 (m, 2H, ArH) 
13C NMR (CDCh) 816.61, 61.22, 61.59, 117.19, 122.32, 122.36, 126.15, 126.48, 
127.23, 127.51, 127.78, 149.80, 150.44 
HREIMS Found 280.0095 (Calcd. for C13H130/9Br 280.0010) 
FTIR 3415.7,2935.5, 1575.7 cm-1 
Anal. Calcd for C13H130 2Br: C 55.5; H 4.7. Found: C 56.1; H 4.6. 
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4-( 4-Methoxybenzyloxy)butan-l-ol (3.63)8 
r7'Y0Me HO~O~ 
145 
Sodium hydride (7.09 g of a 50% dispersion in oil, 0.09 mmol, 1.1 equiv) was 
prepared by washing four times with petroleum ether under an atmosophere of 
nitrogen. The sodium hydride was then dissolved in dry DMF (35 mL) and added to a 
solution of butan-1,4-diol (5rnL, 0.08 mol) in dry DMF (35 rnL), stirring under 
nitrogen at -15 DC. After 30 min, freshly preparedp-methoxybenzylbromide9 (18.00 
g, 0.09 mol, 1.15 equiv) in DMF (20 mL) was added. This was stirred at 5 DC for a 
further 45 min, followed by stirring at room temperature for 1 h. The resulting 
solution was poured into an ice-water solution (200 mL) and extracted with ether (3 x 
l30 mL) during which time the milky white solution cleared. The organic fractions 
were combined and washed with saturated aqueous NaCl, dried (MgS04) and the 
solvent removed to give crude product. This was purified by column chromatography 
eluting with a 1: 1 mixture of ethyl acetate:petroleum ether. The desired protected 
alcohol (3.63) was isolated as a yellow oil (7.98 g, 48%). 
IH NMR (CDCh) 0 1.68 (m, 4H, HOCH2CHzCHz), 3.49 (t, J=5.8 Hz, 2H, CHzO), 
3.62 (t, J=5.9 Hz, 2H, HOCHz), 3.79 (s, 3H, OCH3), 4.44 (s, 2H, OCHzAr), 6,95 (d, 
J=8.8 Hz, 2H, ArH), 7.26 (d,J=8.8 Hz, 2H, ArH) 
4-( 4-Methoxybenzyloxy)butanal (3.64)8 
r7'Y0Me H~o~ 
o 
A solution of dimethy1sulphoxide (1 mL, 14.30 mmol, 3 equiv) in dichloromethane 
(12 mL) was stirred and cooled to -78 DC under a nitrogen atmosphere. To this a 
solution of freshly distilled oxalyl chloride (0.84 rnL, 9.50 mmol, 2 equiv) in 
dichloromethane (6 mL) was added slowly. This was stirred for 5 min before the 
addition of3.63 (1 g, 4.76 mmol) in dichloromethane (8 rnL). This was stirred at-78 
DC for 30 min before the dropwise addition of triethylamine (2.65 mL, 19.01 mmol, 4 
equiv). The solution was warmed to room temperature and stirred for 1.5 h during 
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which time the milky white solution turned slightly yellow. The reaction was 
quenched via the addition of 5% aqueous HCI (24 mL) and the organic fraction 
collected and washed with saturated aqueous NaHC03, saturated aqueous NaCI, and 
dried (MgS04)' Removal of the solvent under reduced pressure afforded 3.64 as a 
yellow oil (820 mg, 83%). 
1H NMR (CDCh) (3 1.93 (m, 2H, CHzCH20), 2.54 (t, J= 8.8 Hz, 2H, CHOCHz), 3.47 
(t, J=6.3 Hz, 2H, CHzO), 3.80 (s, 3H, OCH3), 4.41 (s, 2H, CHzAr), 6.87 (d, J=8.3 Hz, 
2H, ArH), 7.23 (d, J=8.3 Hz, 2H, ArH), 9.77 (s, 1H, CHO) 
Ethy16-(4-methoxybenzyloxy)hex-2-enoate (3.65)10 
. ~OMe 
Et02C~O~ 
A solution of aldehyde (3.64) (50 mg, 2.40 mmol) and [(ethylcarbonyl)methyleneJ-
triphenylphosphorane (16.4 mg, 0.47 mmol, 2 equiv) in dichloromethane (2 mL) was 
stirred under a nitrogen atmosphere. After 2 h the solvent was evaporated to give the 
crude product as an orange oil. This was purified by column chromatography eluting 
with 1:4 ethyl acetate:petroleum ether. The desired allylic ester (3.65) was isolated as 
an oil (54 mg, 81 %). 
1H NMR (CDCh) (3 1.27 (t, J=7.3 Hz, 3H, OCH2CH3), 1.74 (m, 2H, CHzCH20), 2.28 
(m, 2H, =CHCHz), 3.44 (t, J=6.0 Hz, 2H, CHzO), 3.77 (s, 3H, OCH3), 4.17 (q, J=7.3 
Hz, 2H, OCHzCH3), 4.41 (s, 2H, CHzAr), 5.81 (d, J=15.5 Hz, 1H, COCH=), 6.86 (d, 
J=8.5 Hz, 2H, ArH), 6.89 (m, 1H, =CHCH2), 7.24 (d, J=8.5 Hz, 2H, ArH) 
HREIMS Found 278.1512 (Calcd. for C16H2204 278.1519) 
6-( 4-Methoxybenzyloxy)hex-2-en-l-ol (3.66)11 
~OMe 
HO~O~ 
A solution of 3.65 (109 mg, 0.39 mmol) in dichloromethane (2 mL) was stirred under 
a nitrogen atmosphere at -78°C. To this was added diisobutylaluminium hydride 
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(123 mg, 0.86 mmol, 2.2 equiv) and the solution was stirred at -78 DC for 30 min 
before wanning to room temperature and stirring for 12 h. The reaction solution was 
slowly poured into a mixture of 2:1 ice:glacial acetic acid (15 mL) and stirred for 45 
min until the solution cleared. The aqueous layer was separated and extracted with 
dichloromethane (x2) and the combined organic fractions were washed with saturated 
aqueous NaCI (x2), water, and dried (MgS04)' Solvent was removed under reduced 
pressure to afford 3.66 as a yellow oil (71 mg, 77%). 
IH NMR (CDCb) 8 1.69 (m, 2H, =CHCH2CH2), 2.12 (m, 2H, =CHCH2), 3.45 (t, 
J=6.3 Hz, 2H, CH20), 3.80 (s, 3H, OCH3), 4.06 (d, J=4.9 Hz, 2H, HOCH2), 4.43 (s, 
2H, OCH2Ar), 5.65 (m, 2H, CH=CH), 6.88 (dd, J=2.0 and 6.8 Hz, 2H, ArH), 7.25 
(dd, J=2.0 and 6.8 Hz, 2H, ArH) 
l3C NMR (CDCh) 8 28.52, 28.80, 54.94, 62.95, 69.03, 72.19, 113.50, 129.06, 130.22, 
131.88,168.87 
HREIMS found 236.1415 (Calcd. for C14H2003 236.1412) 
I-Bromo-6-( 4-methoxybenzyloxy)hex-2-ene (3.60)11 
~OMe 
Br~o~ 
To a stirred solution of 3.66 (1.302 g, 5.51 mmol) and carbon tetrabromide (2.28 g, 
6.87 mmol, 1.25 equiv) in dichloromethane was added portionwise triphenyl-
phosphine (2.17 g, 8.27 mmol, 1.5 equiv). During this addition the solution went pale 
orange and a fine precipitate appeared. This was stirred at room temperature for 5 
min and the solvent removed under reduced pressure. This crude product was 
purified by column chromatography eluting with 1:4 ethyl acetate:petroleum ether, to 
afford 3.60 as a pale yellow oil (1.27 g, 77% yield). 
IH NMR (CDCh) 8 1.69 (m, 2H, CH2CH20), 2.17 (m, 2H, =CHCH2), 3.44 (t, J=6.3 
Hz, 2H, CH20), 3.81 (s, 3H, OCH3), 3.93 (d, J=6.3 Hz, 2H, BrCH2), 4.43 (s, 2H, 
OCH2Ar), 5.73 (m, 2H, CH=CH), 6.88 (dd, J=2.0 and 6.8 Hz, 2H, ArH), 7.26 (dd, 
J=2.0 and 6.8 Hz, 2H, ArH) 
2-(3, 7 -Dimethylocta-2,6-dienyl)-3-methyl-l,4-dimethoxynaphthalene (3.67)3 
OMe 
OMe 
General method A was carried out using bromonaphthalene 3.11 (500 mg, 1.78 mmol, 
1 equiv) and nBuLi (1.36 mL of 1.6 M solution in hexane, 2.00 mmol, 1.15 equiv). 
To this was added copper bromide dimethyl sulfide complex (256 mg, 1.24 mmol, 0.7 
equiv) and geranyl bromide (0.39 mL, 1.96 mmo1, 1.1 equiv). Work up afforded the 
crude product as an orange oil which was purified by radial chromatography eluting 
with 1:20 ethyl acetate:petroleum ether. This gave an orange oil (509 mg) containing 
a mixture of 3.67 and 2-methyl-1 ,4-dimethoxynaphthalene (10: 1 by IH NMR). 
IHNMR (CDCh) for 2-methyl-1,4-dimethoxynaphthalene: 8 2.45 (s, 3H, ArCH3) , 
3.86 (8, 3H, OCH3), 3.97 (8, 3H, OCH3), 6.61 (8, IH, ArH), 7.46 (m, 2H, ArH), 8.01 
(d, J= 8.3 Hz, 1H, ArH), 8.19 (d,J= 8.3 Hz, 1H, ArH) 
IH NMR (CDCb) for 3.67: 8 1.56 (s, 3H, CH3), 1.63 (8, 3H, CH3), 1.82 (s, 3H, 
=CCH3), 2.03 (m, 4H, 2x CHz), 2.37 (s, 3H, ArCH3), 3.56 (d, J=5.4 Hz, 2H, ArCHz), 
3.87 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 5.10 (m, 2H, CH=C), 7.45 (m, 2H, ArH), 
8.03 (m, 2H, ArH) 
BC NMR (CDCb) for 3.67: 8 12.27, 16.26,25.61,26.27,26.49,34.17, 61.19, 62.08, 
121.39, 122.04, 122.21, 122.90, 124.19, 125.20, 125.32, 126.37, 126.87, 127.20, 
131.27, 135.56, 149.67, 150.01 
HREIMS Found 338.2248 (Caled. for C23H3002 338.2246) 
FTIR 2931.6, 1593.1 cm-I 
3-Bromo-8-(3-methyl-l,4-dimethoxynaphthalen-2-yl)-2,6-dimethylocta-6-en-2-o1 
(3.76) 
OMe 
Br 
OMe 
General method B was carried out with 3.67 (562 mg, 1.60 mmol, 1 equiv) and N-
bromosuccinimide (340 mg, 1.90 mmol, 1.15 equiv) in THF (60mL). Work up and 
purification by radial chromatography eluting with 1:9 ethyl acetate:petroleum ether 
to 1:1 ethyl acetate:petroleum ether afforded 3.76 as a yellow oil (425 mg, 59%) 
IH NMR (CDCh) 8 1.31 (s, 3H, CH3), 1.33 (s, 3H, CH3), 1.81 (m, IH, CH2aCBr), 
1.84 (s, 3H, =CCH3), 2.02 (m, IH, CH2bCBr), 2.15 (m, IH, =CCH2a), 2.35 (m, IH, 
=CCH2b), 2.40 (s, 3H, ArCH3), 3.59 (d, J=6.4 Hz, 2H, ArCH2), 3.88 (s, 3H, OCH3), 
3.90 (s, 3H, OCH3), 3.93 (dd, J=1.9 and 11.2 Hz, IH, CHBr), 5.22 (t, J= 6.4 Hz, IH, 
CH=), 7.46 (m, 2H, ArH), 8.06 (m, 2H, ArH) 
l3C NMR (CDCh) 8 12.46, 16.25, 25.93, 26.30, 26.4, 31.98, 38.15, 61.29, 62.15, 
70.51, 72.40,122.09,122.21, 124.37, 125.29, 125.43, 126.69, 127.19, 127.49, 130.49, 
133.90, 149.70, 150.12 
HRFABMS Found 434.1463 (Calcd. For C23H310/9Br 434.1454) 
FTIR 3465.8, 2933.5, 2841.0, 1739.7, 1591.2, 1456.2 cm-! 
3-[5-(3-Methyl-l,4-dimethoxynaphthalen-2-yl)-3-methylpent-3-enyl]-2,2-
dimethylonrane (3.73)12 
OMe 
OMe 
General method C was carried out using bormohydrin (3.76) (380 mg, 0.87 mmol) 
and potassium carbonate (8.4 g, 0.06 mol, 70 equiv). Work up gave 3.73 as a pale 
yellow oil (280 mg, 91 %), which was not purified further. 
NMR (CDCb) 1.23 (s, 3H, CH3), 1.24 (s, 3H, CH3), 1.65 (m, 2H, =CCHz), 1.85 
(s, 3H, =CCH3), 2.13 (m, 2H, CH2CHzCO), 2.37 (s, 3H, ArCH3), 2.67 (t, J=6.4 Hz, 
1H, CHO), 3.57 (d, J=6.4 Hz, 2H, ArCHz), 3.86 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 
5.17 (t, J=1.5 and 6.4 Hz, 2H, CH=), 7.45 (m, 2H, ArH), 8.04 (m, 2H, ArH) 
l3C NMR (CDCh) 8 12.41, 16.38, 18.68, 24.79, 26.31, 27.42, 36.30, 58.28, 61.29, 
62.15,64.07, 122.10, 122.24, 123.37,125.28,125.42, 126.73, 127.22, 127.49,130.58, 
134.82, 149.73, 150.10 
HREIMS Found 354.2203 (Ca1ed. for C23H3003 354.2195) 
FTIR 2993.5,2841.0,1591.2,1456.2 em-l 
6-(3-Methyl-l,4-dimethoxynaphthalen-2-y 1)-4-methylhex -4-enal (3.77) 
OMe 
o 
H 
OMe 
General method D was carried out using epoxide 3.73 (275 mg, 0.78 mmol) and 
periodic acid (177 mg, 0.78 mmol, 1 equiv) in THF (22 mL). Work up afforded 3.77 
as yellow oil (217 mg, 90%), which was not purified further. 
lH NMR (CDCb) 8 1.84 (s, 3H, =CCH3), 2.35 (s, 3H, ArCH3), 2.36 (m, 2H, =CCHz), 
2.52 (t, J=2.0 Hz, 2H, CHzCHO), 3.56 (d, J= 6.4 Hz, 2H, ArC Hz) , 3.86 (s, 3H, 
OCH3), 3.87 (s, 3H, OCH3), 5.15 (t, J= 6.4 Hz, 1H, =CH), 7.46 (m, 2H, ArH), 8.03 
(m, 2H, ArH), 9.72 (s, 1H, CHO) 
l3C NMR (CDCh) 8 12.39, 16.45,26.24, 31.70,42.05,61.30,62.15, 122.09, 122.21, 
123.88, 125.32, 125.47, 126.66, 127.17, 127.51, 130.28, 133.69, 149.72, 150.10, 
202.32 
HREIMS Found 312.1725 (Caled. for C2oH2403 312.1725) 
FTIR 2933.5,2839.0, 1591.2 em-] 
6-(3-Methyl-I,4-dimethoxynaphthalen-2-yl)-4-methylhex-4-en-I-ol (3.78) 
OMe 
'" OR 
OMe 
General method E was carried out using sodium borohydride (1.8 mg, 0.05 mmol) and 
3.77 (15 mg, 0.05 mmol, 1 equiv). Work up afforded 3.78 as a yellow oil (9 mg, 
60%), which was not purified further. 
IH NMR (CDCh) 01.67 (m, 2H, CH2CH2CH2), 1.84 (s, 3H, CCH3), 2.07 (t, J==7.3 
Hz, 2H, =CCH2), 2.37 (s, 3H, ArCH3), 3.57 (t, J=5.4 Hz, 2H, CH20H), 3.59 (d, 
J=12.7 Hz, 2H, ArCH2), 3.87 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 5.15 (dt, J=1.5 and 
6.4 Hz, 1H, CH=), 7.45 (m, 2H, ArH), 8.05 (m, 2H, ArH) 
BC NMR (CDCh) 0 12.42, 16.29, 26.30, 30.81, 35.88, 61.30, 62.15, 62.71, 122.09, 
122.24, 123.19, 125.29, 125.42, 126.75, 127.22, 127.48, 130.65, 135.32, 149.73, 
150.10 
HREIMS Found 314.1883 (Caled. For C2oH2603 314.1882) 
FTIR 3346.3,2937.4, 1591.2, 1456.2 cm-I 
6-(3-Methyl-l,4-dimethoxynap hthalen-2-yl)-4-methylhex-4-enyl hydrogen 
succinate (3.79) 
OMe 
OMe 
o 
O~OR 
o 
General method F was carried out using succinic anhydride (68 mg, 0.68 mmol, 2.1 
equiv), dimethylaminopyridine (2 mg, 0.02 mmol, 0.05 equiv), triethylamine (0.07 
mL, 0.49 mmol, 1.5 equiv) and the alcohol 3.78 (80 mg, 0.32 mmol, 1 equiv). Work 
up afforded 3.79 as a yellow solid (76mg, 68%), which was not purified further. Mp 
97-99°C 
lH NMR (CDCh) 0 1.73 (m, 2H, CH2CH2CH2), 1.82 (s, 3H, =CCH3), 2.05 (t, 2.4 
Hz, =CCH2), 2.36 (s, 3H, ArCH3), 2.59 (m, 4H, 2x CH2), 3.55 (d, J=6.4 Hz, 2H, 
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ArCHz), 3.87 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 4.05 (t, 6.8 Hz, 2H, CRzO), 5.13 
(t, J=6.4 Hz, IH, CR=), 7.45 (m, 2H, ArR), 8.04 (m, 2H, ArR) 
13C NMR (CDCh) B 12.37, 16.22, 26.26, 26.88, 29.76, 30.93, 35.73, 61.23, 62.09, 
64.64, 122.06, 122.21, 123.37, 125.25, 125.39, 126.70, 127.17, 127.45, 130.51, 
134.53, 149.68, 150.06, 174.20, 180.61 
HRFABMS Found 414.2043 (Ca1cd. for C24H3006 414.2044) 
FTIR 2937.4, 1733.9, 1591.2 cm'! 
6·(3~Methyl-l,4-naphthoquinon-2-yl)-4-methylhex-4-enyl hydrogen succinate 
(3.70) 
o 
O~OH 
o 
General method G was carried out using 3.79 (12 mg, 0.04 mmol) and cerric 
ammonium nitrate (53 mg, 0.10 mmol, 2.5 equiv). Work up and purification by radial 
chromatography eluting with dichloromethane to 1: 19 MeOH:dichloromethane 
afforded 3.70 as yellow oil (8 mg, 72%). 
IH NMR (CDCh) B 1.70 (m, 2H, CHzCH20), 1.78 (s, 3H, =CCH3), 2.03 (t, J=7.8 Hz, 
2H, =CCRz), 2.18 (s, 3H, ArCH3), 2.58 (m, 2H, CHZC02H), 2.63 (m, 2H, COCHz), 
3.35 (d, J=6.8 Hz, 2H, ArCHz), 4.03 (t, J=6.4 Hz, 2H, CHzO), 5.04 (dt, .5 and 6.8 
Hz, lH, CH=), 7.68 (m, 2H, ArH), 8.06(m, 2H, ArH) 
13C NMR (CDCh) B 12.69, 16.22,25.98,26.64,28.80 (x2), 35.70,64.35, 119.84, 
126.16, 126.27, 132.04 (x2), 133.32, 133.35, 136.26, 143.43, 145.82, 172.12, 177.62, 
184.52, 185.40 
HRFABMS Found 384.1565 (Caled. for C22H2406 384.1572) 
Chapter 6 
16-(3-Metbyl-l,4-diacetoxynaphthalen-2-yl)-2,6,10,14-tetramethylhexadeca-
2,6,10,14-tetraene (3.85) 
OAc 
OAc 
153 
To a refluxing solution of vitamin K2 (250 mg, 0.56 mmol, 1 equiv) in acetic 
anhydride (2.5 mL) was added zinc powder slowly so a slight excess of solid zinc was 
always present. The reaction mixture was refluxed for 45 mins before the addition of 
sodium acetate (160 mg, 1.95 mmol, 3.5 equiv). After refluxing for a further 15 mins 
the reaction was poured into ice and extracted with ethyl acetate. The combined 
organic fractions were washed with water, saturated aqueous NaHC03, water, dried 
(MgS04) and solvent removed to give 3.85 as a yellow oil (295 mg, 99%), which was 
not further purified. 
IH NMR (CDCh) 81.57 (s, 6H, =C(CH3)2), 1.59 (s, 3H, CH3), 1.67 (s, 3H, CH3), 
1.78 (s, 3H, CH3), 1.95-2.09 (m, 12H, 6x CHz), 2.22 (s, 3H, ArCH3), 2.46 (s, 3H, 
COCH3), 2.48 (s, 3H, COCH3), 3.41 (d, J=4.4 Hz, 2H, ArCHz), 5.06-5.09 (m, 4H, 4x 
CH=), 7.46 (m, 2H, ArH), 7.68 (m, 2H, ArH) 
13C NMR (CDCh) 8 13.04, 16.00, 16.34, 17.64, 20.59, 20.66, 22.14, 25.66, 26.54, 
26.62, 26.74, 27.02, 39.58, 39.66, 39.69, 121.09, 121.16, 121.37, 123.92, 124.22, 
124.37, 126.21, 126.30, 128.39, 128.72, 130.31, 131.20, 133.58, 133.83, 134.85, 
135.14, 136.27, 142.26, 166.37, 168.97 
HREIMS Found 530.3395 (Calcd. For C35~604 530.3396) 
Chapter 6 
16-(3-Methyl-l,4-dimethoxynaphthalen-Z-yl)-Z,6,lo,14-tetramethylhexadeca-
Z,6,lO,14-tetraene (3.89)13 
OMe 
OMe 
METHOD A 
154 
To a solution of vitamin K2 (50 mg, 0.11 mmo1) and tetrabutylammoniumiodide (4.3 
mg, 0.01 mmol, 0.12 equiv) in tetrahydrofuran (0.3 mL) and water (0.1 mL) was 
added a solution of sodium dithionite (117 mg, 0.67 mmo1, 6 equiv) in water (0.3 
mL). This was stirred at room temperature under a nitrogen atmosphere for 15 min 
before the slow addition of potassium hydroxide (145 mg, 2.60 mmol, 23 equiv) in 
water (0.16 mL). The reaction was stirred for 5 min during which time the solution 
turned orange, dark red and dark green. Dimethylsulfate (0.13 mL, 1.30 mmol, 12 
equiv) was added and the solution went orange. This was stirred at room temperature 
for 18 h. The reaction mixture was extracted with dichloromethane (x2) and 
combined organic fractions washed with water dried (MgS04) and solvent removed to 
give crude product. Purification by radial chromatography eluting with 1: 19 ethyl 
acetate:pet ether afforded 3.89 as a yellow oil (30 mg, 56%). 
IH NMR (CDCh) 8 1.59 (s, 3H, CH3), 1.60 (s, 3H, CH3), 1.61 (s, 3H, CH3), 1.69 (s, 
3H, CH3), 1.86 (s, 3H, CH3), 1.95-2.12 (m, 12H, 6x CH2), 2.40 (s, 3H, ArCH3), 3.59 
(d, J=6.3 Hz, 2H, ArCH2), 3.89 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 5.09-5.14 (m, 4H, 
CH=), 7.47 (m, 2H, ArH), 8.07 (m, 2H, ArH) 
13C NMR (CDCh) 8 12.35, 15.91, 15.97, 16.36, 17.63, 25.64, 26.30, 26.52, 26.59, 
26.72, 30.84, 39.66, 61.25, 62.12, 122.06, 122.22, 122.80, 124.02, 124.16, 124.37, 
125.21, 125.34, 126.87, 127.22, 127.44, 130.85, 131.16, 134.84, 135.03, 135.68, 
149.70, 150.05 
HREIMS Found 474.3492 (Calcd. for C33~602 474.3498) 
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METHODB 
A solution of vitamin K2 (250 mg, 0.56 mmol) in ether (10 mL) was added via 
cannular to a solution of sodium dithionite (3.92 g, 0.02 mol, 40 equiv) in water (39 
mL). The resulting solution was stirred vigorously under a nitrogen atmosphere for 
30 min before the layers were allowed to separate and the ether layer was transferred 
via cannular to a nitrogen flushed two-necked flask. The original solution was 
washed with ether and the combined organic layers evaporated to give a dark red 
solid. This was suspended in dimethyl sulfate (0.75 mL, 7.90 mmol, 14 equiv) and 
stirred under nitrogen. A solution of potassium hydroxide (1.26 g, 0.02 mol, 40 
equiv) in water (2.90 mL) was added dropwise with stirring. Once addition was 
complete the reaction was heated at 80°C for 1 h and allowed to cool slowly. The 
reaction was diluted with water and extracted (3x) with diethyl ether. The combined 
organic fractions were washed with water, 10% NaOH, water, dried (MgS04) and 
solvent removed to give a crude product which was purified by radial chromatography 
eluting with 1: 19 ethyl acetate:petroleum ether. The desired product 3.89 was isolated 
as a yellowoil (89 mg, 33%). Data for this compound is given above. 
3-Bromo-16~(3-methyl-l,4-dimethoxynaphthalen-2-yl)-2,6,10,14-tetramethyl­
hexadeca-6,4,10-trien-2-o1 (3.90) 
OMe 
General method B was carried out using 3.89 (35 mg, 0.07 mmol) and N-
bromosuccinimide (15 mg, 0.08 mmol, 1.15 equiv). Work up and purification by 
radial chromatography eluting with 1:9 ethyl acetate:petroleum ether gave 3.90 as a 
yellow oil (21 mg, 50%) 
IH NMR (CDCb) 8 1.32 (s, 3H, CH3), 1.33 (s, 3H, CH3), 1.56 (s, 3H, CH3), 1.58 (s, 
3H, CH3), 1.84 (s, 3H, CH3), 1.93-2.10 (m, 12H, 6x CHz), 2.38 (s, 3H, ArCH3), 3.57 
(d, J=6.3 Hz, 2H, ArCHz), 3.87 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.95 (dd, J=2.0 
and 11.2 Hz, IH, CHBr), 5.09-5.16 (m, 3H, CH=), 7.45 (m, 2H, ArH), 8.06 (m, 2H, 
ArH) 
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l3C NMR (CDCh) 8 12.35, 15.75, 15.94, 16.36, 25.79, 26.29, 26.52, 32.07, 38.10, 
39.54, 39.63, 61.25, 62.12, 70.78, 72.40, 122.06, 122.22, 122.82, 124.20, 125.22, 
125.35, 125.86, 126.87, 127.20, 127.42, 130.85, 132.94, 134.80, 135.65, 149.68, 
150.04 
HREIMS Found 490.3457 (-HBr) (Calcd for C33H4603 490.3449) 
3-[13-(3-Methy-l,4-dimethoxynaphthalen-2-yl)-3, 7 ,11-trimethyltrideca-3, 7 ,11-
trienyl]-2,2-dimethyloxirane (3.91) 
OMe 
OMe 
General method C was carried out using 3.90 (32 mg, 0.06 mmol) and potassium 
carbonate (542 mg, 3.92 mmol, 70 equjv). Work up afforded 3.91 as a yellow oil (22 
mg, 80%), which was not purified further. 
IH NMR (CDCh) 8 1.25 (s, 3H, CH3), 1.29 (s, 3H, CH3), 1.57 (s, 3H, CH3), 1.58 (s, 
3H, CH3), 1.83 (s, 3H, CH3), 1.94-2.10 (m, 12H, 6x CH2), 2.38 (s, 3H, ArCH3), 2.69 
(t, J=6.4 Hz, 1H, CH20), 3.57 (d, J=6.4 Hz, 2H, ArCH2), 3.87 (s, 3H, OCH3), 3.89 (s, 
3H, OCH3), 5.10 (m, 3H, CH=), 7.45 (m, 2H, ArH), 8.06 (m, 2H, ArH) 
l3C NMR (CDCh) 8 12.35, 15.91, 15.96, 16.36, 18.68, 24.83, 26.29, 26.51, 26.56, 
27.42, 36.23, 39.56, 39.63, 58.26, 61.25, 62.12, 64.14, 122.06, 122.22, 122.80, 
124.10, 124.78, 125.21, 125.34, 126.86, 127.20, 127.42, 130.84, 133.94, 134.88, 
135.64, 149.69, 150.04 
HREIMS Found 490.3456 (Calcd. for C33~603 490.3449) 
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14-(3-Methyl-l,4-dimethoxynaphthalen-2-yl)-4,S,12-trimethyltetradeca-4,S,12-
trienal (3.92) 
OMe 
OMe 
General method D was carried out using 3.91 (22 mg, 0.04 mmol) and periodic acid 
(10 mg, 0.04 romol, 1 equiv). Work up afforded 3.92 as a yellow oil (19 mg, 95%), 
which was not purified further. 
IH NMR (CDCh) 8 1.56 (s, 3H, CH3) , 1.57 (s, 3H, CH3) , 1.83 (s, 3H, CH3), 1.95-
2.07 (m, 8H, 4x CH2), 2.27 (t, J=7.3 Hz, 2H, CH2CH2CHO), 2.38 (s, 3H, ArCH3), 
2.47 (t, J=7.3 Hz, 2H, CH2CHO), 3.57 (d, J=6.3 Hz, 2H, ArCH2) , 3.87 (s, 3H, 
OCH3), 3.88 (s, 3H, OCH3), 5.09 (m" 3H, CH=), 7.45 (m, 2H, ArH), 8.05 (m, 2H, 
ArH), 9.71 (s, 1H, CHO) 
BC NMR (CDCh) 812.35, 15.93, 15.98, 16.36, 26.29, 26.47, 31.78, 39.43, 39.62, 
42.08, 61.26, 62.13, 67.91, 122.06, 122.22, 122.82, 124.24, 125.22, 125.29, 125.35, 
126.87, 127.20, 127.44, 130.84, 132.82, 134.71, 135.62,149.69, 150.04,202.67 
HREIMS Found 448.2980 (Caled. for C3oli4003 448.2978) 
14-(3-Methyl-l,4-dimethoxynaphthalen-2-yl)-4,S,12-trimethyltetradeca-4,S,12-
trien-l-01 (3.93) 
OMe 
OR 
OMe 
General method E was carried out using 3.92 (31 mg, 0.07 romol) and sodium 
borohydride (4 mg, 0.07 rom01, 1 equiv). The reaction was followed by TLC and 
after 20 min at room temperature starting material was still present, so more sodium 
borohydride (4 mg, 1 equiv) was added and the reaction stirred for a further 20 min. 
Work up afforded 3.93 as a yellow oil (23 mg, 74%), which was not further purified. 
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1.83 (s, 3H, CH3), 1.92-2.28 (m, 10H, 5x CHz), 2.38 (s, 3H, ArCH3), 3.58 (t, J=5.9 
Hz, 2H, CHzOH), 3.61 (d, J=6.3 2H, ArCHz), 3.87 (s, 3H, OCH3), 3.89 (s, 3H, 
OCH3), 5.05-5.13 (m, 3H, 3x CH=), 7.45 (m, 2H, ArH), 8.05 (m, 2H, ArH) 
l3C NlVIR (CDCh) (3 12.35, 15.76, 15.93, 16.36, 26.30, 26.45, 29.66, 30.67, 35.91, 
39.56, 39.62, 61.26, 62.13, 62.71, 122.06, 122.22, 122.82, 124.13, 124.66, 125.22, 
125.35, 126.88, 127.20, 127.44, 130.85, 134.53, 134.88, 135.65, 149.68, 150.04 
HREIMS Found 450.3143 (Caled for C3oH4203 450.3134) 
14-(3-Methyl-l,4-dimethoxynaphthalen-2-yl)-4,8,12-trimethyltetradeca-4,8,12-
trienyI hydrogen succinate (3.94) 
OMe 
o 
O~OH 
o 
General method F was carried out using succinic anhydride (5 mg, 0.05 mmol, 2.1 
equiv) , dimethylaminopyridine (0.15 mg, 0.05 equiv), triethylamine (5 ~L, 0.04 
mmol, 1.5 equiv) and the alcohol 3.93 (11 mg, 0.02 mmol, 1 equiv). Work up and 
purification by radial chromatography eluting with 1:4 ethyl acetate:petroleum ether 
afforded 3.94 as yellow oil (8 mg, 60%). 
IH NMR (CDC h) (3 1.56 (s, 6H, 2x CH3), 1.69 (m, 2H, CHzCH20), 1.82 (s, 3H,CH3), 
1.92-2.10 (m, lOH, 5x CH2), 2.37 (s, 3H, ArCH3), 2.65 (m, 4H, C=OCHzCHzC=O), 
3.56 (d, J=6.3 Hz, 2H, ArCH2), 3.87 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 4.05 (t, 
J=6.8 Hz, 2H, CHzO), 5.06 (m, 3H, CH=), 7.45 (m, 2H, ArH), 8.06 (m, 2H, ArH) 
13C NMR (CDCh) (3 12.35, 15.78, 15.97, 16.37, 26.30, 26.52, 26.59, 26.77, 29.22, 
35.66, 39.58, 39.62, 50.74, 51.84, 61.29, 62.15, 64.57, 122.06, 122.22, 122.76, 
124.09, 124.98, 125.25, 125.38, 126.90, 127.20, 127.44, 130.88, 133.62, 134.95, 
135.72, 149.68, 173.55 
HRMS Found 550.3311 (Caled. for C34fu606 550.3294) 
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14-(3-Methyl-l ,4-naphthoquinon-2-yl)-4,8,12-trimethyltetradeca-4,8,12-trienyl 
hydrogen succinate (3.80) 
General method G was carried out using cerric ammonium nitrate (17 mg, 0.03 mmol, 
2.5 equiv) and 3.94 (7 mg, 0.01 mmol, 1 equiv). Work up and purification by radial 
chromatography eluting with dichloromethane afforded 3.80 as a yellow oil (4 mg, 
60%). 
IH NMR (CDCh) 81.55 (s, 6H, 2x CH3), 1.69 (m, 2H, CHzCH20), 1.79 (s, 3H CH3), 
1.94~2.05 (m, 10H, 5x CHz), 2.19 (s, 3H, ArCH3) , 2.65 (m, 4H, COCHzCHzCO) , 
3.37 (d, J=6.8 Hz, 2H, ArCHz), 4.05 (t', J=6.0 Hz, 2H, CHzO), 5.04 (m, 3H, 3x CH=), 
7.68 (m, 2H, ArH), 8.08 (m, 2H, ArH) 
6.4 EXPERIMENTAL WORK DESCRIBED IN CHAPTER 4 
Methyl 2-acetylamino-6-[ 4-methyl-6-(3-methyl-l,4-naphthoquinon-2-yl)hex-4-
enoylamino ]hexanoate (4.2) 
o 
General method H was carried out using analogue 3.70 (10 mg, 0.03 mmol), and N-a-
acetyl-lysine methyl ester hydrochloride (7 mg, 0.03 mmol, 1.1 equiv). Extraction 
and purification by radial chromatography eluting with l: 19 MeOH:dichloromethane 
afforded 4.2 (7 mg, 55%). 
1 . H NMR (CDCh) 81.35 (m, 2H, NHCH2CHz), 1.51 (m, 2H, NHCH2CH2CHz), 1.69 
(m, lH, CHzaCHC02Me), 1.71 (m, 2H, CHzCH20), 1.80 (s, 3H, =CCH3), 1.82 (m, 
IH, CHZbCHC02Me), 2.04 (s, 3H, COCH3), 2.05 (t, J=l4.2 Hz, 2H, =CCHz), 2.19 (s, 
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3H, ArCH3), 2.43 (t, J=6.8 Hz, 2H, CHzCONH), 2.64 (dt, J=5.4 and 6.8 Hz, 2H, 
OCOCHz), 3.20 (m, IH, NHCHza), 3.26 (m, IH, NHCHZb), 3.37 (d, J=7.3 Hz, 2H, 
ArCHz) , 3.74 (s, 3H, OCH3), 4.02 (t, J=6.3 Hz, 2H, CHzO), 4.56 (m, 1H, 
CHC02Me), 5.04 (dt, .0 and 6.8 Hz, IH, 
NH), 7.70 (m, 2H, ArH), 8.08 (m, 2H, ArH) 
5.94 (brs, IH, NH), 6.37 (brs, IH, 
13C NMR (CDCb) 0 12.71, 16.26, 22.11, 23.06, 26.00, 26.67, 28.77, 29.66, 30.95, 
31.75, 35.74, 38.74, 51.83, 52.38, 64.31, 119.84, 126.19, 126.28, 132.09, 133.34, 
133.38,136.31,143.45,145.85,170.31,171.77,172.94, 173.06, 184.53, 185.43 
HRESMS (M+H) Found 591.2687 (Calcd. for C31IitlN20S 569.2863) 
Methyl 2~(2-acetylamino-acetylamino )-6-[ 4-methyl-6-(3-methyl-l,4-naphtho-
quinon-2-yl)hex -4-enoylamino ]hexanoate (4.4) 
General method H was carried out using analogue (3.70) (15 mg, 0.04 mmol) and N-
acetyl-gly-lys methyl ester acetate (14 mg, 0.04 mmol, 1.1 equiv). Extraction and 
purification by radial chromatography eluting with 1: 19 MeOH:dichloromethane 
afforded 4.4 as an orange oil (12 mg, 50%). 
IH NMR (CDCI3) 0 1.34 (m, 2H, NHCH2CHz), 1.47 (m, 2H, NHCH2CH2CHz) 1.70 
(t, J=6.8 CHzCH20), 1.70-1.85 (m, 2H, CHzCHC02Me), 1.78 (s, 3H, =CCH3), 
2.03 (s, 3H, COCH3), 2.04 (t, )'=9.8 Hz, 2H, =CCHz), 2.18 (s, 3H, ArCH3), 2.44 (m, 
2H, COCHz), 2.62 (m, 2H, CHzCO), 3.15 (m, 1H, NHCHza), 3.26 (m, IH, NHCHzb), 
3.35 (d, J=6.8 Hz, ArCHz), 3.72 (s, 3H, OCH3), 3.88 (dd, J=4.9 and 16.6 Hz, 1H, 
COCHzaNH), 4.01 (t, J=6.8 Hz, 2H, CHzO), 4.04 (dd, J=4.9 and 16.6 Hz, IH 
COCHzbNH), 4.54 (m, 1H, CHC02Me), 5.02 (dt, J=1.5 and 6.8 Hz, IH, CH=) , 6.25 
(m, IH, NH), 6.74 (m, 1H, NH), 7.04 (m, IH, NH), 7.69 (m, 2H, ArH), 8.06 (m, 2H, 
ArH) 
l3C NMR (CDCI3) 0 12.72, 16.27, 21.97, 22.89, 25.99, 26.66, 28.54, 29.48, 30.74, 
31.24, 35.73, 38.57, 43.11, 51.91, 52.45, 64.36, 119.81, 126.20, 126.28, 132.07, 
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133.36, 133.40, 136.32, 143.47, 145.85, 169.14, 170.98, 171.86, 172.51, 173.33, 
184.56, 185.44 
HRESMS (M+H) found 626.3079 (Ca1cd. For C33~4N309 626.3078) 
6-(3-Methyl-l,4-dimethoxynaphthalen-2-yl)-4-methylhex-4-enoic acid (4.8)14 
OMe 
o 
~ OH 
OMe 
A solution of 3.77 (120 mg, 0.38 mmo1) in ethanol (2.4 mL) was added to a solution 
of silver nitrate (89 mg, 0.58 mmol, 1.5 equiv) in ethanol (4.2 mL) and stirred under a 
nitrogen atmosphere. To this a solution of sodium hydroxide (0.2 mL of 5N aqueous 
solution) in ethanol (2.4 mL) was added dropwise over a ten min period. The 
resulting black solution was stirred overnight at room temperature. The reaction 
mixture was filtered and the ethanol removed. Water was added and the solution was 
extracted with ethyl acetate (x3). The combined organic fractions were dried 
(MgS04) and solvent removed to give 4.8 as a yellow oil (62 mg, 50%), which was 
not purified further. 
1H NMR (CDCb) 8 1.85 (s, 3H, =CCH3), 2.33 (m, 2H, =CCH2), 2.35 (s, 3H, ArCH3), 
2.44 (m, 2H, CH2C02H), 3.56 (d, J=6.4 Hz, 2H, ArCH2), 3.86 (s, 3H, OCH3), 3.87 (s, 
3H, OCH2), 5.17 (t, J=6.4 Hz, 1H, =CH), 7.46 (m, 2H, ArH), 8.04 (m, 2H, ArH) 
l3C NMR (CDCh) 8 12.34, 16.26, 26.23, 32.74, 34.20, 60.45, 61.27, 62.15, 122.0, 
122.20, 123.92, 125.28, 125.44, 126.72, 127.46, 130.36, 133.67, 177.34, 179.41, 
213.29 
6-(3-Methyl-l,4-naphthoquinon-2-yl)-4-methylhex-4-enoic acid (4.5) 14 
~\I ~~OH 
o 
General method G was carried out using CAN (84 mg, 0.15 mmol, 2.5 equiv) and 4.8 
(20 mg, 0.06 mmol). Work up and purification by radial chromatography eluting with 
dichloromethane afforded 4.5 as a yellow oil (11 mg, 60%). 
IH NMR (CDCb) 8 1.81 (s, 3H, =CCH3), 2.17 (s, 3H, ArCH3), 2.29 (m, 2H, =CCH2), 
2.41 (m, 2H, CH2C02H), 3.36 (d, J=6.8 Hz, 2H, ArCH2), 5.06 (t, J=6.4 Hz, 1H, 
CH=), 7.68 (m, 2H, ArH), 8.06 (m, 2H, ArH) 
BC NMR (CDCh) 812.70, 16.28, 25.93, 32.55, 34.27, 120.32, 126.19, 126.32, 
132.07, 133.34, 133.38, 135.45, 143.57, 145.67, 178.57, 184.45, 185.36 
Ethyl 2-(3-methyl-l,4-dimethoxynaphthalen-2-yl)acetate (4.9) 
General method A was carried out using 3.11 (500 mg, 1.78 mmol), nBuLi (1.26 mL 
of 1.6 M solution in hexane, 2.00 mmol, 1.15 equiv), copper bromide dimethyl sulfide 
complex (256 mg, 1.24 mmol, 0.7 equiv) and ethyl bromoacetate (0.22 mL, 1.96 
mmol 1.1 equiv). Standard work up gave a crude product which, upon by radial 
chromatography eluting with 1: 19 ethyl acetate:petroleum ether to 1 :4 ethyl 
acetate:petroleum ether, afforded 4.9 as a yellow oil (174 mg, 34%). 
1H NMR (CDCh) 8 1.26 (t, J=5.4 Hz, 3H, OCH2CH3), 2.36 (s, 3H, ArCH3), 3.87 (s, 
3H, OCH3), 3.91 (s, 3H, OCH3), 3.92 (s, 2H, ArCH2) , 4.19 (q, J=7.3 Hz, 2H, 
OCH2CH3), 7.48 (m, 2H, ArH), 8.06 (m, 2H, ArR) 
l3C NMR (CDCh) 8 12.54, 14.13, 32.97, 60.80, 61.30, 62.23, 122.13, 122.36, 
124.01,125.37,125.92,126.54,126.93,128.17, 150.01, 150.66, 171.64. 
HREIMS Found 288.1366 (Calcd. for C17Hzo04 288.1362) 
Anal. Calcd for C17HZ004: C 70.81; H 6.99. Found C 70.51; H 7.03. 
FTIR 2987.5,2941.2,2837.1, 1732.0, 1595.0 cm-1 
2-(3-Methyl-1,4-dimethoxynaphthalen-2-yl)ethanol (4.10) 
~ ~OH 
OMe 
To a solution of ester (4.9) (110 mg, 0.38 mmol) in diethyl ether (3.60 mL), stirred 
under an argon atmosphere, was added lithium aluminiumhydride (29 mg, 0.76 mmol, 
2 equiv) and the reaction was stirred at room temperature for 20 min. TLC analysis 
showed the reaction to be incomplete so additional lithium aluminiumhydride (10 mg) 
was added and the reaction stirred for a further 30 min. After this time no starting 
material was present by TLC. The reaction was quenched via the addition of 
saturated aqueous NH4Cl and the organic layer separated. The aqueous phase was 
extracted with ethyl acetate and the combined organic fractions washed with water, 
brine, dried (MgS04) and solvent removed. Purification by radial chromatography 
eluting with 1:4 ethyl acetate:petroleum ether to 1: 1 ethyl acetate:petroleum ether 
gave 4.10 as a white solid (85 mg, 90%), which was used without further purification. 
Mp 66-69 °c. Rr (4.9) = 0.61, Rf (4.10) = 0.14, 1:4 ethyl acetate:petroleum ether. 
IH NMR (CDCb) 02.43 (s, 3H, ArCH3), 3.12 (t, J=6.8 Hz, 2H, ArCH2), 3.85 (t, 
J=6.8 Hz, 2H, CH20H), 3.86 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 7.47 (m, 2H ArH), 
8.04 (m, 2H, ArH) 
BC NMR (CDCh) 0 12.54, 30.61, 61.32, 61.87, 62.62, 122.17, 122.19, 125.46, 
125.72, 126.43, 126.91, 127.33, 127.81, 150.32, 150.50 
HREIMS Found 246.1255 (Calcd. For C1sH1s03 246.1256) 
Anal. Calcd for C1sH1S03: C 73.1; H 7.4. Found C 72.8; H 7.4. 
FTIR 3265.3,2935.5,2841.0, 1589.2 cm-1 
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2-(3-Metbyl-l,4-dimetboxynapbtbalen-2-yl)ethyl hydrogen succinate (4.11) 
OMe 
~o,~l 
OMe 1r "-/ 'OR 
General method F was carried out using succinic anhydride (23 mg, 0.23 romol, 2.1 
equiv), dimethylaminopyridine (1 mg, 0.05 equiv), triethylamine (0.02 mL, 0.16 
romol, 1.5 equiv) and 4.10 (27 mg, 0.11 romol). Work up afforded 4.11 as a yellow oil 
(21 mg, 55%), with no further purification. 
IH NMR (CDCh) (5 2.45 (s, 3H, ArCH3), 2.66 (q, J=4.9 Hz, 4H, 2x CH2), 3.17 (t, 
J=7.3 Hz, 2H, ArCH2) , 3.86 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 4.29 (t, J=7.3 Hz, 
2H, CH20), 5.29 (s, IH, OH), 7.47 (m, 2H, ArH), 8.03 (m, 2H, ArH) 
BC NMR (CDCh)(5 12.48, 26.68, 28.85 (x2), 61.30, 62.14, 63.93, 122.18, 122.27, 
125.43, 125.81, 126.l2, 126.49, 127.01, 127.92, 150.15, 150.89, 172.13, 177.93 
HRFABMS found 346.1420 (Caled. For C19H2206 346.1416) 
AnaL Calcd for C19H2206: C 65.9; H 6.4. Found: C 66.3; H 6.8. 
2-(3-Methyl-l,4-naphthoquinon-2-yl)ethyl hydrogen succinate (4.7) 
dY ,~1 ~Olf '-/ 'OR 
o 0 
General method G was carried out using 4.11 (58 mg, 0.l7 romol) and cerric 
ammonium nitrate (230 mg, 0.42 romol, 2.5 equiv). Work up and purification by 
radial chromatography eluting with dichloromethane to 1: 19 MeOH:petroleum ether 
afforded 4.7 as a bright yellow oil (40 mg, 76%). 
IH NMR (CDCh) (5 2.19 (s, 3H, ArCH3), 2.55 (m, 4H, 2x CH2), 2.96 (t, J=5.9 Hz, 
2H, ArCH2), 4.21 (t, J=6.4 Hz, 2H, CH20), 7.66 (m, 2H, ArH), 8.02 (m, 2H, ArH) 
BC NMR (CDCh) (5 12.92, 26.60, 28.66 (x2), 62.88, 126.23 (x2) , 131.80, 131.91, 
133.44,133.47,142.49,145.41,172.06,177.27,184.29,184.86 
HRFABMS found 315.0874 (Calcd for C17HlS06 315.0869) 
2-(3-Methyl-l,4-dimethoxynaphthaJen-2-yl)acetic acid (4.12) 15 
~g ~OH 
OMe 
A solution of 4.9 (58mg, 0.20 mmol) and potassium carbonate (47 mg, 0.34 mmol, 
1.2 equiv) in 10:1 MeOH:water (5.5 mL) was refluxed for 18 h during which time the 
solution went orange. The MeOH was removed under reduced pressure and 10% 
aqueous HCI (5 mL) was added with vigorous stirring. The reaction mixture was 
extracted with ethyl acetate (x2), combined organic fractions were dried (MgS04) and 
solvent removed to give 4.12 as an orange solid (38 mg, 73%). 
IH NMR (CDCh) 8 2.40 (s, 3H, ArCH3), 3.88 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 
3.98 (s, 2H, ArCHz), 7.50 (m,2H, ArH), 8.07 (m, 2H, ArH), 9.89 (brs, 1H, OH) 
l3C NMR (CDCb) 8 12.64, 32.71, 61.41, 62.31, 122.24, 122.40, 123.16, 125.57, 
126.l6, 126.42, 126.88, 128.37, 150.11, 150.75, 178.06 
HREIMS Found 260.1047 (Calcd for C15H1604 260.1049) 
Anal. Calcd for ClsH1604; C 69.2; H 6.2. Found: C 69.0; H 6.3. 
FTIR 3423.4, 2922.0, 1701.1 cm-l 
Methyl 2-acetylamino-6-[4-methyl-6-(3-methyl-1,4-naphthoqllinon-2-yl)hex-4-
enoylamino ]hexanoate (4.13) 
o Me02C 0 N~NJlMe 
o H H 
General method H was carried out using analogue 4.5 (6 mg, 0.02 mmol) was reacted 
with N-a-acetyl-Iysine methyl ester hydrochloride (5 mg, 0.02 mmol, 1.1 equiv), and 
after extraction and purification by radial chromatography eluting with 1: 19 
MeOH:dichloromethane afforded 4.13 as an orange oil (5 mg, 51 %). 
IH NMR (CDCb) 8 1.28 (m, 2H, NHCH2CHZ), 1.46 (m, 2H, NHCH2CH2CHz), 1.68 
(m, 1H, CHzaCHNH), 1.80 (m, 1H, CHzbCHNH), 1.81 (s, 3H, =CCH3), 2.02 (s, 3H, 
COCH3), 2.17 (s, 3H, ArCH3), 2.28 (m, 4H, CHzCHzCO), 3.17 (m, 2H, NHCHz), 
3.36 (d, J=6.8 Hz, 2H, ArCHz), 3.73 (s, 3H, OCH3), 4.53 (m, 1H, CHC02Me), 5.06 
(t, J=6.4 Hz, 1H, CH=), 5.72 (brs, 1H, NH), 6.32 (d, J=7.3 Hz, 1H, NH), 7.70 (m, 2H, 
ArH), 8.07 (m, 2H, ArH) 
l3C NMR (CDCb) 8 12.73, 16.38, 22.21, 23.13, 26.07,28.84, 31.85, 35.18,35.29, 
38.70,51.81,52.41,120.16, 126.26, 126.69, 132.07 (x2), 133.43 (x2), 136.24, 143.56, 
145.60, 170.20, 172.97, 172.99, 184.79, 185.35 
HRESMS (M+H) found 483.2504 CCalcd. for C27H35N206 483.2495) 
Methyl 2-(2-acetylamino-acetylamino )-6-[4-methyl-6-(3-methyl-1,4-naphtho-
quinon-2-yl)hex-4-enoylamino ]hexanoate (4.14) 
o 
o 
General method was carried out using analogue 4.5 (9 mg, 0.03 mmo1) and N-
acety1-g1y-lys methyl ester acetate(11 mg, 0.03 mmol, 1.1 equiv). Following 
extraction and purification by radial chromatography eluting with 1: 19 
MeOH:dichloromethane 4.14 was isolated as an orange oil (5 mg, 31 %). 
IH NMR (CDCh) 8 1.24 (m, 2H, NHCH2CH2CHz), 1.40 (m, 2H, NHCH2CHz), 1.65 
(m, 1H, CHzaCHNH), 1.78 (s, 3H, =CCH3), 1.80 (m, 1H, CHZbCHNH), 2.03 (s, 3H, 
COCH3), 2.16 (s, 3H, ArCH3), 2.28 (m, 4H, =CCHzCHz), 3.12 (m, 2H, NHCHz), 
3.33 (d, J=6.8 Hz, 2H, ArCHz), 3.70 (s, 3H, OCH3), 3.90 (dd, J=4.9 and 19.0 Hz, lH, 
COCHzaNH), 4.00 (dd, J=4.9 and 19.0 Hz, 1H, COCHZbNH), 4.50 (m, 1H, 
CHC02Me), 5.04 (t, J=5.9 Hz, 1H, CH=) , 6.17 (brs, 1H, NH), 6.80 (brs, 1H, NH), 
7.10 (d, J=7.3 Hz, 1H, NH), 7.68 (m, 2H, ArH), 8.06 (m, 2H, ArH) 
l3C NMR (CDCb) 8 12.70, 16.23, 22.87, 26.04, 28.71, 29.66, 31.14, 35.04, 35.26, 
38.68,43.17, 52.06, 52.44, 120.18, 126.21, 126.25, 126.63, 132.04 (x2), 133.42 (x2), 
136.11,143.57,145.67,171.37,172.40,173.49,184.58,185.31 
HRESMS (M+H) found 540.2706 (Calcd. for C29H3SN307 540.2710) 
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Methyl 2-(2-acetylamino-acetylamino )-6-{3-[2-(3-methyl-l,4-naphthoquinon-2-
yl)ethoxycarbonyl]propionylamino} hexanoate (4.15) 
° ~ 0 Me02C 0 ~°nJN~Nj~~IIMe 
o 0 H H 0 
General method H was carried out using 4.7 (10 mg, 0.03 romol) and N-acetyl-gly-lys 
methyl ester acetate (11 mg, 0.03 romol, 1.1 equiv). Following extraction and 
purification by radial chromatography eluting with 1: 19 MeOH:dichloromethane 4.15 
was isolated as an orange oil (15 mg, 85%). 
IH NMR (CDCh) 8 1.34 (m, 2H, NHCH2CH2CH2), 1.47 (m, 2H, NHCH2CH2), 1.69 
(m, 1H, CH2aCHNH), 1.84 (m, 1H, CH2bCHNH), 2.03 (s, 3H, COCH3), 2.24 (s, 3H, 
ArCH3), 2.61 (m, 4H, COCH2CH2CO), 3.01 (t, J=6.8 Hz, 2H, ArCH2CH2), 3.14 (m, 
1H, NHCH2a), 3.24 (m, 1H, NHCH2b), 3.72 (s, 3H, OCH3), 3.90 (dd, J=5.4 and 17.1 
Hz, 1H, COCH2aNH), 4.03 (dd, J=5.4 and 17.1 Hz, 1H, COCH2bNH), 4.27 (t, J=6.8 
Hz, 2H, ArCH2) , 4.54 (m, 1H, CHC02Me), 6.41 (m, 1H, NH), 6.86 (m, 1H, NH), 
7.16 (d, J=7.8 Hz, 1H, NH), 7.71 (m, 2H, ArH), 8.08 (m, 2H, ArH) 
BC NMR (CDCh) 8 13.00, 22.06, 22.76, 26.63, 28.49, 29.38 (x2), 31.22, 38.65, 
43.01, 51.91, 52.41, 62.88, 126.30, 126.34, 131.89, 132.05, 133.55 (x2) , 142.55, 
145.57, 169.25, 171.25, 171.77, 172.60, 173.16, 184.48, 184.95 
HRESMS (M+H) Found 558.2464 (Calcd. for C28H36N309 558.2452) 
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6.5 EXPERIMENTAL WORK DESCRIBED IN CHAPTER 5 
2,3,6-Tribromo-4-methylphenol (5.47)16 
B'yty 
HO~ 
Br 
To a solution of p-cresol (25g, 0.23 mol) in chloroform (27 mL) containing iron 
filings (0.9 g, 0.02 mol, 0.07 equiv) was added bromine (37 ml, 0.72 mol, 3.1 equiv) 
dropwise, over 5 h at room temperature. During this addition a large amount of RBr 
gas was produced which was trapped by bubbling through water. The reaction 
solution turned dark red and solidified upon addition of the last 4-5 mL of bromine. 
More chloroform (5 mL) was added and the reaction stirred for 48 h. The reaction 
was filtered, the filtrate washed with dilute aqueous sodium hydrogen sulfite and 
dried (MgS04). Solvent was removed under reduced pressure to afford a crude 
product which was recrystallised from petroleum ether to give 5.47 (48.54 g) as off-
white needles, in 61 % yield. Mp 96-98 °C (lit. mp 102 oC)16 
lR NMR (CDCh) 82.39 (s, 3R, ArCH3), 5.90 (s, lR, OH), 7.39 (s, IR, ArH) 
HREIMS Found 341.7901 (Calcd. for C7Rs079Br3 341.7891) 
I-Methyl-2,3,4,5-tetramethoxybenzene (5.48)16 
OMe 
Meo* ~I MeO 
OMe 
2,3-Dimethoxy-5-methyl-I,4-benzoquinone (lg, 5.49 mmol, I equiv) was dissolved 
in hot ethanol and cooled rapidly in ice. To this was added a solution of stannous 
chloride (4.95g, 0.02 mol, 4 equiv) in cone. RCI (5mL) during which time the red 
colour faded to pale yellow. This was extracted with ethyl acetate (3x), dried 
(MgS04) and solvent removed to give pale yellow crystals. This was suspended in 
dimethyl sulfate (7.2 mL, 0.08 mmol, 14 equiv) and stirred in a two-necked flask 
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under nitrogen. To this was added portionwise a solution of potassium hydroxide (12 
g, 0.22 mol, 40 equiv) in water (26 mL) not allowing the solution to reflux. During 
this addition a thick white precipitate formed, which then redissolved leaving a yellow 
solution that faded to white. Upon completion of the addition of potassium hydroxide 
the reaction was heated to 80°C under a nitrogen atmosphere for 1 h, then allowed to 
cool slowly. The reaction was diluted with water (180 mL) and extracted with ether 
(3x). The combined organic fractions were washed with 5% aqueous NaOH, water, 
dried (MgS04) and solvent removed to afford 5.48 as a pale yellow oil (990 mg, 
85%), which was not purified further. 
1HNMR (CDCb) 82.22 (s, 3H, ArCH3), 3.78 (s, 3H OCH3), 3.81 (s, 3H OCH3), 3.86 
(s, 3H OCH3), 3.93 (s, 3H OCH3), 6.44 (s, 1H, ArH) 
BC NMR (CDCh) 8 15.84, 56.10, 60.65, 61.08, 61.17, 108.31, 125.89, 140.79, 
145.40, 147.00, 149.11 
HREIMS Found 212.1057 (Ca1cd. For CllH160 4 212.1049) 
FTIR 2937.4,2837.1, 1591.2 cm-1 
I-Bromo-2-methyl-3,4,5,6-tetramethoxybenzene (5.42)16 
Meo*~e I~ 
MeO Br 
OMe 
To a stirred solution of 5.48 (490 mg, 2.30 mmo1, 1 equiv) in dich1oromethane (2.3 
mL) at 3-5 °c was added slowly a solution of bromine (0.12 mL, 2.30 mmo1, 1 equiv) 
in dichloromethane (0.46 mL). The resulting dark orange solution was stirred for a 
further 5 min. The reaction mixture was washed with water (3x), dilute aqueous 
NaOH (3x), water, dried (MgS04) and solvent removed to give 5.42 as a yellow oil 
(566 mg, 84%), which was not purified further. 
1H NMR (CDCh) 8 2.30 (s, 3H, ArCH3), 3.78 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 
3.91 (s, 6H, 2x OCH3) 
BC NMR (CDCh) 815.98, 60.86, 60.90, 61.15, 61.39, 114.32, 127.31, 145.50, 
146.35, 147.23, 148.31 
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HREIMS Found 290.0163 (Calcd. for CllH1S0479Br 290.0151) 
FTIR 2937.4,2858.3 cm-1 
Ethyl 2-(2-methyl-3,4,5,6-tetramethoxyphenyl)acetate (5.44) 
OMe 
Meo~o Ih 
MeO OEt 
OMe 
170 
General method A was carried out using 5.42 (475 mg, 1.60 mmo1), nBuLi (1.35 mL 
of a 1.6M solution in hexane, 1.87 mmol, 1.15 equiv), copper bromide dimethyl-
sulfide complex (235 mg, 1.14 mmo1, 0.7 equiv) and ethyl bromo acetate (0.2 mL, 
1.79 mmo1, 1.1 equiv). Standard work up gave a crude product which, upon 
purification by radial chromatography eluting with 1:4 ethyl acetate:petroleum ether, 
afforded 5.44 as a yellow oil (21 mg, 7%). 
IH NMR (CDCh) 0 1.28 (t, J=6.8 Hz, 3H, CH2CH3), 2.09 (s, 3H, ArCH3) , 3.51 (s, 
2H, ArCH2), 3.78 (s, 3H, OCH3) , 3.79 (s, 3H, OCH3) , 3.89 (s, 3H, OCH3) , 3.90 (s, 
3H, OCH3), 4.19 (q, J=6.8 Hz, 2H, CH2CH3) 
13C NMR (CDCh) 012.05, 14.04, 32.34, 60.61, 60.64, 60.92, 60.96, 61.01, 122.19, 
125.94, 144.49, 146.04, 147.70, 148.09, 171.71 
2,6-Dimethyl-8-(2-methyl-3,4,5,6-tetramethoxyphenyl)octa-2,6-diene (5.41) 17 
OMe 
MeO 
MeO 
OMe 
General method A was carried out using 5.42 (735 mg, 2.50 mmo1) and gerany1 
bromide (0.55 mL, 2.78 mmo1). Upon workup and purification by radial 
chromatography eluting with 1: 19 ethyl acetate:petro1eum ether, 5.41 was isolated as 
a yellow oil (426 mg, 48%). 
1H NMR(CDCh) 0 1.57 (s, 3H, =CCH3), 1.64 (s, 3H, =CCH3), 1.77 (s, 3H, =CCH3), 
2.00 (m, 2H, =CCH2), 2.07 (m, 2H, =CCH2CH2), 2.14 (s, 3H, ArCH3), 3.32 (d, J=6.8 
Chapter 6 171 
Hz, 2H, ArCH2), 3.78 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.91 
(s, 3H, OCH3), 5.04 (m, 2H, 2x CH=) 
I3C NMR (CDCb) 8 11.61, 16.11, 17.61,25.62,25.73,26.55,39.64,60.61,61.01, 
61.03, 107.01, 122.88, 124.23, 125.35, 129.23, 131.25, 134.93, 144.63, 144.87, 
147.61, 147.80 
HREIMS Found 348.2306 (Calcd for C21H3204 348.2301) 
FTIR 2931.6,2860.2, 1467.7 em-I 
3-Bromo-2,6-dimethyI-8-(2-methyl-3,4,5,6-tetramethoxyphenyI)oct-6-en-2-o1 
(5.51) 
OMe 
MeO 
Br 
OH 
MeO 
OMe 
General method B was carried out using 5.41 (420 mg, 1.20 mmol) and N-
bromosuccinimide (236 mg, 1.33 mmol, 1.1 equiv). Work up and purification by 
radial chromatography, eluting with 1:9 ethyl acetate:petroleum ether to 1:4 ethyl 
acetate:petroleum ether afforded the bromohydrin 5.51 as a yellow oil (347 mg, 65%). 
IH NMR (CDCh) 8 1.32 (s, 3H, C(OH)CH3) 1.33 (s, 3H, C(OH)CH3), 1.77 (s, 3H, 
=CCH3), 1.79 (m, IH, CH2aCBr), 1.98 (m, 2H, CH2bCBr), 2.09 (m, IH, =CCH2a), 
2.35 (m, IH, =CCH2b), 2.14 (s, 3H, ArCH3) , 3.33 (m, 2H, ArCH2), 3.79 (s, 3H, 
OCH3), 3.78 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 3.95 (dd, .5 
and 11.7 Hz, IH, CBBr), 5.13 (t, J=6.4 Hz, IH, CH=) 
13CNMR (CDCh) 811.78,16.14,25.81,25.86,26.62,32.10,38.23,60.70 (x2), 61.10 
(x2), 70.85, 72.44, 124.42, 125.28, 128.85, 133.24, 144.70, 145.00, 147.62, 147.87 
HREIMS found 444.1516 (Caled for C21H330s79Br 444.1509) 
FTIR 3477.4,2935.5, 1739.7 em-I 
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3-[3-Metbyl-5-(2-metbyl-3,4,5,6-tetrametboxypbenyl)pent-3-enyl]-2,2-dimetbyl-
oxirane (5.52)12 
OMe 
OMe 
General method C was carried out using potassium carbonate (2.17 g, 0.02 mol, 70 
equiv) and 5.51 (100 mg, 0.22 mmol). Work up afforded 5.52 as a pale yellow oil (64 
mg, 78%), with no further purification. 
IH NMR (CDCb) 0 1.24 (s, 3H, CCH3), 1.25(s, 3H, CCH3), 1.64 (m, 2H, CH2CO) 
1.80 (s, 3H, =CCH3), 2.10 (m, 2H, =CCH2), 2.17 (s, 3H, ArCH3), 2.67 (t, J=6.4 Hz, 
1H, CHO), 3.32 (d, J=2.9 Hz, 2H, ArCH2), 3.78 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 
3.90 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 5.10 (t, J=5.4 Hz, IH, CH=) 
l3C NMR (CDCh) 0 11.62, 16.07, 18.59, 24.67, 25.67, 27.26, 36.19, 58.17, 60.51, 
60.90,60.93,63.99, 123.37, 125.12, 128.79, 133.94, 144.57, 144.88, 147.50, 147.73 
HREIMS found 364.2254 (Calcd for C21H3205 364.2250) 
FTIR 2960.5,2933.5,2862.2,2829.4 cm-1 
4-Metbyl-6-(2-metbyl-3,4,5,6-tetrametboxypbenyl)bex-4-enal (5.50) 
OMe 
MeO o 
MeO H 
OMe 
General method D was carried out using periodic acid (75 mg, 0.33 mmol, 1 equiv) 
and 5.52 (120 mg, 0.33 mmol). Work up gave 5.50 as a pale yellow oil (90 mg, 85%), 
with no further purification. 
1H NMR (CDCh) 0 1.79 (s, 3H, =CCH3), 2.12 (s, 3H, ArCH3), 2.33 (t, J=7.8 Hz, 2H, 
CH2CH2CHO), 2.52 (dt, J=2.0 and 7.3 Hz, 2H, CH2CHO), 3.32 (d, J=5.9 Hz, 2H, 
ArCH2), 3.78 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.91 (s, 3H, 
OCH3), 5.09 (t, 6.4 IH, CH=), 9.74 (t, J= 1.9 Hz, 1H, CHO) 
13C NMR (CDCh) 0 11.72, 16.27,25.76,31.79,42.13,60.68 (x2), 6l.07 (x2), 123.99, 
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125.27, 128.62, 133.00, 144.68, 145.07, 147.62, 147.85,202.47 
HREIMS Found 322.1771 (Calcd. for C18H260S 322.1780) 
Anal. Calcd for C18H260S: C 67.1; H 8.1. Found: C 66.9; H 7.9. 
FTIR 2935.5, 1724.2 cm-1 
4-Methyl-6-(2-methyl-3,4,5,6-tetramethoxyphenyl)hex-4-enoic acid (5.53)14 
OMe 
MeO o 
MeO OR 
OMe 
173 
To a solution of silver nitrate (82 mg, 0.54 mmol, 1.5 equiv) in ethanol (3.9 mL) 
stirring at room temperature under a nitrogen atmosphere, was added a solution of 
5.50 (115 mg, 0.36 mmol) in ethanol (2.3 mL). To this was added dropwise a 
solution of NaOH (0.18 mL of a 5N aqueous solution) in ethanol (2.3 mL) over a 
period of 10 min. The resulting black solution was stirred at room temperature for 16 
h. The reaction was filtered and ethanol removed under reduced pressure. Water was 
added, and the solution acidified and extracted with ethyl acetate (2x). Combined 
organic fractions were dried (MgS04) and solvent removed to afford 5.53 as a yellow 
oil (94 mg, 78%), which was not purified further. 
1H NMR (CDCh) (31.79 (s, 3H, =CCH3), 2.12 (s, 3H, ArCH3), 2.31 (t, J=7.3 Hz, 2H, 
=CCH2), 2.45 (t, J=6.8 Hz, 2H, CH2C02H), 3.32 (d, J=6.4 Hz, 2H, ArCH2), 3.77 (s, 
3H, OCH3), 3.78 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 5.09 (t, J= 
6.8 Hz, 1H, CH=) 
13C NMR (CDCh) (3 11.69, 16.13,25.75,32.67,34.27,60.68 (x2), 61.08 (x2), 123.98, 
125.32, 128.72, 133.03, 144.65, 145.02, 147.62, 147.83, 178.47 
HREIMS Found 338.1729 (Calcd. for C18H2606 338.1729) 
Anal. Cacld for C18H2606: C 63.9; H 7.7. Found: C 64.1; H 7.8. 
FTIR 2935.5,2659.7, 1708.8 cm-1 
4-Methyl-6-(3-methyl-5,6-dimethoxy-l,4-benzoquinon-Z-yl)hex-4-enoic acid 
(5.37)14 
MeG 
MeG GR 
General method G was carried out using cerric ammonium nitrate (365 mg, 0.66 
mmol, 2.5 equiv) and 5.53 (90 mg, 0.27 mmol). Work up and purification by radial 
chromatography eluting with dichloromethane to 1:19 MeOH:dichloromethane gave 
5.37 as a bright orange oil (45 mg, 55%). 
lH NMR (CDCh) 8 1.77 (s, 3H, =CCH3), 2.00 (s, 3H, ArCH3), 2.30 (m, 2H, =CCHz), 
2.43 (m, 2H, =CCH2CHz), 3.19 (d, J=6.8 Hz, 2H, ArCHz), 3.98 (s, 3H, OCH3), 3.99 
(s, 3H, OCH3), 5.00 (m, lH, CH=) 
13C NMR (CDCh) 8 11.88, 16.13, 25.17, 32.61, 34.19, 61.09 (x2) , 120.02, 135.50, 
139.01, 141.17, 144.17, 144.27, 179.03, 183.79, 184.60 
HREIMS Found 308.1263 (Calcd. For C1~2006 308.1260) 
4-Methyl-6-(Z-methyl-3,4,5,6-tetramethoxyphenyl)hex-4-en-l-ol (5.54)12 
OMe 
MeO 
MeG OR 
GMe 
General method E was carried out using sodium borohydride (10 mg, 0.27 mmol, 1 
equiv) and 5.50 (88 mg, 0.27 mmol). Work up afforded 5.54 as a yellow oil, (65 mg, 
74 %), which was not further purified. 
IH NMR (CDCb) 8 1.65 (m, 2H, CHzCH20H), 1.76 (s, 3H, =CCH3), 2.04 (t, J=6.8 
Hz, 2H, =CCHz), 2.11 (s, 3H, ArCH3), 3.30 (d, J=6.8 Hz, 2H, ArCHz), 3.59 (t, J=6.4 
Hz, 2H, CHzOH), 3.76 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.89 
(s, 3H, OCH3), 5.06 (dt, J=1.5 and 6.8 Hz, IH, CH=) 
13C NMR (CDCh) 811.88, 16.08, 25.90, 30.77, 36.26, 60.94, 61.99, 61.24 (x2), 
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62.76, 123.24, 125.22, 129.03, 134.82, 144.72, 145.03, 147.62, 147.92 
HREIMS Found 324.1937 (Calcd. for CIsH2SOs 324.1937) 
Anal. Calcd for ClsH2gOS: C 66.6; H 8.7. Found: C 66.7; H 8.6. 
FTIR 3435.0, 2935.5, 1465.8, 1407.9 cm-l 
175 
4-Methyl-6-(2-methyl-3,4,5,6-tetramethoxyphenyl)hex-4-enyl hydrogen succinate 
(5.55) 
OMe 
MeO 
MeO ~ 
OMe 
o 
O~OH 
o 
General method F was carried out using succinic anhydride (34 mg, 0.34 mmol, 2.1 
equiv), N,N-dimethylaminopyridine (1 mg, 0.01 mmol, 0.05 equiv), triethylamine 
(0.03 mL, 0.24 mmol, 1.5 equiv) and 5.54 (52 mg, 0.16 mmol). Work up and 
purification by radial chromatography eluting with 1:9 ethyl acetate:petroleum ether 
afforded 5.55 as a pale yellow oil (24 mg, 37%). 
IH NMR (CDCh) 8 1.73 (m, 2H, CH2CH20), 1.76 (s, 3H, =CCH3), 2.03 (t, J=6.8 Hz, 
2H, =CCH2), 2.12 (s, 3H, ArCH3), 2.59 and 2.65 (m, 4H, COCH2CH2C02H), 3.30 (d, 
J=6.4 Hz, 2H, ArCH2), 3.78 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 
3.90 (s, 3H, OCH3), 4.05 (dt, J=2.4 and 6.8 Hz, 2H, CH20), 5.05 (t, J=6.4 Hz, 1H, 
CH=) 
l3C NMR (CDCb) 8 11.66, 15.98, 25.71, 26.19, 26.69, 28.87, 35.65, 60.65, 61.05, 
64.46,64.66, 123.57, 125.32, 126.98, 128.92, 133.71, 144.59, 144.90, 147.48, 147.78, 
172.22, 176.96 
HREiMS Found 424.2129 (Calcd. For C22H320g 424.2097) 
Anal. Calcd for C22H320g: C 62.3; H 7.6. Found: C 62.4; H 7.7. 
FTIR 2937.4, 1737.7 cm-l 
4-Methyl-6-(3-methyl-5,6-dimethoxy-l,4-benzoquinon-2-yl)hex-4-enyl hydrogen 
succinate (5.38) 
o 
MeO 
MeO 
General method G was carried out using (24 mg, 0.06 mmol) and cerric 
ammonium nitrate (77 mg, 0.14 mmo1, 2.5 equiv). Work up and purification by radial 
chromatography eluting with dichloromethane to 1: 19 MeOH:dichloromethane gave 
5.38 as an orange oil (20 mg, 90%). 
IH NMR (CDCh) 8 1.72 (m, 2H, CH2CH20), 1.74 (s, 3H, =CCH3), 2.02 (s, 3H, 
ArCH3), 2.03 (m, 2H, =CCH2), 2.60-2.66 (m, 4H, COCH2CH2C02H), 3.18 (d, J=6.8 
Hz, 2H, ArCH2) , 3.98 (s, 3H, OCH3), 4.00 (s, 3H, OCH3), 4.03 (t, J=6.3 Hz, 2H, 
CH20), 4.95 (t, 1 Hz, 1H, CH=) 
13C NMR (CDCh) 8 11.95, 16.12, 25.32, 26.58, 28.79, 28.82, 35.66, 61.14 (x2), 
64.29, 119.73, l36.27, 138.94, 141.38, 144.21, 144.34, 172.l3, 177.24, 183.93, 
184.74 
HREIMS Found 394.1621 (Caled. for C2oH260g 394.1623) 
Methyl 2-acetylamino-6-[ 4-methyl-6-(3-methyl-5,6-dimethoxy-l ,4-benzoquinon-
2-yl)hex-4-enoylamino]hexanoate (5.58) 
o 
MeO o COzMe 
N~N/COMe MeO H H 
General method H was carried out using 5.37 (10 mg, 0.032 mmol) and N-a-acetyl-
lysine methyl ester hydrochloride (8.5 mg, 0.036 mmol, 1.1 equiv). Work up and 
purification by radial chromatography eluting with 1:19 MeOH:dichloromethane, 
afforded 5.41 as an orange oil (10 mg, 63%). 
IH NMR (CDCb) 8 1.35 (m, 2H, NHCH2CH2), 1.50 (m, 2H, NHCH2CH2CH2), 1.68 
(m, lH, CH2aCHC02Me), 1.76 (s, 3H, =CCH3), 1.82 (m, 1H, CH2bCHC02Me), 2.01 
(s, 3H, ArCH3), 2.04 (s, 3H, COCH3), 2.24 (m, 2H, =CCH2), 2.29 (m, 2H, 
=CCH2CH2), 3.18 (d, J=6.8 Hz, 2H, ArCH2), 3.21 (m, 2H, NHCH2), 3.74 (s, 3H, 
C02CH3), 3.99 (s, 3H, OCH3), 4.00 (s, 3H, OCH3), 4.55 (m, lH, CHC02Me), 4.99 (t, 
J=7.3 Hz, lH, CH=), 5.77 (brs, lH, NH), 6.40 (d, J=6.8 Hz, lH, NH) 
13C NMR (CDCh) 8 11.95, 16.23,22.25,23.05,25.33,28.84, 31.79, 35.13, 35.27, 
38.68,51.82,52.38,61.13,61.16, 119.91, 136.23, 139.06, 141.24, 144.20, 170.30, 
172.85,172.98,182.30,183.90 
HRESMS Found 492.2465 (Calcd. for C2sH36N20g 492.2472) 
Methyl 2-(2-acetylamino-acetylamino )-6-[4-methyl-6-(3-methyl-5,6-dimethoxy-
1,4-benzoqmnon-2-yl)hex-4-enoylamino]hexanoate (5.59) 
MeO 
MeO 
General method H was carried out using 5.37 (10 mg, 0.03 mmol) and N-acetyl-gly-
lys methyl ester acetate (11 mg, 0.04 mmol, 1.1 equiv). Purification by radial 
chromatography eluting with 1: 19 MeOH:dichloromethane afforded 5.42 as an orange 
oil (6 mg, 34%). 
IH NMR (CDCh) 8 1.34 (m, 2H, NHCH2CH2), 1.46 (m, 2H, NHCH2CH2CH2), 1.71 
(m, 1H, CH2aCHC02Me), 1.76 (s, 3H, =CCH3), 1.85 (m, 1H, CH2bCHC02Me), 2.01 
(s, 3H, ArCH3), 2.05 (s, 3H, COCH3), 2.28 (in, 2H, =CCH2), 3.15 (m, 1H, NHCH2a), 
3.17 (d, J=7.3 Hz, ArCH2), 3.23 (m, lH, NHCH2b), 3.74 (s, 3H, C02CH3), 3.91 (dd, 
J=5.4 and 16.1 Hz, 1H, COCH2aNH), 3.99 (s, 3H, OCH3), 4.00 (s, 3H, OCH3), 4.01 
(dd, J= 5.4 and 16.1 Hz, 1H, COCH2bNH), 4.53 (m, IH, CHC02Me), 4.98 (t, J=6.8 
Hz, CH=), 6.03 (brs, 1H, NH), 6.74 (brs, IH, NH), 7.08 (d, J=7.3 Hz, 1H, NH) 
13CNMR (CDCh) 8 11.97, 16.28, 22.17, 22.89, 25.37, 28.86, 31.21, 35.04, 35.23, 
38.55,43.13, 52.01, 52.45, 61.15, 61.18, 119.85, 136.27, 139.10, 141.25, 143.01, 
144.32,169.08,170.91,172.51,173.01,183.96,184.65 
HRESMS Found 549.2677 (Ca1cd. For C27H3909N3 549.2686) 
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